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YM155 is a dioxonaphthoimidazolium analog with potent growth inhibitory activities on a variety 
of cancer cell lines. Although initially reported as a suppressor of survivin, its specificity has 
been queried with concerns raised over its purported DNA damaging activity. The purpose of 
this thesis was to investigate the hypothesis that a detailed understanding of the mode of action 
of YM155 would promote the development of dioxonaphthoimidazolium analogs as a promising 
class of anti-cancer therapeutics. To this end, we investigated the hitherto unreported structure-
activity relationships (SAR) of YM155 with regards to growth inhibition, DNA intercalation and 
redox cycling using a library of synthesized YM155 analogs. This was followed by investigations 
on the mechanism of action with emphasis placed on the NF-κB pathway and the induction of 
apoptosis. 
 
With regards to growth inhibition, two salient points have emerged. First, the intact 
dioxonaphthoimidazolium scaffold was essential for potent growth inhibitory activity. Second, 
the pyrazin-2’-ylmethyl and 2’-methoxyethyl side chains served to fine-tune activity. Two 
promising analogs AB1 (IC50 17 – 44 nM) and AB7 (IC50 8.6 – 29 nM) were identified which had 
comparable or slightly more potent activity than YM155 (IC50 14 – 54 nM) on the renal cell 
carcinoma (RCC786-0, RCC4/VA) and non-small cell lung carcinoma (H1299, H1666) cell lines. 
Potency against malignant cells was approximately 10 times greater than on non-malignant 
fibroblast IMR-90 cells. SAR for DNA intercalation and redox cycling showed limited overlaps 
with that for growth inhibition and together with the delayed increase in γH2AX, a DNA damage 
marker, it is concluded that DNA damage was unlikely to contribute in a significant capacity to 




As survivin is regulated by the NF-κB pathway, the effects of YM155 and AB1 on this pathway 
were investigated. A key finding was that YM155 and AB1 inhibited phosphorylation of the p50 
subunit of NF-κB and reduced reporter activity in malignant cells. Disruption of NFkB signaling 
would lead to apoptosis with upregulation of cleaved caspases 3/7 and downregulation of 
antiapoptotic proteins survivin, Mcl1 and Bcl-xl.  
 
Reports of YM155 as a potential therapeutic agent for the eradication of rogue stem cells in 
differentiated tissues inspired a SAR study on two embryonal carcinoma (NCCIT, NTERA-2) cell 
lines employed as surrogates of embryonic stem cells. YM155 and analogs displayed greater 
potency on these cells as compared to malignant cells. Selectivity ratios which exceeded 100-
fold were highly favorable. A subset of analogs including YM155 were then tested and found to 
be as potent on embryonic stem cell line H9 and an induced pluripotent stem cell line HCT-8 
3.11. YM155, AB1 and AB7 reduced mRNA and protein levels expression of a pluripotency-
related gene Sox2 in NCCIT, H9 and HCT-8 3.11. Phosphorylation of p50 was also inhibited, 
suggesting a putative role for NF-κB in maintaining pluripotency and viability of stem cells.  
 
In conclusion, dioxonaphthoimidazolium analogs hold promise as anticancer agents for renal 
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Figure 6.1. Small molecules with ability to clear remnant stem cells. 
Figure 6.2. Morphology of H9-MEF cultures following 24 h treatment with 5 nM and 50 nM of 
(A) YM155 and (B) AB1 in comparison with DMSO vehicle control. The characteristic clear 
demarcation of colonies’ boundaries were lost as the concentration of YM155 and AB1 
increased. Eventually, the colonies collapsed, indicating loss of viability. A set of background 
control with only MEF showed negligible loss of viability for MEF (< 5%) under similar conditions 
(data not shown). Images presented are representative of the triplicates performed in the 
experiment. 
Figure 6.3. Expression levels of Sox2 mRNA following 12 or 24 h of treatment with YM155, 
AB1 or AB7 quantified by qRT-PCR. Bars represent the fold-change of cDNA normalized 
against GAPDH in the same sample. Error bars represent the standard deviations of three 
separate experiments. Significant statistical difference from vehicle control is represented by an 
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asterisk (*) when p<0.05, two asterisks (**) when p<0.01 and three asterisks (***) when p<0.001 
(Tukey post-hoc test of respective populations of treated groups vs control). 
Figure 6.4. Expression levels of Oct4 mRNA following 12 or 24 h of treatment with YM155, AB1 
or AB7 quantified by qRT-PCR. Bars represent the fold-change of cDNA normalized against 
GAPDH in the same sample. Error bars represent the standard deviations of three separate 
experiments. Significant statistical difference from vehicle control is represented by an asterisk 
(*) when p<0.05, two asterisks (**) when p<0.01 and three asterisks (***) when p<0.001 (Tukey 
post-hoc test of respective populations of treated groups vs control). 
Figure 6.5. Expression levels of Nanog mRNA following 12 or 24 h of treatment with YM155, 
AB1 or AB7 quantified by qRT-PCR. Bars represent the fold-change of cDNA normalized 
against GAPDH in the same sample. Error bars represent the standard deviations of three 
separate experiments. Significant statistical difference from vehicle control is represented by an 
asterisk (*) when p<0.05, two asterisks (**) when p<0.01 and three asterisks (***) when p<0.001 
(Tukey post-hoc test of respective populations of treated groups vs control). 
Figure 6.6. Expression levels of p50 mRNA following 12 or 24 h of treatment with YM155, AB1 
or AB7 quantified by qRT-PCR. Bars represent the fold-change of cDNA normalized against 
GAPDH in the same sample. Error bars represent the standard deviations of three separate 
experiments. Significant statistical difference from vehicle control is represented by an asterisk 
(*) when p<0.05, two asterisks (**) when p<0.01 and three asterisks (***) when p<0.001 (Tukey 
post-hoc test of respective populations of treated groups vs control). 
Figure 6.7. Cleaved caspase 3, survivin, Sox2 and NF-κB subunits p50, p65, p105 and their 
phosphorylated forms (p.p50, p.p65) levels in NCCIT, HCT-8 and HCT-8 3.11 after treatment 
with YM155 and AB1 for 48 h. GAPDH was used as loading control. 
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Chapter 1:  Introduction 
1.1. Survivin as an anticancer target 
The 16.5 kDa protein survivin is the smallest member of the family of Inhibitor of Apoptosis (IAP) 
proteins.1 IAP proteins are characterized by the presence of at least one ~ 70 amino acid-long 
baculovirus IAP repeat (BIR) domain and the ability to inhibit apoptosis. By this criteria, eight 
IAPs have been identified and they include c-IAP1, c-IAP2 and XIAP.2, 3 The BIRs are the sites 
to which executioner caspases are bound and inhibited. These interactions are well studied for 
XIAP4-6 and may apply to other IAP proteins (including survivin) as well.7, 8 Notwithstanding, the 
precise mechanism by which survivin suppresses apoptosis is still poorly understood and 
conflicting reports abound. One study proposes that survivin does not directly inhibit caspase 3.9 
Others have reported that survivin inhibits caspases indirectly by interacting with intermediate 
proteins like Smac/DIABLO. The pro-apoptotic Smac/DIABLO binds XIAP, thus preventing it 
from inhibiting apoptosis.6, 10-12 By sequestering Smac/DIABLO from XIAP, survivin effectively 
frees XIAP for binding to pro-caspases, thus blocking their conversion to the activated states. 
Yet another possibility is that survivin requires the cofactor hepatitis B X-interacting protein 
(HBXIP) to bind pro-caspase 9 before it can prevent apoptosis via the intrinsic pathway.13  
Survivin also regulates cell division, a property that is not shared by other IAP proteins. It forms 
part of the chromosomal passenger complex (CPC) which includes aurora B kinase, inner 
centromere protein (INCENP) and borealin.14, 15 The CPC oversees the proper alignment of 
chromosomes to the mitotic spindle during cell division. Survivin also promotes the proper 
assembly of the mitotic spindle and cytokinesis. Knockdown of survivin expression resulted in 
cells that fail to divide in a proper manner and thus succumb to mitotic catastrophe and cell 
death.16 Taken together, survivin has a unique bifunctional role as an inhibitor of apoptosis and 




Given its important roles in cellular dynamics, it comes as no surprise that survivin is over-
expressed in a plethora of cancers, including melanoma17, gastric cancer18, lymphoma19-21, 
NSCLC22 and RCC.23, 24 High survivin expression correlates with metastatic spread, tumor 
invasiveness and poor prognosis arising from chemoresistance.1, 25 Because survivin is rarely 
expressed in terminally differentiated adult tissues and is among the most tumor specific of all 
gene products, there is considerable interest in its potential as a target for anti-cancer therapy.26-
29       
Figure 1.1. Small molecules with anticancer activities reportedly linked to suppression or 
inhibition of survivin. 
 
Despite its potential as an anticancer target, few small molecule inhibitors of survivin have been 
reported to date. The more widely cited members are listed in Figure 1.1. The 
dioxonaphthoimidazolium YM155 is arguably the most widely investigated survivin suppressant 
to date.  It was discovered in 2010 by Astellas Pharma, a Japanese pharmaceutical company 
during a high-throughput screen for survivin suppressants in a gene promoter assay.1 YM155 
will be discussed in greater detail in Section 1.2. Like YM155, FL118 was discovered in a high-
throughput screen for suppressors of survivin.30, 31 FL118 downregulates the expression of 
survivin, two other IAP proteins (XIAP, c-IAP2) and Mcl1, an anti-apoptotic member of the Bcl-2 
family of proteins. Terameprocol is a synthetic lignan derivative of nordihydroguaiaretic acid 
found in extracts of the creosote bush.32 It downregulates survivin by inhibiting the function of 
the transcription factor specificity protein 1 (Sp1).33 YM155, terameprocol and FL118 are 
transcriptional inhibitors of survivin gene expression and do not directly interact with the survivin 
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protein. This raises the question as to whether these compounds suppress survivin solely by 
inhibiting its gene expression or if they have other protein targets that lie upstream from survivin 
and whose interception would also result in the suppression of survivin. 
 
Unlike the aforementioned compounds, the 5-deazaflavin analog is unique in that it directly 
interferes with the interaction between survivin and the pro-apoptotic Smac/DIABLO.11 
Consequently, Smac/DIABLO is free to bind to XIAP, hence preventing it from binding and 
inhibiting caspases.  
 
1.2. YM155: A potent anticancer agent  
YM155 is a potent survivin suppressor. It downregulates survivin expression in prostate cancer 
PC3 cells at nanomolar concentrations and has potent growth inhibitory activities on a variety of 
refractory prostate cancer and melanoma cell lines, besides suppressing  the growth of tumor-
bearing xenografts in mice when delivered via subcutaneous pumps.34 
 
Subsequent studies affirm the potent growth inhibitory activity of YM155 on a wide panel of 
malignant cell lines.35 These include cells derived from solid tumors (non-small cell lung cancer 
(NSCLC), small cell lung cancer, renal cancer, colorectal cancer, breast cancer), hemapoietic 
malignancies (lymphomas, leukemias) and brain malignancies (gliomas). Overall, the mean 
concentration for 50% inhibition of cell growth (GI50) was less than 16 nM. Cell lines with or 
without an intact p53 gene were equally susceptible to YM155, suggesting limited involvement 
of p53 in the mechanism of action. 
 
Following its promising in vitro results, YM155 was evaluated in phase I and phase II clinical 
trials. It was reported to achieve a 5.4% overall response rate in stage III/IV non-small cell lung 
cancer (NSCLC) patients with another 37.8% of patients attaining a stable disease state .36 In 
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patients with stage III/IV melanoma, the overall response rate was only 3.4%.37 YM155 also 
produced a 6.2% partial response rate in patients with taxane-pretreated prostate cancer.38 
More recently, YM155 and docetaxel were used in combination for the treatment of stage IV 
triple-negative breast cancer39 and stage III/IV melanoma40. In both cases, YM155 did not 
confer any significant benefit when combined with docetaxel. The modest response rates 
notwithstanding, YM155 was well tolerated in the clinical trials and was associated with only 
rare incidences of high-grade toxicities. 
 
Many factors could have accounted for the modest response rates of YM155 in the clinical trials. 
For one, the majority of patients involved in the trials had highly resistant tumors that failed to 
respond to prior chemotherapy. The other reason may be that the mechanistic basis for the 
anticancer activity of YM155 has yet to be fully understood. YM155 may thus be suited for 
certain cancers only or should be used in combination, rather than a single drug. In addition, 
YM155 is positively charged and this physicochemical characteristic might affect its ability to 
penetrate tumors and malignant cells.  
 
1.3. Mode of action of YM155 
YM155 intercepts the binding of various transcription factors to the survivin promoter. One of 
these is the interleukin enhancer-binding factor 3 (ILF3), or more specifically its nuclear factor 
110 (NF110) isoform.41, 42 YM155 blocks ILF3 from binding to the survivin promoter by 
interfering with the association of ILF3 and p54nrb.42 YM155 also interferes with the binding of 
the transcription factor Sp1 to the survivin promoter region (-149 to -71).43 The survivin gene is 
activated by other transcription factors as well, such as nuclear factor-kappa B (NF-κB)44, 45 and 
signal transducer and activator of transcription 3 (STAT3).46 In view of its exceptionally potent 
activity as a survivin suppressant, it is tempting to speculate that YM155 acts on other 




Figure 1.2. Schematic diagram of the interactions between Bcl-2 family (boxed in blue), 
caspases (boxed in orange) and the IAP family including survivin. Upon apoptotic stimuli, BH3-
only members such as Noxa Puma, Bid, Bad, which possess only a BH3 (Bcl-2 homology 3) 
domain sequester anti-apoptotic Bcl-2, Bcl-xl and Mcl1 which are bound to BAX and BAK. This 
releases the latter pro-apoptotic proteins which oligomerize and open pores in the mitochondrial 
outer membrane. Subsequent release of cytochrome C activates caspase 9, which in turn 
cleaves and activates caspases 3 and 7, the effectors of apoptosis. Survivin and the other IAPs 
(inhibitors of apoptosis) bind to and inhibit caspase function.  
 
Reports in recent literature support an alternative view that the suppression of survivin gene 
transcription is not the sole means by which YM155 induces cell death. A widely cited target of 
YM155 is Mcl1, a member of Bcl-2 family of proteins.47-49  Mcl1, like Bcl-2 and Bcl-xl are anti-
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and BAK, preventing the latter from oligomerization and forming pores on the outer 
mitochondrial membrane, which is an essential step in the intrinsic apoptotic pathway.47, 48 The 
pores permeabilize the mitochondrial membrane and cause cytochrome c to be released from 
the intermembrane space. This is turn leads to the formation of the apoptosome and activation 
of the caspase cascade, which begins with the stepwise activation of initiator caspases (such as 
caspase 9) followed by executioner caspases 3 and 7. In a detailed study, Tang et al  
demonstrated that downregulation of Mcl1 by YM155 occurred at the transcriptional level and 
was independent of survivin expression and caspase activity.49 The downregulation of Mcl1 by 
YM155 has been usefully exploited by combining it with BH3-only peptidomimetics ABT-263 
and ABT-737.49, 50 ABT-263 and ABT-737 inhibit Bcl-2 and Bcl-xl and cause apoptosis in cancer 
cells. However, cells with high Mcl1 expression bypass this inhibition by compensating for the 
functions of Bcl-2 and Bcl-xl, thus reducing the apoptotic effects of ABT-263 and ABT-737. On 
the other hand, when YM155 was used together with these compounds, the concurrent 
downregulation of Mcl1 synergized with the inhibition of Bcl-2 and Bcl-xl to restore apoptotic cell 
death.  
 
YM155 has been reported to downregulate EGFR in pancreatic cancer cell lines, leading to the  
suppression of downstream proteins PI3K, p-ERK and p-STAT3.51 It also downregulates 
XIAP.50, 52 Dohi et al noted that XIAP forms a complex with survivin which protects XIAP from 
ubiquitination and proteasomal degradation.53 The concurrent downregulation of survivin and 
XIAP by YM155 would result in synergistic inhibition of apoptosis. A transcriptome analysis of 
Wilms’ tumor cells treated with YM155 revealed down-regulation of several other genes besides 
survivin as well as the up-regulation of the pro-apoptotic genes caspase 9 and Smac/DIABLO. 
That study also highlighted tumor necrosis factor receptor 1 (TNFR1) signaling as one of the 




A widely cited claim for YM155 is its ability to induce a DNA damage response.55 Here, the 
authors subjected YM155 and another dioxonaphthoimidazolium analog (NSC80467) to the 
COMPARE analysis against two DNA damaging agents (chromomycin A3, bisantrene) and a 
DNA directed inhibitor of transcription (actinomycin D). Briefly, this analysis involved elucidating 
the GI50 values for the above agents on the NCI-60 panel of 60 malignant cell lines representing 
a large variety of cancer types. The GI50 values for YM155 and NSC80467 were then correlated 
with those of the three reference compounds. It was found that the growth inhibitory profiles of 
the two dioxonaphthoimidazoliums were strongly and positively correlated to that of the three 
DNA targeting agents. YM155 and NSC80467 were then shown to preferentially inhibit DNA 
synthesis over RNA and protein synthesis. Subsequently, they demonstrated that YM155 and 
NSC80467 effectively stimulated the phosphorylation of the histone H2AX and the 
transcriptional repressor KAP1 at concentrations lower than that required to reduce survivin 
levels. Phosphorylated H2AX (γH2AX) and phosphorylated KAP1 (pKAP1) are biomarkers for 
DNA double stranded breaks, and their appearance at concentrations of YM155 that did not 
induce a decline in survivin levels was taken to signify that survivin suppression was secondary 
to the DNA damage response.  
 
A separate study by Winter et al showed that YM155 induced a dose dependent increase in 
γH2AX and pKAP1.56  It also interfered with topological changes in plasmid DNA caused in vitro 
by topoisomerase treatment. In this regard, YM155 behaved like ethidium bromide, an 
intercalator of DNA. Furthermore, YM155 did not inhibit topoisomerase I or interfered with DNA 
replication. The authors concluded that YM155 has the features of a DNA intercalator. They 
noted that chloroquine, another DNA intercalator also inhibited DNA replication and induced 




The proposition that YM155 intercalates with DNA is consistent with its structural features. The 
positively charged planar scaffold of YM155 would strongly promote DNA intercalation. A point 
to note is that YM155 is also a quinone and this moiety is an established pharmacophore for 
redox cycling.57 It is conceivable that free radicals generated during the quinone to semiquinone 
interconversion could initiate DNA strand breaks and trigger the DNA damage response as 
proposed by Glaros et al.55 If YM155 is indeed a DNA damaging agent, this would call into 
question its relatively low toxicity profile as reported in clinical trials. Anticancer drugs that act by 
inducing DNA damage are unlikely to act selectively on cancer cells and would elicit severe side 
effects. Doxorubicin and irinotecan are such examples. Interestingly, Cheng et al reported that 
the silencing of survivin with siRNAs resulted in elevated levels in γH2AX.52 This raises the 
question as to whether the increases in γH2AX are due to YM155-induced DNA damage or is 
an outcome of survivin suppression. Furthermore, work by Véquaud et al. suggested that DNA 
damage was a consequence of autophagy which was in turn a consequence from an unknown 
mechanism of action of YM155 on the NF-κB pathway. From the foregoing discussion, it is clear 
that important unknowns remain with regard to the interaction of YM155 and DNA and its 
significance to the mode of action of YM155.  
 
Table 1.1. Summary table of research investigating the mechanisms of action of YM155. 
Research Group Year Mechanism 
Nakahara et al.34 2007 - ↓ survivin 
Nakamura et al.41 2012 - Blocks ILF3 binding to survivin promoter 
Yamauchi et al.42 2012 - Blocks ILF3-p54nrb association 
Cheng et al.43 2012 - Blocks Sp1 binding to survivin promoter 
Na et al.51 2012 - ↓ EGFR, PI3K, p-ERK, p-STAT3 and XIAP 
Glaros et al.55 2012 - Damages DNA 
- ↑ γH2AX, pKAP1 
Tao et al.54 2012 - Affects TNFR1 signaling 
Winter et al.56 2015 - Intercalates and damages DNA 
Cheng et al.52 2015 - Induces autophagy 
- ↑ LC3-II (autophagy marker) 
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Véquaud et al.58 2015 - ↑ LC3-II 
- NF-κB pathway implicated in autophagy and DNA damage 
 
1.4. Uptake of YM155 into cancer cells 
Another aspect of YM155 that has received considerable attention is its uptake by malignant 
cells. The charged state of YM155 would hamper its diffusion into cells. Thus physiological 
transporters may be involved in its uptake into cells. Early investigations on the cellular uptake 
of YM155 showed that the mechanisms by which YM155 gained access into cancer cells and 
hepatocytes were distinctly different.59-61 The organic cation transporter OCT1 played a key role 
in uptake into hepatocytes but not into cancer cells. The implication was that a yet to be 
identified transporter(s) was involved and this was indeed proven by Winter et al when they 
reported the involvement of a relatively uncharacterized transporter, the solute carrier family 
member 35F2 (SLC35F2), in the uptake of YM155 into cancer cells.56 SLC35F2 was 
upregulated in several cancers and in the absence of SLC35F2, growth inhibition by YM155 
was greatly attenuated. Additionally, SLC35F2 expression and YM155 sensitivity were 
correlated across a panel of cancer cell lines. The authors noted that YM155 retained some 
growth inhibitory activity on SLC35F2 knockout cells, suggesting that OCT still had a role in the 
uptake of YM155. Taken together, the mechanism by which YM155 gains access into cancer 
cells is clearly as important as its binding targets in defining the mechanistic basis of its mode of 
action.  
 
1.5. YM155 inhibits teratoma formation 
Survivin is found in abundance in primary tumors but rarely expressed in terminally 
differentiated cells. It is however present in fetal tissues, actively dividing tissues such as those 
of hematopoietic lineage, and in stem cells of embryonic and mesenchymal origin.26, 62-66 Its 
presence in undifferentiated stem cells is traced to the need for stem cells to maintain low 
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mutation frequencies in order to ensure the genomic integrity of subsequent generations of 
somatic cells. Consequently, stem cells preferentially succumb to cell death under genotoxic 
stress rather than resorting to DNA repair. To achieve this end, stem cells express a large 
number of pro-apoptotic genes and relatively fewer anti-apoptotic genes compared to their 
differentiated counterparts. The abundance of pro-apoptotic genes would mean that the survival 
and self-renewal of stem cells are critically dependent on the few resident anti-apoptotic genes, 
including survivin. This was illustrated by Guvenc et al where glioma stem cells lost viability 
when protein interactions of survivin were inhibited.67 
 
In 2013, Lee et al showed that nanomolar concentrations of YM155 induced apoptosis in human 
pluripotent stem cells.68  This effect was attributed to the suppression of survivin and was 
proposed as a viable means of eliminating remnant rogue undifferentiated stem cells which 
would otherwise transform into teratomas or teratocarcinomas. Teratoma formation would 
seriously undermine the safety of stem cell-based therapies.69, 70 There has been growing 
interest in the use of small molecules like YM155 to eliminate remaining undifferentiated 
pluripotent cells from differentiated populations destined for regenerative therapies. Ideally, 
these compounds should selectively eliminate undifferentiated stem cells without affecting 
lineage specific differentiation or functionality of differentiated cells. 
 
1.6. Hypothesis 
YM155 is a dioxonaphthoimidazolium analog with exceptionally potent growth inhibitory activity 
on a variety of cancer cell lines. In spite of its potent activity and good safety profile, it has failed 
to perform to expectations in clinical trials. One of the reasons for its poor showing may stem 
from gaps in our understanding of the mechanistic basis of its cell killing effects. YM155 is 
commonly cited as a survivin suppressant but recent findings have questioned if this is the sole 
and main effect of the drug. The likelihood of DNA as a target of YM155 has been proposed by 
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several investigators and in its wake, caution has been advised with regards to its clinical 
deployment. There is also limited information on structure-activity correlations with regard to 
YM155. 
 
Against this backdrop, it is hypothesized that a detailed understanding of selected aspects of 
the mode of action of YM155 will promote the development of dioxonaphthoimidazolium analogs 
as potent anti-cancer therapeutics.  
 
To this end, the focus will be on DNA and the NF-κB signaling pathway as putative targets of 
YM155. A focused library of functionalized dioxonaphthoimidazoliums will be synthesized and 
structure-activity relationships (SAR) elucidated for growth inhibitory activity on malignant cells 
and stem cells, DNA binding and redox cycling. These studies will (i) provide insight into the 
structural requirements for activity, (ii) support a reasoned approach towards the design of more 
potent analogs and (iii) validate DNA as a preferred target of the scaffold. 
 
With regards to the NF-κB pathway, it is known that survivin overexpression is a biological sequela 
of NF-κB activation in several malignancies. Hence, YM155 may conceivably disrupt the pathway 





Chapter 2: Design and synthesis of YM155 analogs 
2.1. The dioxonaphthoimidazolium analog YM155 
The structure of YM155 comprises the fused tricyclic dioxonaphthoimidazolium core and the 
substituents attached to the core. The tricyclic ring consists of a central quinone (B) flanked by a 
benzene ring (A) and positively charged imidazolium (C) (Figure 2.1). The substituents are 
found exclusively on the imidazolium ring. The positively charged state and embedded quinone 
in YM155 are not commonly present in drugs. Drug candidates which are positively charged are 
normally deemed to have suboptimal permeability and may be overly dependent on specific 
transporters for uptake into cells. The quinone is an acknowledged PAIN (Pan-Assay 
Interference compound) because of its potential for redox cycling.71 Notwithstanding, YM155 
complies with the Rule-of-Five mnemonic which predicts candidates with good oral absorption 
profiles. It has a cLog P that is less than 5, fewer than 5 hydrogen bond donor (HBD) and 10 
hydrogen bond acceptor (HBA) groups and a molecular weight that does not exceed 500 Da.  
 
Figure 2.1. Molecular structure of YM155. The positive charge is delocalized between N1 and 
N3. 
 
There are limited references to the structure-activity relationship (SAR) of YM155 despite 
detailed description of more than 250 related analogs in the original patent .72 There, growth 
inhibitory activities (IC50) were determined on HelaS3 and melanoma A375 cells but the results 
were reported as “1 µM or less” for the entire series, without details on structure-activity trends. 
In a report that predated the patent by almost a decade, a dioxonaphthoimidazole 1 (Figure 2.2) 
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was found to be cytotoxic with a mean IC50 of 2.3 µM on tumor cell lines of the NCI panel.73 Its 
good activity raises the question as to whether the positive charge on the YM155 scaffold was a 
necessary feature. Furthermore, two intermediates (2, 3) involved in the synthesis of 1 and 
related compounds were equally active, which adds to the uncertainty over the role of the 
dioxonaphthoimidazolium scaffold for growth inhibition. 
 
Figure 2.2. Naphtho[2,3-d]imidazole-4,9-dione 1 and intermediates (2,3) with anticancer activity 
on NCI cancer cell lines.  
 
Another report highlighted the growth inhibitory property of functionalized imidazoliums (Figure 
2.3).74, 75 Two hits IBN-1 and IBN-9 were identified, with IC50 values of 100 μM and 120 μM 
respectively on a hepatocellular carcinoma (HCC) cell line. Although much less potent than 
YM155, they were reported to down-regulate survivin. Further optimization yielded a more 
potent analog (IBN-65, IC50  5 μM on a panel of HCC cell lines) which also suppressed 
survivin. This again raises the question as to whether the intact dioxonaphthoimidazolium 
scaffold of YM155 is required for growth inhibition and survivin suppression.  
 





The objective of this chapter is to design and synthesize a series of dioxonaphthoimidazolium 
analogs in order to address the research gap that exists in the understanding of the SAR of 
YM155. To achieve this end, a focused library comprising 53 compounds were designed and 
synthesized. The compounds were organized into four series. Series A compounds focused on 
modifications to the pyrazin-2’-ylmethyl side chain located at N3 of YM155 with no change to the 
2’-methoxyethyl side chain at N1. Conversely, series B compounds dealt with modifications to 
the N1 2’-methoxyethyl side chain while retaining the N3 pyrazin-2’-ylmethyl side chain. Series C 
consisted of compounds modified at the core dioxonaphthoimidazolium scaffold. Series AB was 
conceived after the evaluation of the preceding series and sought to validate the SAR gleaned 
from series A and B by combining promising substituents identified from these series onto a 
common scaffold. Hence, its designation as “series AB”.  
 
2.3. Rationale for design of compounds 
2.3.1. Series A 
The 22 compounds in series A are shown in Figure 2.4. They are subdivided into A1-X to A6-X 
subgroups base on the nature of the N3 side chain. A1-1 to A1-3 replaces the polar pyrazine 
ring on YM155 with non-polar rings such as phenyl (A1-1), cyclohexyl (A1-2) and thienyl (A1-3). 
These replacements serve to elucidate the importance of retaining a polar heteroaromatic ring 
at N3.  
 
Attempts were made to introduce azoles (pyrrole, N-methylpyrrole, imidazole) in place of 
pyrazine at N3. Only the imidazol-4’-ylmethyl analog A2-1 was successfully synthesized. The 
imidazole ring of A2-1 is electron rich (-excessive) unlike pyrazine which is electron poor (-
deficient). The azomethine N in imidazole is also more basic (pKa  7) than those present in 
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pyrazine and would be protonated at physiological pH. Thus, greater polarity would be expected 
for A2-1. 
 
Figure 2.4. Series A analogs. a Compounds have been reported in SciFinder 
 
In the A3-X subgroup, the pyrazine ring was replaced by an assortment of azines. A3-1, A3-2, 
A3-3 are regioisomeric pyridinylmethyls, in which the azomethine N is ortho, meta or para. 
These compounds would determine if the location of the azomethine N in pyridine is an 
important determinant of activity. A3-4, A3-5, A3-6 are regioisomeric pyrimidinylmethyls in 
which the azomethine nitrogens are positioned at ortho (A3-4), ortho-para (A3-5) or meta (A3-6) 
positions. Like the pyridinylmethyls, they serve to report on the importance of positional 
isomerism in the pyrimidinylmethyl side chain. A3-7 is pyridazin-4’-ylmethyl. The pyridazin-3’-
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ylmethyl regioisomer could not be prepared because the starting material was not available. A3-
8 is essentially YM155 with a para-methyl attached to the pyrazine ring. It was synthesized after 
A3-3, A3-5 and A3-7 were found to have greater growth inhibitory properties than their 
regioisomers. Since they have in common an azomethine nitrogen at the para position of the 
azine, A3-8 was designed to query the effect of “blocking” putative interactions at that position. 
 
A4-1 and A5-1 are homologs of YM155 in which the methylene spacer linking the pyrazine ring 
to N3 is either extended to ethyl or removed altogether. Lastly, the A6-X subgroup examines the 
impact of removing the pyrazinylmethyl moiety. In A6-1, it is replaced by methoxyethyl, thus 
yielding an N1, N3-symmetrically substituted analog. In A6-2 to A6-8, it is replaced by a series of 
homologous alkyl substituents (methyl to n-butyl), branched analogs (isopropyl, isobutyl) and 
cyclopropyl.  
 
2.3.2. Series B 
There are 15 compounds in series B (Figure 2.5) and they are organized into four subgroups 
B1-X to B4-X. In B1-X, the terminal methoxy of the N1 methoxyethyl side chain was removed to 
give the hydroxyl (B1-1), incorporated into a tetrahydrofuran ring (B1-2) or extended to its ethyl 
homolog (B1-3). The additional hydrogen bonding group in B1-1 will increase polarity whereas 
homologation/cyclization will increase lipophilicity and steric bulk. 
 
B2-X is the largest subgroup with 8 members and they serve to investigate the effects of 
replacing the 2’-methoxyethyl side chain with the same alkyl residues explored in series A.  Also 
included is the cyclopentyl side chain (B2-8) which has no series A counterpart. Aromatic side 
chains are introduced in B3-1 and B3-2 in lieu of the methoxyethyl group. B3-2 is analogous to 
A6-1 in that both compounds are symmetrically substituted at N1 and N3. B3-2 is symmetrically 
substituted with pyrazine-2’-ylmethyl moieties. In B4-1 and B4-2, the 2’-methoxyethyl is 
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replaced by a basic N’,N’-dimethylaminoethyl or N’,N’-diethylaminoethyl side chain which would 
be protonated at pH 7. Consequently, increased polarity would be expected for these 
compounds.  
 
Figure 2.5. Series B analogs. B3-2 has been reported in SciFinder 
 
2.3.3. Series C 
The series C compounds were designed to probe the importance of the intact 
dioxonaphthoimidazolium scaffold for activity (Figure 2.6). C1-1 which features an extension of 
the C2 methyl is an exception. In C1-2, the scaffold is reduced to a dihydrobenzo[d]imidazolium 
by the removal of the distal benzene ring. Two methyl groups were introduced at C5 and C6 of 
the quinone ring to reduce the reactivity of these positions to Michael addition by nucleophiles. 
In C2-X, the quinone is removed from the scaffold to give the benzoimidazolium C2-1 and 
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imidazolium C2-2 or replaced to give the imidazoquinoxalinium C2-3. C2-2 is structurally similar 
to the IBN compounds which have been reported to be survivin suppressants.79,80 The central 
pyrazine ring of C2-3 is deemed an appropriate isostere of the quinone because the azomethine 
nitrogens are hydrogen bond acceptors like the quinone carbonyls. 
 
Figure 2.6. Series C analogs. C1-1, C1-2, C2-1, C2-2 and C2-3 were synthesized as bromides. 
C4-1 and C4-2 have been reported in Scifinder. 
 
The indoles C3-1 and C3-2 were designed in attempts to scaffold hop. They can also be viewed 
as a modification of C2-1 in which the charged benzoimidazolium is replaced by an uncharged 
indole. C4-1 and C4-2 are analogs of compound 1 (Figure 2.1) and would report on the 
importance of retaining the positive charge on the scaffold. Without the charged centre, only one 
of the two side chains of YM155 can be introduced to the scaffold and this was done in turn for 
C4-1 and C4-2. C4-1 and C4-2 should also be compared to B2-1 and A6-2 respectively as they 
are essentially the N3-demethylated analogs of these compounds. These comparisons will 




Lastly, two other analogs were considered (Figure 2.7). Denoted C5-1 and C5-2, these are 
pyrrolo[2,3-b]naphthoquinone analogs of YM155 where one of the imidazolium nitrogens is 
replaced by a carbon. These analogs would complement C4-1 and C4-2 with regard to the 
importance of the positive charge. Unfortunately, they were not synthetically accessible and 
were dropped from the final library. 
 
 
Figure 2.7. Analogs C5-1 and C5-2. 
 
2.3.4. Series AB 
 
Figure 2.8. Series AB analogs. Compounds were synthesized as bromides. AB7 has been 




Series AB compounds are planned after assessing the growth inhibitory activities of series A 
and B on clear cell renal cell carcinoma (ccRCC) and non-small cell lung carcinoma (NSCLC) 
cell lines. A3-3, B2-2 and B2-5 were found to be the most potent members in their respective 
series. Thus, the N3 (pyridine-4’-ylmethyl, A3-3) and N1 (ethyl, B2-2; cyclopropyl, B2-5) side 
chains are introduced simultaneously to the dioxonaphthoimidazolium scaffold in the 
anticipation that it will result in compounds of comparable or superior activity to YM155. The 
resulting compounds are AB1 and AB2 (Figure 2.8). To validate the preceding approach, less 
optimal substituents identified in series A such as pyrimidin-5’-ylmethyl, pyridine-3’-ylmethyl and 
methyl are also introduced at N3. In AB3 – AB6, N1 is ethyl or cyclopropyl. Special mention 
should be made of AB7 because it is substituted with methyl groups at both N1 and N3. 
Consequently, it is the most minimally substituted YM155 analog investigated here. AB7 was 
conceived after observing the good growth inhibitory properties of A6-2 (N3-methyl) and B2-1 
(N1-methyl). 
 
The detailed SAR and growth inhibitory activities of the series A, B, C and AB compounds are 
discussed in Chapter 3.  
 
2.4. Chemistry 
2.4.1. Synthesis of series A, B and AB 
The synthesis of compounds in series A, B and AB followed the general method described in 
the literature.72 As shown in Scheme 2.1, nucleophilic displacement of chlorine in 2,3-dichloro-
1,4-naphthoquinone was effected by a primary amine in the presence of triethylamine to yield 
compounds 4-15. The amino nitrogen was then acetylated to give N-acetylamides 16-27, 
followed by displacement of the second chlorine by another primary amine to give compounds 
28-70. Finally, ring closure was effected by hydrobromic acid to give the final compounds 




Scheme 2.1. Reagents and conditions: (a) R1-amines, EtOH, rt, 18 h; (b) acetic anhydride, 
conc. H2SO4, rt, 1.5 h; (c) R2-amines, toluene, 45°C, 4 h; (d) 48% HBr (aq), EtOH + EtOAc, 
45°C, 4 h to rt, overnight.  
 
A different route was applied for the synthesis of A5-1. The N-acetylamide 16 was subjected to 
a modified Buchwald-Hartwig coupling reaction with 2-aminopyrazine to give 71, followed by 
ring closure in the presence of hydrobromic acid (Scheme 2.2). 
 
Scheme 2.2. Reagents and conditions: (a) 2-aminopyrazine, Pd(dba)2, BINAP, t-BuOK, toluene, 
60°C, 5 h; (b) 48% HBr (aq), EtOH + EtOAc, 45°C, 4 h to rt, overnight. 
 
2.4.2. Synthesis of series C 
Scheme 2.1 also applied to the Series C compounds C1-1, C1-2 and C2-3 with some 
modifications. To obtain C1-1, propionic anhydride was used in place of acetic anhydride for the 
acylation of 4. The resulting N-propionate 72 was reacted with pyrazin-2-ylmethylamine to afford 
73 which was then cyclized to C1-1. In the case of C1-2 and C2-3, the same sequence of 
reactions were followed starting from 2,3-dichloro-5,6-dimethyl-1,4-benzoquinone and 2,3-
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dichloroquinoxaline respectively, except that the initial displacement of chlorine was effected by 
pyrazin-2-ylmethylamine and not 2-methoxyethylamine as shown in Scheme 2.3.  
 
Scheme 2.3. Reagents and conditions: (a) pyrazin-2-ylmethylamine, triethylamine; (b) acetic 
anhydride, conc. H2SO4; (c) 2-methoxyethylamine, toluene; (d) 48% HBr (aq), EtOH + EtOAc, 
45°C, 4 h to rt, overnight. 
The benzimidazolium C2-1 and imidazolium C2-2 were synthesized by N-alkylation with 2-
methoxyethyl bromide to give 77 and 78 respectively, followed by quaternization of the 
azomethine nitrogen with 2-bromomethylpyrazine.76, 77 Scheme 2.4 outlines the synthesis of C2-
1, which also applies to C2-2. 
 
Scheme 2.4. Reagents and conditions: (a) 2-methoxyethyl bromide, KOH, DMSO, rt, 1.5 h; (b) 
2-bromomethylpyrazine, CH3CN, 80°C, 24 h. 
 
Scheme 2.5 outlines the syntheses of the isomeric indoles C3-1 and C3-2. 2-Methylindole was 
reacted with pyrazin-2-carbaldehyde in the presence of triethylsilane and trifluoroacetic acid to 
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give 8278 which was then N-alkylated in the presence of KOH in DMSO to afford C3-1.79 In the 
case of C3-2, 2-methylindole was reacted with methyl magnesium bromide at the indole 
nitrogen, followed by electrophilic substitution at C3 with 2-methoxyethyl bromide.54 The 
pyrazinylmethyl side chain was then introduced at the indole N in the usual way.79 
 
Scheme 2.5. Reagents and conditions: (a) pyrazin-2-carbaldehyde, Et3SiH, TFA, DCM, 0°C, 1 
h; (b) 2-methoxyethyl bromide, KOH, DMSO, rt, 1.5 h; (c) MeMgBr, dry toluene, DCM, 0oC, 30 
min; (d) 2-methoxyethyl bromide, 0oC  40oC, 24 h; (d) 2-bromomethylpyrazine, KOH, DMSO, 
rt, 30 min.  
 
The synthesis of C4-1 and C4-2 was adapted from Scheme 2.1. Nucleophilic displacement of 
chlorine in 2,3-dichloro-1,4-naphthoquinone with concentrated ammonia gave 84, followed by 
acetylation by acetic anhydride to give 85. Nucleophilic displacement of the second chlorine by 
2-methoxyethylamine or pyrazin-2-ylmethylamine yielded 86 and 87 respectively. Finally, ring 






Scheme 2.6. Reagents and conditions: (a) NH3 in MeOH, EtOH, 35°C, 3 h; (b) Acetic 
anhydride, conc. H2SO4, rt, 1.5 h; (c) 2-methoxyethylamine/pyrazin-2-ylmethylamine, 
triethylamine, toluene + EtOh, 45°C, 1h; (d) 48% HBr (aq), 2 drops of 2M NaOH(aq), EtOH, 
50°C, 1 h. 
 
2.5. Experimental 
2.5.1. General details 
Reagents (synthetic grade or better) were obtained from commercial sources and used without 
further purification. Reactions were monitored by thin layer chromatography using pre-coated 
aluminium plates (silica gel 60, F254, Merck). Compounds were purified by column 
chromatography on silica gel 60 (230-400 mesh, Merck).1H NMR spectra (400 MHz) were 
recorded on a Bruker Avance 400 Ultrashield instrument (Bruker, Billerica, MA, USA), and 
referenced to residual solvent peaks (CDCl3 at δ7.26, D6-DMSO at δ2.50). 13C NMR spectra 
(100 MHz) were recorded on the same instrument and referenced to residual solvent peaks 
(CDCl3 at δ77.00, D6-DMSO at δ39.40). Coupling constants (J) were reported in Hertz (Hz).  
 
Nominal mass spectra were captured on an AB Sciex QTrap 2000 mass spectrometer (AB 
Sciex, Framingham, MA, USA) by electrospray ionization (ESI). Accurate mass information was 
obtained on a Bruker micrOTOFQII mass spectrometer (Bruker, Billerica, MA, USA) by ESI. 
Purity was determined on a reverse-phase HPLC on a Shimadzu Nexera SR HPLC system 
(Shimadzu Scientific Instruments, Columbia, MD, USA) with a Zorbax Eclipse XDB-C18 column 
(Agilent Tech. Inc., Loveland, CO) at two wavelengths: 254 and 280nm. Solvent systems used 
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as well as purity values are provided in Appendix 1. Purity of C2-3 was determined by elemental 
analysis (C, H, N) with the Elementar Vario Micro Cube instrument (Elementar 
Analysensysteme GmbH, Hanau, Germany). 
 
Spectral characteristics and purity data of intermediates and final compounds are reported in 
Appendix 1. The synthetic details of promising analogs AB1, AB7 and the intermediates leading 
up to these two promising analogs are outlined in the following sections. 
 
2.5.2. Synthesis of 2-chloro-3-(methylamino)-1,4-naphthoquinone (7) 
To 2,3-dichloro-1,4-naphthoquinone (0.341g, 1.50mmol) in 1.5ml of ethanol was added 
methylamine (0.0465g, 1.50mmol) and triethylamine (0.227g, 2.25mmol) and the mixture stirred 
at r. t. for 18h. The red precipitate formed was filtered under suction, washed with distilled water 
and dried to afford (7) as a red solid, 91.0%. 1H (CDCl3) δ 8.15 (dd, 1H, J=0.9, 7.7Hz), 8.03 (dd, 
1H, J=0.9, 7.7Hz), 7.72 (dt, 1H, J=1.3, 7.6Hz), 7.62 (dt, 1H, J=1.3, 7.6Hz), 6.10 (br s, 1H), 3.45 
(d, 3H, J=5.6Hz); 13C (CDCl3) δ 180.53, 144.89, 134.94, 132.78, 132.45, 132.39, 129.74, 
126.84, 126.76, 32.55. 
 
2.5.3. Synthesis of 2-chloro-3-cyclopropylamino-1,4-naphthoquinone (11) 
To 2,3-dichloro-1,4-naphthoquinone (0.341g, 1.50mmol) in 1.5ml of ethanol was added 
cyclopropylamine (0.0856g, 1.50mmol) and triethylamine (0.227g, 2.25mmol) and the mixture 
stirred at r. t. for 18h. The red precipitate formed was filtered under suction, washed with 
distilled water and dried to afford (11) as a red solid, 93.9%. 1H (CDCl3) δ 8.16 (dd, 1H, J=1.1, 
7.7Hz), 8.02 (dd, 1H, J=1.1, 7.7Hz), 7.72 (dt, 1H, J=1.3, 7.6Hz), 7.62 (dt, 1H, J=1.3, 7.6Hz), 
6.12 (br s, 1H), 3.34-3.28 (m, 1H), 0.97-0.92 (m, 2H), 0.78-0.73 (m, 2H); 13C (CDCl3) δ 180.27, 




2.5.4. Synthesis of N-(3-chloro-1,4-dioxo-1,4-dihydro-naphthalen-2-yl)-N-methyl-acetamide 
(19) 
Two drops of concentrated sulfuric acid were added to a suspension of (7) (0.443g, 2.00mmol) 
in acetic anhydride (1.84g, 18.0mmol) and stirred for 1.5h at r. t. 10ml of distilled water was 
added slowly to the reaction mixture with stirring to quench excess anhydride, and extracted 
with EtOAc. The organic layer was washed with saturated NaHCO3 solution and brine and dried 
over anhydrous Na2SO4. Purification by column (1:4 EtOAc/Hexanes) afforded (19) as a yellow 
solid, 92.6%. 1H (CDCl3) δ 8.28-8.08 (m, 2H), 7.86-7.77 (m, 2H), 3.19 (s, 3H), 1.93 (s, 3H); 13C 
(CDCl3) δ 183.10, 179.16, 177.84, 134.89, 134.77, 134.72, 134.69, 134.62, 134.16, 131.31, 
127.57, 40.11, 21.76. 
 
2.5.5. Synthesis of N-(3-chloro-1,4-dioxo-1,4-dihydro-naphthalen-2-yl)-N-cyclopropyl-
acetamide (23) 
Two drops of concentrated sulfuric acid were added to a suspension of (11) (0.495g, 2.0mmol) 
in acetic anhydride (1.84g, 18.0mmol) and stirred for 1.5h at r. t. 10ml of distilled water was 
added slowly to the reaction mixture with stirring to quench excess anhydride, and extracted 
with EtOAc. The organic layer was washed with saturated NaHCO3 solution and brine and dried 
over anhydrous Na2SO4. Purification by column (1:4 EtOAc/Hexanes) afforded (23) as yellow 
plates, 89.1%. 1H (CDCl3) δ 8.20-8.12 (m, 2H), 7.84-7.74 (m, 2H), 3.27-3.17 (m, 1H), 2.43 (s, 
3H), 0.98-0.68 (m, 4H); 13C (CDCl3) δ 178.01, 134.81, 134.66, 134.56, 134.46, 134.29, 131.40, 
131.15, 127.43, 127.40, 31.31, 22.33, 8.86, 8.60. 
 
2.5.6. Synthesis of N-cyclopropyl-N-{1,4-dioxo-3-[(pyridin-4-ylmethyl)-amino]-1,4-dihydro-
naphthalen-2-yl}-acetamide (64) 
To a suspension of (23) (0.955g, 3.30mmol) in 5ml of toluene was added pyridin-4-
ylmethylamine (0.535g, 4.95mmol) and triethylamine (0.500mg, 4.95mmol) and stirred at 45°C 
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for 2h. The reaction mixture was cooled, and the precipitate was filtered under suction and 
washed with EtOH and distilled water to afford (64) as a yellow-brown solid, which was unstable 
and used immediately for the next step. 
 
2.5.7. Synthesis of N-[1,4-dioxo-3-methylamino-1,4-dihydro-naphthalen-2-yl]-N-methyl-
acetamide (70) 
To a stirred suspension of (19) (0.400g, 1.52mmol) in 2mL of toluene was added dropwise 
methylamine (0.0564g, 1.82mmol) and triethylamine (0.230g, 2.28mmol). The mixture was 
stirred at r.t for 1h. The precipitate was filtered under suction, washed with distilled water and 
EtOH to afford (70) as red solids, 62.0%. 1H (CDCl3) δ 8.15 (dd, 1H, J=0.8, 7.7Hz), 8.08 (dd, 1H, 
J=0.8, 7.7Hz), 7.78 (dt, 1H, J=1.3, 7.6Hz), 7.66 (dt, 1H, J=1.3, 7.6Hz), 6.24 (br s, 1H), 3.13 (s, 
3H), 3.11 (d, 3H, J=5.8Hz), 1.99 (s, 3H); 13C (CDCl3) δ 182.30, 179.35, 172.36, 144.11, 135.47, 
132.77, 132.66, 130.14, 126.86, 126.76, 118.44, 37.50, 30.65, 21.94. 
 
2.5.8. Synthesis of 1-cyclopropyl-2-methyl-4,9-dioxo-3-(pyridin-4-ylmethyl)-4,9-dihydro-1H-
naphtho[2,3-d]imidazol-3-ium hydrogen dibromide (AB1) 
48% Hydrobromic acid (30.0mmol) was added dropwise to a solution of crude (64) in a 4mL 
mixture of 1:1 EtOH/EtOAc and stirred at 45°C for 4h and subsequently r.t. for an additional 
12h. The reaction mixture was concentrated in vacuo and purified by column chromatography 
(8:92 MeOH/CH2Cl2) to afford (AB1) as a yellow solid, 22.0%. 1H (D6-DMSO) δ 8.76 (d, 2H, 
J=6.4Hz), 8.23 (dd, 1H, J=1.1, 7.7Hz), 8.09 (dd, 1H, J=1.3, 7.5Hz), 8.01 (dt, 1H, J=1.6, 7.6Hz), 
7.96 (dt, 1H, J=1.4, 7.5Hz), 7.72 (d, 2H, J=6.4Hz), 6.08 (s, 2H), 3.77-3.71 (m, 1H), 2.90 (s, 3H), 
1.43-1.38 (m, 2H), 1.30-1.26 (m, 2H); 13C (D6-DMSO) δ 174.87, 173.50, 155.98, 147.98, 146.17, 
135.58, 135.11, 132.51, 132.09, 131.24, 129.62, 127.16, 126.76, 123.23, 49.16, 29.84, 11.85, 
9.00. ESI-MS: m/z 344.1 [M-Br]+. High resolution MS (ESI) calcd for C21H18 BrN3O2 [M-
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Br]+ 344.1394. Found: 344.1405. HPLC purity: system A: 99.85% (254nm), 100.00% (280nm); 
system B: 99.38% (254nm), 99.40% (280nm). 
 
2.5.9. Synthesis of 1,2,3-trimethyl-4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium 
bromide (AB7) 
48% hydrobromic acid (10.0mmol) was added dropwise to a solution of (70) (0.263mg, 
1.0mmol) in a 1.5ml mixture of 1:1 EtOH/EtOAc and stirred at 40°C for 4h followed by r.t. for an 
additional 12h. The reaction mixture was concentrated in vacuo and purified by column 
chromatography (8:92 MeOH/CH2Cl2) to afford AB7 as a beige solid, 21.9%. 1H (D6-DMSO) δ 
8.18 (dd, 1H, J=3.3, 5.7Hz), 7.99 (dd, 1H, J=3.3, 5.7Hz), 4.13 (s, 6H), 2.79 (s, 3H); 13C (D6-
DMSO) δ 175.36, 153.39, 135.60, 131.91, 130.34, 127.18, 34.37, 10.17. High resolution MS 
(ESI) calcd for C14H13 BrN2O2 [M-Br]+ 241.0972. Found 241.0967. HPLC purity: system A: 
99.83% (254nm), 99.89% (280nm); system B: 99.74% (254nm), 99.74% (280nm). 
 
2.6. Summary  
53 analogs of YM155 were successfully synthesized and characterized by 1H-NMR, 13C-NMR 
and nominal mass. Of these 53, 32 compounds were not reported previously. Final compounds 
had acceptable purities (> 95%) when determined by reverse phase HPLC on two different 








Chapter 3: Growth inhibitory properties and structure-activity relationship of YM155 and 
analogs 
3.1. Objectives 
This chapter describes the growth inhibitory properties of YM155 and its synthesized analogs on 
a panel of clear cell renal cell carcinoma (ccRCC) and non-small cell lung cancer (NSCLC) cell 
lines. ccRCC and NSCLC are malignances that have few therapeutic options and were thus 
selected for investigation. Sections 3.2 and 3.3 provide an overview of the prevalence and 
etiologies of ccRCC and NSCLC, as well as the therapeutic agents that are currently used in the 
clinics. The objectives of this chapter are to (i) elucidate SAR, (ii) determine if there are 
overlapping structural requirements for these disparate malignancies and (iii) evaluate the 
selective activity of these compounds against malignant cells as compared to the non-malignant 
human lung fibroblast IMR-90 cells.   
 
3.2. Clear cell renal cell carcinoma (ccRCC) 
Renal cell carcinoma (RCC) constitute about 3% of all adult malignancies and 90-95% of renal 
cancers worldwide.80 It is gender related with a strong male dominance.81 There are various 
histological subtypes of RCC of which the clear cell subtype (ccRCC) is the most common and 
synonymous with renal cell carcinoma in terms of disease management.82, 83 
 
RCC is usually detected late due to the asymptomatic nature of the early stages of the 
disease.84 Consequently nearly 25-30% of patients present with metastasis at the point of 
diagnosis.85, 86 The prognosis is poor for these patients as surgery is not a viable option, the 
malignancy is highly resistant to  radiotherapy and chemotherapy87-90, and conventional 
chemotherapeutic agents such as vinblastine and 5-fluorouracil give dismal objective response 
rates ( 10%).89 These factors make metastatic RCC a highly lethal cancer, with a median 
survival of less than 13 months and a 5-year overall survival rate of less than 20%.81, 91 
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3.2.1. The von Hippel-Lindau gene and its role in ccRCC 
ccRCC is characterized by a unique set of genetic aberrations, the most prominent of which is 
the von Hippel-Lindau (VHL) tumor-suppressor gene. In more than 60% of sporadic ccRCC 
cases, the VHL gene and its associated downstream pathways are implicated in tumorigenesis. 
This aberration is also  manifested in von Hippel-Lindau disease, a rare familial disease where 
patients are predisposed to ccRCC in addition to other forms of cancers.81, 92 
 
The VHL gene is located on the short arm of chromosome 3 at the 3p25 position and encodes 
its protein product pVHL.93 pVHL is an essential part of the E3 ubiquitin ligase complex where it 
functions as the substrate recognition component of the hypoxia-inducible factor-α (HIF-α). HIF-
α senses hypoxia in cells and the VHL-HIF-α pathway is a critical physiological response to 
hypoxia. HIF-α exists in three isoforms (HIF-1α, HIF-2α, HIF-3α) of which HIF-2α is most 
commonly cited in the context of ccRCC carcinogenesis.94-96 
 
Under normal oxygen levels (normoxia), HIF-α is hydroxylated by prolyl hydroxylases and the 
presence of a hydroxylated proline promotes interaction with pVHL (Figure 3.1).97, 98 Interaction 
and binding between HIF-α and pVHL leads to polyubiquitination and proteasomal degradation 
by the 26S proteasome. Conversely, hypoxic conditions inhibit the prolyl hydroxylases, inhibit 
hydroxylation of HIF-α, and block its interaction with pVHL.99 Consequently, HIF-α levels are 
stabilized and dimerizes with HIF-β to give an active transcription factor complex which binds to 
its cognate hypoxia response element (HRE).98 This promotes the transcription of downstream 
target genes, many of which encode cytokines and proteins that are pivotal in relieving the cell 
of hypoxia. These gene products include those implicated in angiogenesis (VEGF, PDGF), 
glucose transport (GLUT-4), pH regulation (CAIX), cell survival (IGF1R, TGF-) and cell 




Figure 3.1. Regulation of the VHL pathway. (A): Under normal O2 levels, HIF-1α and 2α 
(represented as HIF-α) are ubiquitinated by the pVHL/E3 ubiquitin ligase complex. This marks 
HIF-α for proteosomal-mediated degradation. (B): Under low O2 level, the pVHL/E3 ubiquitin 
ligase is unable to ubiquitinate HIF-α, allowing it to dimerize with HIF-β. The resulting complex 
translocates to the nucleus where it acts as a transcription factor and upregulates the 
transcription of genes that encode the growth factors VEGF, PDGF and TGF-α among others. 
(C): When the VHL gene undergoes a mutation, deletion or methylation event, the defective 
pVHL is unable to interact with E3 ubiquitin ligase to give a functional complex. Ubiquination of 
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HIF-α decreases, leading to its accumulation and subsequent upregulation of growth factors 
even in normoxic conditions. 
 
In sporadic ccRCC or familial VHL disease, the VHL alleles are defective or absent. 
Consequently, the interaction between VHL and HIF- is prevented and HIF-α levels remain 
high regardless of oxygen status. This leads to the upregulation of the target genes of HIF-, 
many of which promote the growth and proliferation of cancer cells. The cytokines VEGF and 
PDGF which are involved in angiogenesis and neovascularization of tumors are important in this 
regard. VEGF plays a critical role in the early stages of angiogenesis where it signals 
endothelial cells to proliferate and form new vasculature.105 PDGF is implicated in the late 
stages of angiogenesis where it promotes the maturation of new vasculature.106 Indeed, ccRCC 
tumors are highly vascularized due to the upregulation of these angiogenesis-promoting 
cytokines.107-109  
 
The VHL-HIF-α pathway is linked to other oncogenic pathways such as the mammalian Target 
of Rapamycin (mTOR) and nuclear factor-kappa B (NF-κB). mTOR is a significant regulator of 
cell growth and proliferation and is upregulated in ccRCC.110, 111 It upregulates HIF-α and 
promotes HIF-α-regulated protein expression.96, 112 mTOR is in fact a valid target in ccRCC and 
mTOR inhibitors are currently used as targeted therapies for ccRCC. The NF-κB pathway is 
widely known for regulating immunity and inflammation.113-115 However, many of its target genes 
promote cell growth and proliferation and are thus implicated in cancer.116, 117 A more detailed 
discussion on the NF-κB pathway will follow in Chapter 5, but it should be noted that HIF- 





3.2.2. Current targeted chemotherapeutics for RCC  
The current paradigm in chemotherapy is the use of targeted therapies which are small 
molecules or protein-based drugs capable of directly inhibiting a particular errant pathway that is 
involved in oncogenesis. Many targeted therapies are used clinically, for example small 
molecules kinase inhibitors like imatinib and antibodies such as bevacizumab. They have 
revolutionized the treatment of those cancers which respond particularly well to such treatment 
modalities. 
 
Before the development of targeted therapies, RCC was treated by immunotherapy using 
cytokines such as interferon-α (IFN-α) and interleukin-2 (IL-2). IFN-α increases the 
immunogenicity of the tumor whereas IL-2 recruits natural killer and activated T cells to directly 
kill cancer cells.119, 120 A meta-analysis of IFN-α showed that overall response rates were less 
than 12% and overall survival of patients was extended by a modest 3.8 months.120 IL-2 
performed similarly, with overall response rates of 15% and complete remission of the cancer in 
4% of patients, a figure considered high in metastatic RCC. To date, IL-2 remains the only agent 
that is able of producing significant remissions.120 However, its main drawbacks are the high 
incidence of grades III and IV toxicities120, 121, deaths in some cases (4%), and cumbersome 
modes of administration and dosing schedules. Consequently, immunotherapy has largely fallen 
out of favour except for a small subset of RCC patients. 
 
As noted earlier, ccRCC accounts for an overwhelming percentage of all RCC cases, such that 
the two are generally considered to be synonymous. A clearer understand of the link between 
the VHL pathway and ccRCC has been pivotal in the development of targeted therapies. A 




Table 3.1. Current targeted therapies available for RCC. Response rates and progression free 
survivals are from placebo-controlled studies where available. CR: complete response; PR: 













































Despite the availability of different targeted therapies for RCC, response rates remain low and 
more importantly, these agents do not significantly extend progression-free survival and overall 
survival compared to placebo. They are also associated with serious adverse events, although 
these are significantly fewer compared to IL-2 or IFN-α. For example, bevacizumab and other 
VEGF targeting agents often lead to hypertension. Bevacizumab is itself implicated in increasing 
the risk of gastrointestinal bleeding and bowel perforation.135 Liver damage has been reported 
with pazopanib, and fatal cardiac failure with axitinib.136 Temsirolimus is paradoxically 
associated with increased mortality despite producing responses in cancer patients.137 
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Therefore, there is a clear need for novel chemotherapeutics for the treatment of RCC. Since 
the targeting of the mTOR and VEGF-related pathways have not led to promising anti-RCC 
agents, novel agents should preferably target an alternative pathway. 
 
3.3. Non-small cell lung carcinoma (NSCLC) 
Lung cancer has the highest incidence worldwide in men and ranks third in women. Overall, it 
accounts for 13% of all adult malignancies.138 Yearly, an estimated 1.8 million new cases are 
diagnosed, most commonly among smokers.139  
 
Lung cancer is a heterogeneous disease and comprises two main subtypes, non-small cell lung 
carcinoma (NSCLC) and small cell lung carcinoma. NSCLC accounts for 85% of all lung 
cancers and will be the focus of the following discussion.140 NSCLC can be further sub-divided 
into adenocarcinoma, squamous cell carcinoma and large cell carcinoma, but clinical 
management generally does not distinguish between these NSCLC subtypes. Like RCC, nearly 
70% of NSCLC patients present with late stage metastatic disease at diagnosis, due to a 
combination of an asymptomatic early stage and the lack of effective screening tools.140, 141 
Survival rates are optimistic for early stage disease, but late stage NSCLC has a dismal 5-15% 
5-year survival rate.139, 142  
 
For early stage and localized NSCLC, surgical resection and radiotherapy are treatment options 
but they are of limited utility in the management of patients with metastatic NSCLC where 
chemotherapy is the only viable option. Unfortunately, NSCLC is notorious for its resistance to 
chemotherapy.143 Before a clearer understanding of the genetic aberrations fueling NSCLC 
emerged , the treatment of choice was platinum-doublet therapy which consisted of a platinum 
based drug, usually carboplatin or cisplatin, coupled with another drug that acts by a different 
mode of action.144 Examples of platinum doublet regimens are combinations of carboplatin with 
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paclitaxel, gemcitabine or docetaxel. A meta-analysis showed that these regimens increased 
the overall survival by 6 months which is 1.5 months longer than untreated patients.145  
 
3.3.1. The EGFR pathway in NSCLC 
Among the cell signaling pathways implicated in NSCLC, the epidermal growth factor receptor 
(EGFR) pathway is the most widely studied. EGFR is a transmembrane receptor tyrosine 
kinase, and part of the HER/ErbB family of four structurally similar RTKs – EGFR 
(HER1/ErbB1), HER2 (neu/ErbB2), HER3 (ErbB3) and HER4 (ErbB4).146 EGFR is significantly 
overexpressed in NSCLC, and activating mutations which transform EGFR into a constitutively 
self-activating tyrosine kinase are found in 10-20% of patients depending on their ethnicity.147 
Incidence is lower among Caucasians but higher among east Asians.148  
 
EGFR is encoded by the EGFR gene which is located on the short arm of chromosome 7 
(7p11.2). The 170 kDa protein product possesses a cysteine-rich extracellular receptor domain 
which binds to its ligand epidermal growth factor (EGF). This extracellular domain is linked by a 
single alpha helix through the cell membrane to its intracellular tyrosine kinase domain which is 
linked to a carboxy terminal signaling domain essential for downstream signaling.149 In the 
absence of ligand binding, EGFR exists as discrete monomers (Figure 3.2). Binding of EGF 
exposes a “dimerization arm” on the extracellular region which then dimerizes with another 
EGFR or heterodimerizes with other members of the HER/ErbB family, notably HER2, which 
lacks a receptor-binding domain and acts solely as a dimerization partner for the other three 
members.150, 151 Dimerization of EGFR activates its tyrosine kinase activity resulting in the 
autophosphorylation of a set of 7 tyrosine residues located on the adjacent cytoplasmic domain. 
Cross-phosphorylation is also possible between dimerized partners.152 Phosphorylation of the 
tyrosine residues leads to the recruitment of a variety of proteins such as growth receptor 
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binding protein-2 (Grb-2) which then transduces the signals along the downstream pathways of 
EGFR.153, 154  
 
Figure 3.2. The EGFR pathway. Binding of EGF to EGFR leads to receptor dimerization and 
phosphorylation of cytoplasmic domains. At least three pathways lie downstream. Grb-2 
recruitment sets off a phosphorylation cascade through the Ras-Raf-MEK-ERK pathway. 
Transcription factor STAT3 is directly activated by EGFR dimers, and localizes in the nucleus 
where it upregulate its target genes. Activated EGFR also directly activates PI3K, which 
phosphorylates PIP2 to PIP3. PIP3 binds to Akt, and together with phosphorylation by mTORC2 
and PDPK1, activates the latter. The three downstream pathways subsequently contribute to 

































The Ras-Raf-MEK-ERK pathway is one of the more significant downstream pathways activated 
by EGFR. Grb-2 binds to the cytoplasmic domain of phosphorylated EGFR and recruits/ 
activates Ras.155 Activated Ras binds to Raf and triggers a phosphorylation cascade that 
involves MEK, MAPK and ERK.156 The cascade ends with the activation of transcription factors 
c-Myc, CREB and NF-κB (among others), which are implicated in cell growth, proliferation and 
prevention of apoptosis. In particular c-Myc is well recognized as a proto-oncogene and is 
dysregulated in many cancers.157 The Ras-Raf-MEK-ERK pathway also tilts the balance of the 
Bcl-2 family of proteins towards the antiapoptotic state.158, 159  
 
Besides the Ras-Raf-Mek-Erk pathway, EGFR activation also stimulates the signal transducer 
and activator of transcription (STAT) family of transcription factors.160 In particular, STAT3 and 
STAT5 have been implicated in lung cancer.161 STAT3 activation upregulates proteins involved 
in angiogenesis (VEGF), cellular migration (MMP-2, MMP-9) and prevention of apoptosis 
(survivin, Bcl-xl, Mcl1).162 The PI3K-Akt pathway is also activated by EGFR. Phosphoinositide-3 
kinase (PI3K) is recruited to the plasma membrane by activated EGFR dimers, in particular 
those containing HER3. Recruitment of PI3K leads to phosphorylation of phosphatidylinositol-
4,5-bisphosphate (PIP2) to form phosphatidylinositol-3,4,5-trisphosphate (PIP3). PIP3 recruits 
Akt to the plasma membrane where it is activated sequentially by mTOR complex 2 (mTORC2) 
and 3-phosphoinositide dependent protein kinase 1 (PDPK1).163 Upon activation, Akt prevents 
apoptosis by phosphorylating and promoting the degradation of crucial proteins such as BAD (a 
pro-death protein) and IκB kinase (IKK) which inhibits the NF-κB pathway. Akt also activates 
murine double minute 2 (mdm2) which inhibits p53 and upregulates pro-survival proteins Bcl-2 
and Mcl1.164  
 
10-20% of NSCLC patients exhibit mutations in the EGFR gene. Most mutations involve 
deletions, insertions or point mutations at the kinase domain, and lead to an exaggerated and 
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sustained response to EGF binding or constitutive activity even in the absence of a ligand.165, 166 
While the above pathways activated by EGFR are essential for proper control of cellular and 
tissue function in non-malignant cells, EGFR overexpression or mutation in NSCLC cause these 
downstream pathways to take on a more nefarious role of promoting tumorigenesis and survival 
of cancer cells. 
 
3.3.2. Current targeted therapies for NSCLC 
Conventional chemotherapy regimens, such as platinum doublet regimens are marginally 
effective in NSCLC. The prominent role of the EGFR pathway in NSCLC has resulted in 
targeted therapies against EGFR and its associated pathways. Although there is a sound 
rationale for deploying these therapies, the clinical benefits are only limited to those patients 
with sensitizing mutations. These are a minority (~20%) when compared to the general NSCLC 
population and the overall survivability remains low. Novel chemotherapeutics targeting 
alternative pathways are therefore in dire need, perhaps more so than in RCC. Drugs that are 
currently deployed against NSCLC are outlined in Table 3.2. 
 
Gefitinib, erlotinib and afatinib are tyrosine kinase inhibitors that are selective for EGFR. 
Gefitinib is the drug of choice for NSCLC patients with EGFR mutations, which are highly 
represented in women and non-smokers. Clinical guidelines require confirmation of EGFR 
mutations before these drugs are used in patients. In the absence of these mutations, minimal 
benefit is derived from their deployment, as can be seen from the lower overall responses in 
non-enriched trials (Table 3.2). Unfortunately, resistance to EGFR TKIs is widely encountered in 
the clinical setting due to conformational changes in the kinase domain or the activation of 
bypass pathways that do not respond to EGFR TKIs. Afatinib is the most recent EGFR inhibitor 
that is used clinically. Unlike its predecessors, it covalently binds to EGFR. Recent studies 
support a role for afatinib in patients who have developed resistance to gefitinib and erlotinib.167 
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Table 3.2. Current targeted therapies available for treatment of RCC. Response rates and 
progression free survival presented are from placebo-controlled phase III studies where 
available. CR: complete response; PR: partial response. OR: overall response (CR+PR). 
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3.4.1. Cell-based growth inhibitory activities of YM155 and analogs 
YM155 and the synthesized analogs were evaluated for their growth inhibitory effects on the 
clear cell renal cell carcinoma (ccRCC) cell lines (RCC786-0, RCC4/VA), the non-small cell lung 
carcinoma (NSCLC) cell lines (H1299, H1666) and the non-malignant human lung fibroblast 
IMR-90 cells. RCC786-0 and RCC4/VA are deficient in the von Hippel-Lindau (VHL) gene and 
reflect the genotype found in most patients with ccRCC.97 H1299 cells are p53-null whereas 
H1666 cells are p53 positive, however both are EGFR wild-type. Growth inhibitory activities 
were determined by a colorimetric tetrazolium (MTT) assay and expressed in terms of IC50 
which is the concentration required to reduce cell viability to 50% of levels observed in untreated 
cells under similar experimental conditions (Table 3.3). 
 
Table 3.3. Growth inhibitory IC50 values of YM155 and synthesized analogs. 
Cpd 
Growth Inhibitory IC50, μM a Range of 
selectivity 
ratios b 





















1.16 ± 0.07 0.4-4.8 














1.45 ± 0.05 0.5-7.0 





2.01 ± 0.11 0.8-11.7 
A3-1 1.14 ± 0.03 2.36 ± 0.40 1.06 ± 0.14 
0.231 ± 
0.033 





































Growth Inhibitory IC50, μM a Range of 
selectivity 
ratios b 













































2.00 ± 0.13 1.8-12.7 





2.81 ± 0.52 1.0-6.6 































































































2.48 ± 0.32 5.9-27.0 
B1-2 1.84 ± 0.07 1.48 ± 0.10 1.36 ± 0.05 
0.758 ± 
0.121 


















































Growth Inhibitory IC50, μM a Range of 
selectivity 
ratios b 












































B2-8 2.70 ± 0.32 2.06 ± 0.32 1.06 ± 0.17 1.47 ± 0.09 6.58 ± 0.18 2.4-6.2 
B3-1 2.52 ± 0,32 5.99 ± 1.36 2.66 ± 0.46 1.37 ± 0.09 5.61 ± 0.38 0.9-4.1 
B3-2 1.12 ± 0.17 1.91 ± 0.34 1.35 ± 0.20 
0.450 ± 
0.052 
3.57 ± 0.71 1.9-7.9 
B4-1 2.12 ± 0.21 2.58 ± 0.30 1.31 ± 0.06 1.44 ± 0.20 7.42 ± 0.76 2.9-5.7 



















1.36 ± 0.15 1.3-3.5 
C2-1 >100 >100 >100 >100 >100 N/A 
C2-2 >100 >100 >100 >100 >100 N/A 
C2-3 >100 >100 >100 >100 >100 N/A 
C3-1 >100 >100 >100 >100 >100 N/A 
C3-2 >100 >100 >100 >100 >100 N/A 
C4-1 34.1 ± 2.1 37.3 ± 0.8 24.4 ± 1.6 22.0 ± 1.5 55.4 ± 4.6 1.5-2.5 








































Growth Inhibitory IC50, μM a Range of 
selectivity 
ratios b 



















































6.38 ± 0.13 5.51 ± 0.96 3.42 ± 0.56 9.78 ± 0.56 13.3 ± 2.0 1.4-3.9 
a Evaluated by MTT assay, 72h incubation, 37oC, 5% CO2. Mean ± SD for n = 3 determinations; 
b Lowest to highest of IC50 IMR-90 / IC50 malignant cell line; c Naphthoquinone. 
 
The median IC50 values were calculated for each cell line and found to be 113 nM (H1666), 192 
nM (H1299), 262 nM (RCC786-0) and 633 nM (RCC4/VA). Differences in the sensitivities to the 
different cell lines were small and did not exceed 6-fold. Ranking of compounds in terms of 
growth inhibitory potency was broadly consistent within each cell line. For example, A5-1 had 
the weakest growth inhibitory activity on all four cell lines while the most potent compounds 
were either A3-3 or AB7. This trend was also reflected in the Spearman correlation coefficients 
() derived from pair-wise comparisons of IC50 values from the four cell lines.  values 
exceeding 0.85 were obtained, indicating a strong monotonic relationship among the 
comparators (Table 3.4). Hence the SAR deduced from one cell line should largely apply to 
other cell lines. In the following paragraphs, SAR is discussed with reference to growth inhibitory 




Table 3.4. Spearman correlation matrix of  values derived from IC50 values of test compounds 
on ccRCC (RCC786-0, RCC4/VA) and NSCLC (H1299, H1666) cell lines.a 
 RCC786-0 RCC4/VA H1299 H1666 
RCC786-0 1.000 0.950 0.942 0.965 
RCC4/VA 0.950 1.000 0.924 0.919 
H1299 0.942 0.924 1.000 0.950 
H1666 0.965 0.919 0.950 1.000 
a Only compounds with measurable IC50 values were analyzed.  
 
3.4.2. SAR of series C 
Series C compounds were designed to report on the importance of the 
dioxonaphthoimidazolium scaffold for activity. A key finding was that the intact scaffold was 
required for potent activity. Thus, removing the distal phenyl ring or the central quinone of 
YM155 to give the bicyclic analogs C1-2 and C2-1, resulted in diminished activities.  As a 
greater loss in activity was incurred on omission of the quinone, a more critical role may be 
attributed to it as compared to the distal phenyl ring. Further trimming of the bicyclic scaffold of 
C1-2 or C2-1 to give an imidazolium (C2-2) did not restore activity. The importance of the 
quinone moiety was further underscored by the negligible activity of the imidazoquinoxalinium 




The contribution of the permanent positive charge on the scaffold to activity is best illustrated by 
comparisons to naphthoquinone, C4-1 and C4-2. Naphthoquinone is basically YM155 without 
the substituted imidazolium ring. Its growth inhibitory activity (IC50 6.4 µM) far exceeded that of 
the benzimidazolium C2-1 (IC50 > 100 μM), clearly showing that the loss of the positively 
charged imidazolium ring was not as detrimental as omission of the quinone. The 
dioxonaphtho[2,3-d]imidazoles (C4-1, C4-2) which retain the quinone moiety but not the positive 
charge, provide added support. Both compounds had diminished potencies (IC50 24-34 μM) 
compared to their charged counterparts A6-2 and B2-1. Scaffold hopping to yield indoles C3-1 
and C3-2 which lack both the quinone and positive charge but retain the side chains was 
equally futile as both compounds were as inactive as the benzimidazolium C2-1 from which they 
differed only in charge. Tellingly, series C analogs (C1-2, C4-1, C4-2)  that retain the quinone 
moiety, even with changes made to other parts of the YM155 scaffold, were consistently more 
potent than those without the quinone moiety (C2-X, C3-X). It also follows that the side chains 





Taken together, omission of the quinone from the tricyclic scaffold had the most adverse effect 
on activity, followed by removal of the permanent positive charge (naphthoquinone, C4-1, C4-2). 
The least disruptive modification to the scaffold was the removal of the distal benzene ring (C1-
2). 
 
Mention should be made of C1-1 which retain the tricyclic scaffold of YM155 but is modified by 
homologation at C2. This modification led to a 7-fold loss in activity (C1-1, IC50 96 nM), 
suggesting strict steric requirements at this position. 
 
 
3.4.3. SAR of series A and B  
Next, the inhibitory activities of series A and B were analyzed to assess the contributions of the 
N3 (pyrazin-2’-ylmethyl) and N1 (2’-methoxyethyl) substituents to activity. 
 
The series A compounds were designed to probe the importance of the pyrazin-2’-ylmethyl side 
chain at N3 while keeping 2’-methoxyethyl at N1. The key observations are as follows. First, the 
one-carbon (methylene) spacer linking the pyrazine ring to N3 should not be lengthened or 





Second, replacing pyrazin-2’-ylmethyl with benzyl (A1-1, IC50 240 nM), cyclohexylmethyl (A1-2, 
415 nM), thien-2’-ylmethyl (A1-3, IC50 207 nM) or imidazol-2’-ylmethyl (A2-1, IC50 279 nM) 
caused significant losses in activity. It may be that the azine at N3 fulfilled a special role (H 
bonding) which is not met by these alternative moieties. Third, in contrast to the 2nd observation, 
replacing the pyrazine ring with other azines like pyridine, pyrimidine and pyridazine was 
generally well tolerated but only if the azomethine nitrogen was located at specific positions. 
The regioisomeric influence was clearly observed in the isomeric pyridinylmethyl analogs A3-1, 
A3-2 and A3-3.  
 
Activity improved when the azomethine nitrogen was moved from ortho (A3-1) to meta (A3-2), 
and likewise when it was shifted from meta (A3-2) to para (A3-3), albeit to a lesser extent. This 
may allude to a possible hydrogen bonding interaction that is accessible to the meta and para 
azomethine nitrogens but not the ortho nitrogen. The regioisomeric bias against an ortho 
nitrogen was again observed in A3-4 which has a pyrimidin-2’-ylmethyl side chain at N3. Its 
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positional isomers A3-5 and A3-6 which have at least one azomethine N at the meta or para 
position fared better. The same was true for A3-7 which has a pyrazine-4’-ylmethyl side chain at 
N3.    
 
The consistent preference for azines with meta or para azomethine nitrogen as well as the 
requirement of maintaining a one-carbon linker between the scaffold and the ring at N3 may 
reflect an optimal orientation of the side chain for a specific interaction like hydrogen bonding. 
When a methyl group was inserted at the para position of the pyrazine ring of YM155, activity 
was reduced by 10-fold (A3-8, IC50 157 nM) which implied that in the absence of a para-
azomethine N, it is best to keep that position unoccupied. Lastly, replacing the pyrazinylmethyl 
side chain with alkyl side chains as exemplified by the A6-X subgroup of compounds was found 
to be an acceptable modification. Seven alkyl side chains were investigated and of these, 
methyl was the most active, followed by cyclopropyl, ethyl, propyl, n-butyl, isopropyl and isobutyl 
in that order. The same sequence of methyl > ethyl > propyl was observed on the other cell 
lines, corroborating a preference for short alkyl side chains that were not branched or cyclized. 
Even so, the highly ranked methyl analog A6-2, like the potent azinylmethyl analogs A3-3, A3-5 
and A3-7, were only comparable to YM155 in terms of growth inhibition.  
    
The series B compounds were designed to report on the effects of modifying the 2’-
methoxyethyl side chain at N1 while retaining the pyrazin-2’-ylmethyl at N3. First, it was noted 
that replacing 2’-methoxyethyl with 2’-hydroxyethyl resulted in an 8-fold loss in activity (B1-1, 
IC50 118 nM). Homologation to 2’-ethoxyethyl incurred a smaller 3-fold loss in activity (B1-3, IC50 
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38 nM). Embedding the ether functionality in a ring (tetrahydrofuran, B1-2) or replacing it with a 
N’, N’-di-substituted aminoethyl (B4-1, B4-2) pushed IC50 values to the micromolar range 
signifying limited tolerance for bulky or charged substituents at this position. Second, replacing 
2’-methoxyethyl with alkyl side chains afforded compounds with surprisingly good activity. The 
side chains investigated were similar to those in series A (methyl, ethyl, propyl, butyl isopropyl, 
isobutyl, cyclopropyl). Short unbranched side chains were again favored but with a different rank 
order of activity (cyclopropyl > ethyl > propyl > methyl > isopropyl > isobutyl) compared to series 
A. The outstanding potency of the N1-cyclopropyl analog (B2-5) was evident on all cell lines 
except RCC786-0, where the methyl and ethyl analogs were more active. Interestingly, B2-8 
which has a cyclopentyl side chain at N1 fared poorly when compared to its potent cyclopropyl 
counterpart B2-5. Thus, the more critical requirement for alkyl substituents appears to be that of 
a sterically small group at N1, regardless of whether it is cyclized or not. 
 
Lastly, replacing 2’-methoxyethyl with an aromatic ring, namely benzyl (B3-1) and pyrazin-2’-
ylmethyl (B3-2) significantly diminished activity. B3-2 is noteworthy as it is symmetrically 
substituted with pyrazinylmethyl moieties at both N1 and N3 and is thus comparable to A6-1 
which is symmetrically substituted at the same positions with 2’-methoxyethyl moieties. That 
A6-1 (IC50 73 nM) was more potent than B3-2 (IC50 450 nM) lends further support to the notion 





3.4.4. SAR of series AB 
Having identified N3-pyridin-4’-ylmethyl and N1-cyclopropyl to be “optimal” substituents at their 
respective positions, these functionalities were then introduced to the scaffold with the 
expectation that it would yield more potent compounds. Less optimal substituents (pyridin-3’-
ylmethyl, pyrimidin-5’-ylmethyl, methyl, ethyl) were concurrently investigated to validate this 
approach. In all, seven series AB analogs were synthesized, of which six were derived from 
permutations of pyridin-4’-ylmethyl, pyridin-3’-ylmethyl or pyrimidin-5’-ylmethyl at N3 and ethyl or 
cyclopropyl at N1. The last compound AB7 was substituted at both N1 and N3 with methyl. Good 
activity was found in analogs that have pyridin-4’-ylmethyl at N3 and cyclopropyl (AB1) or ethyl 
(AB2) at N1. AB1 was broadly equivalent to YM155 in terms of IC50 while AB2 was marginally 
less active than YM155, except on RCC786-0 where it was slightly more potent. Clearly, this 
approach of combining optimal substituents onto the scaffold did not work as well as 
anticipated. This is further endorsed by the disappointing activities of AB3-AB6.  
An unexpected finding was that of AB7 which was substituted with the sub-optimal methyl group 
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at N1 and N3. AB7 displayed outstanding activity, exceeding YM155 by 1.5 to 2-fold and was in 
fact the most promising compound (IC50 9 – 30 nM) identified in this investigation. 
 
3.4.5. Selective activity against non-malignant cell lines 
YM155 and the synthesized compounds were tested on non-malignant lung fibroblast IMR-90 
cells to determine if they selectively affected proliferation of malignant cells. Selectivity was 
assessed from the four selectivity ratios derived from the IC50 on IMR-90 cells and the IC50 on 
the malignant cell line. Average ratios ranging from 1.8 to 19-fold were obtained (Table 1). The 
compounds were most selective for H1666, followed by H1299, RCC786-0 and finally 
RCC4/VA. Unfortunately, higher selectivities (as high as 38-fold) were found for compounds that 
had weaker growth inhibitory activities, such as A6-6, A6-8, B1-1 and B1-3. YM155 and its 
potent analogs (A3-3, A3-5, AB1, AB7) had only modest selectivities that ranged from 3-19-
fold.   
 
3.5. Discussion 
A key SAR finding of this chapter relates to the importance of the intact 
dioxonaphthoimidazolium scaffold for growth inhibition. Attempts to reduce the tricyclic scaffold 
to a bicyclic or monocyclic entity invariably resulted in a loss of activity. Of the various motifs on 
the tricyclic scaffold, the quinone was recognized as the most critical, followed by the positively 




Retention of the quinone moiety ensured a measurable growth inhibitory activity (nanomolar to 
micromolar IC50), despite changes to other parts of the scaffold.  This is evident from the 
activities of naphthoquinone, C1-2, C4-1 and C4-2. In the absence of the quinone, steep losses 
in activity (IC50 > 100 μM) were encountered, even when the tricyclic scaffold is retained. C2-3 is 
a case in point. 
 
Activity was diminished to a lesser extent in the absence of a positive charge on the scaffold. 
The activities of C4-1 and C4-2 are illustrative. Both compounds differ from YM155 in lacking a 
substituent at N3 and hence, a positive charge. When a methyl was inserted at N3 of C4-1 and 
C4-2, the positive charge was restored and with it, a rebound in activity, as seen in B2-1 and 
A6-2 respectively. It is noted that C4-1 and C4-2 are structurally related to the 
dioxonaphthoimidazole 1, previously reported by Kuo et al.73 Intriguingly, 1 was many times 
more potent than C4-1 and C4-2. This would imply that alkyl substitution of the scaffold, as seen 
in 1, is preferred to the more polar H bonding and sterically larger side chains found in C4-1 and 
C4-2. Indeed, sterically compact substituents are favored on N1, C2 and N3. Notably, the most 
potent analog identified here (AB7) is minimally substituted at N1 and N3 with methyl groups. 
 
The distal phenyl ring appears to be the least important feature in the scaffold. In its absence, 
the resulting analog C1-2 incurred the smallest loss in activity compared to the removal of other 
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rings in the scaffold. The diminished activity of C1-2 may be related to the loss of - stacking 
on omission of the phenyl ring. 
 
Mention should be made of the imidazolium C2-2 whose poor activity stands in sharp contrast to 
that of IBN-65 which was reported to have an IC50 of  5μM on a panel of HCC cell lines.74 The 
disparity is likely due to the difference in substitution on the imidazolium ring. Unlike C2-2, IBN-
65 combines a positive charge with highly lipophilic side chains which may favor growth 
inhibitory activity.   
 
Unlike the tricyclic dioxonaphthoimidazolium scaffold which was mandatory for activity, 
functionalization at N1 and N3 served to fine-tune activity. Consequently, a greater degree of 
structural diversity was permitted at these positions without overt losses to activity. Notably, all 
series A and B analogs had determinable IC50 values which were within the nanomolar to low 
micromolar range. However, only one analog (AB7) was modestly more potent than YM155 
although several (AB1, A3-3, A3-7, B2-5) were comparable to it. A striking SAR trend that was 
common to both N1 and N3 positions was the marked preference for short, unbranched and 
cyclized alkyl groups. In fact, this was the only acceptable modification of the 2’-methoxyethyl 
side chain at N1. The resulting compound B2-5 was comparable to YM155 and this raises the 




Greater leeway was permitted at the N3 position which accepts short unbranched alkyl groups 
as well as isosteric modifications of the pyrazine-2’-ylmethyl side chain. A striking regioisomeric 
preference was observed for the latter. Notably, the pyrazine ring could be replaced by pyridine 
or another diazine, as long as an azomethine nitrogen was sited at the para position of the ring.  
The resulting analogs A3-3, A3-7, AB1 bearing pyridin-4’-ylmethyl or pyridazin-4’-ylmethyl side 
chains were in fact equipotent or modestly more potent than YM155 on selected cell lines. Thus 
the SAR at N3 indicates two disparate features that result in optimal activity, namely a short 
unbranched alkyl group and an extended azinylmethyl side chain with a suitably positioned 
azomethine N for H bonding.    
 
With regards to selectivity, most of the potent analogs had comparable selectivities to YM155 
(ca. 5-18-fold). While this is an arguably modest level of selectivity, it is noted that YM155 has 
an unusually low toxicity profile based on clinical trial data. Therefore, this level of selectivity 




The objectives of this chapter were to (i) elucidate SAR of YM155 on RCC and NSCLC cell 
lines, (ii) determine if there are overlapping structure requirements for these disparate 
malignancies and (iii) evaluate selective activity against malignant cells. To this end, the SAR of 
YM155 has been established. The key findings are summarized in Figure 3.3. A3-3, AB1 and 
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AB7 were identified as promising analogs with nanomolar growth inhibitory activities and 
acceptable selectivities (ca. 10-fold) on the ccRCC and NSCLC cells. In view of the close 
concordance in SAR trends observed across the different cell lines, a shared mode of action 
may be implicated for these compounds. This is despite clear differences in the common 
genetic aberrations between RCC and NSCLC, and it suggests that the VHL pathway for RCC 
and the EGFR pathway for NSCLC may not be strongly relevant to the mode of action. 
Conversely, this mode of action may involve particular oncogenic pathway that is prominent in 
both cancer types but less so than the VHL and EGFR pathways. 
 
Figure 3.3. Summary of growth inhibitory structure-activity relationships of YM155 
 
3.7. Experimental information 
3.7.1. General biology 
High glucose Dulbecco’s Modified Eagle’s Media (DMEM) and Roswell Park Memorial Institute 
Media 1640 (RPMI-1640) (Hyclone®, GE Healthcare, Buckinghamshire, UK) and supplemented 
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with 10% heat inactivated fetal bovine serum (FBS) (Hyclone®, GE Healthcare, 
Buckinghamshire, UK) and 0.01% w/v Penicillin-G-Streptomycin mixture (GE Healthcare, 
Buckinghamshire, United Kingdom). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) was purchased from Alfa Aesar, Inc. (Lancashire, United Kingdom), 
reconstituted in phosphate-buffered saline to 2 mg/mL and diluted with appropriate cell culture 
media before use.  
 
3.7.2. Cell culture 
Human clear cell renal cell carcinoma cell lines RCC786-0, RCC4/VA, non-small cell lung 
carcinoma cell lines H1299, H1666 and normal lung fibroblasts IMR-90 cells were obtained from 
American Type Culture Collection (ATCC, Rockville, MD). RCC786-0, RCC4/VA and IMR-90 
cells were cultured in complete DMEM. H1299 and H1666 cells were cultured in complete 
RPMI-1640 and incubated at 37C, 5% CO2. Malignant and IMR-90 cell lines were sub-cultured 
at ratios of 1:6 and 1:3 respectively on reaching 90% confluence. 
 
3.7.3. MTT assay 
Cells were seeded at a density of 3.0 x 103 cells/well for malignant cell lines and 4.0 x 103 
cells/well for IMR-90 in 96-well plates containing 100 μL media per well and incubated for 24 h 
(37C, 5% CO2) for cell adherence. After 24 h, media in each well was removed by aspiration 
and 199 μL of fresh media was added. 1 μL of test compound (prepared in DMSO stock 
solutions at 200-fold higher concentrations) was added to each well. The final DMSO 
concentration in each well was kept at 0.5% v/v. The compound-treated cells were incubated for 
72 h (37C, 5% CO2), media was subsequently removed by aspiration and an aliquot (200 μL) 
of 0.5 mg/mL MTT in media was added to each well. The treated plates were incubated for 2 h 
(malignant cells) or 3 h (IMR-90 cells) after which the MTT containing media was removed by 
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aspiration and 100 μL of DMSO added to each well to dissolve the purple formazan crystals. 
Plates were agitated at 700 rpm, 5 min on a plate shaker before absorbance readings were read 
(570 nm, Tecan InfiniteTM M200 Pro). Viable cells were determined from the following equation:  
 
Percentage viability = [(Abcompound – Abblank)/(Abcontrol – Abblank)] x 100%, 
where Abcompound = Absorbance of compound-treated cells, Abcontrol = Absorbance of 
untreated/control cells and Abblank = Absorbance of DMSO.  
Each test compound was assessed at 8 concentrations in at least 3 separate experiments 
carried out at different times. Cells were from different passage numbers and each compound 
was tested from 2 stock solutions. For each experiment, percentage viability was calculated 
using the mean absorbance value from three technical repeats at a given test concentration. 
The IC50 (the concentration of test compound required to inhibit cell growth by 50%) was 
determined by plotting % viability against logarithmic concentration of test compound 




Chapter 4: DNA intercalating and redox cycling properties of YM155 and analogs 
4.1 Introduction 
The focus of this chapter is to explore the potential of YM155 and its analogs to induce a DNA 
damage response. Glaros et al first proposed that YM155 induced DNA damage when they 
noted from COMPARE analysis data that the growth inhibitory profile of   YM155 was strongly 
correlated to that of DNA damaging agents and a DNA directed inhibitor of transcription.55 They 
proceeded to show that YM155 induced phosphorylation of H2AX and KAP1, which are 
biomarkers for DNA double strand breaks. When phosphorylation was observed at 
concentrations that were lower than that required to reduce survivin, they concluded that YM155 
acted primarily by inducing DNA damage and that any effect on survivin was a secondary event 
caused by the general deactivation of gene expression consequent to DNA damage. Winter et 
al confirmed that YM155 induced the phosphorylation of H2AX and KAP1 but they proposed 
that this was a consequence of the ability of YM155 to intercalate DNA.56 They noted that 
chloroquine inhibited DNA replication and induced phosphorylation of H2AX largely as a result 
of intercalation. Another archetypal DNA intercalator ethidium bromide did not directly cause 
DNA damage but still induced errors in DNA replication due to misreading by polymerases.178 
Acridine-based DNA intercalators such as 9-aminoacridine and quinacrine were originally 
thought to exert their anticancer properties by intercalation, but this was later dismissed when it 
was found that intercalation did not result in DNA damage in cancer cells.179  
     
For an agent to induce DNA damage, it must interact reversibly or irreversibly with DNA.180 
Irreversible binding would involve alkylation of the DNA bases while reversible binding would 
require an initial insertion between the base pairs of the double helix (intercalation) followed by 
a cascade of events culminating in DNA damage. These events may involve topoisomerase-
induced DNA damage as typified by campthothecins or the generation of free radicals that 
cause DNA strand breaks as observed in bleomycin. Structurally, YM155 is an impropable 
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alkylating agent as it lacks features associated with a reactive electrophilic center. On the other 
hand, YM155 is a likely DNA intercalator due to its planar scaffold and positively charged state. 
Intercalation followed by inhibition of topoisomerase can be dismissed as YM155 was not found 
to inhibit topoisomerase I.56 On the other hand, free radical-induced DNA damage is probable 
due to the embedded quinone in YM155. The quinone is an established pharmacophore for 
redox cycling.181 It accepts a single electron to give a semiquinone radical which reacts directly 
with DNA182 or participates in a redox cycle of superoxide radical generation by transfer of 
electrons to oxygen.183 Superoxide and its dismutation product hydrogen peroxide form hydroxyl 
radicals which readily initiate strand breaks when generated in the vicinity of DNA.184 
 
Little is known of the structural features of YM155 that are critical for DNA binding or redox 
cycling. The availability of such information will provide a better understanding of the mode of 
action of YM155 and by extension, its potent growth inhibitory activity.  
 
4.2 Objectives 
The objective of this chapter is to investigate the DNA intercalation and redox cycling properties 
of YM155 and its analogs with the aim of elucidating SAR for these activities. A comparison of 
the structural features required for DNA intercalation/redox cycling and those for growth 
inhibition (Chapter 3) will provide insight as to the extent to which these properties contribute to 
growth inhibition.  
 
4.3 Results 
4.3.1 DNA intercalation 
DNA intercalation by YM155 and analogs was examined by an in vitro fluorescent intercalator 
displacement (FID) assay that was adopted from reported procedures.185, 186 Briefly, the dye 
thiazole orange (ThO) intercalates with non-specific DNA sequences in herring sperm DNA with 
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emission of fluorescence. When it is displaced by a competing intercalator, fluorescence is 
diminished. The test compound was evaluated over a range of concentrations to determine the 
concentration (DC50) at which it reduced the basal fluorescence of ThO (10 µM) by 50%. Strong 
intercalators will have small DC50 values and vice versa. Dose response curves depicting the 
displacement of ThO by YM155 and doxorubicin (positive control) are provided in Figure 4.1. 
DNA intercalation DC50 values are tabulated in Table 4.1. 
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Figure 4.1. Representative dose response curves for the displacement of ThO by YM155 and 
doxorubicin. 
 
Table 4.1. DNA intercalation DC50 and redox cycling EC50 values of test compounds 
Compound DC50 (µM)a  for DNA intercalation EC50 (µM)b for redox cycling 
YM155 20.3 ± 3.1 1.38 ± 0.05 
A1-1 27.5 ± 0.5 3.63 ± 0.71 
A1-2 35.4 ± 1.4 13.0 ± 0.3 
A1-3 28.6 ± 0.4 3.22 ± 0.14 
A2-1 31.9 ± 1.1 6.27 ± 0.26 
A3-1 28.6 ± 3.1 2.10 ± 0.24 
A3-2 16.4 ± 1.3 1.91 ± 0.24 
A3-3 20.0 ± 0.5 2.01 ± 0.10 
A3-4 45.0 ± 3.3 1.36 ± 0.11 
A3-5 25.4 ± 2.4 4.56 ± 0.13 
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Compound DC50 (µM)a  for DNA intercalation EC50 (µM)b for redox cycling 
A3-6 26.7 ± 3.4 3.09 ± 0.08 
A3-7 23.0 ± 1.2 2.37 ± 0.01 
A3-8 18.4 ± 1.2 2.57 ± 0.16 
A4-1 44.0 ± 3.2 7.58 ± 0.20 
A5-1 95.4 ± 7.5 2.96 ± 0.15 
A6-1 32.3 ± 3.8 9.30 ± 0.43 
A6-2 32.3 ± 1.5 5.70 ± 0.43 
A6-3 40.1 ± 4.5 7.08 ± 1.18 
A6-4 48.2 ± 6.0 8.47 ± 0.15 
A6-5 99.0 ± 0.8 10.2 ± 0.5 
A6-6 35.4 ± 4.1 6.37 ± 0.69 
A6-7 44.2 ± 0.2 6.37 ± 0.69 
A6-8 67.0 ± 5.8 8.75 ± 0.43 
B1-1 17.7 ± 1.2 2.36 ± 0.04 
B1-2 13.3 ± 0.9 3.67 ± 0.20 
B1-3 20.9 ± 1.4 0.68 ± 0.00 
B2-1 30.6 ± 0.8 2.94 ± 0.05 
B2-2 24.0 ± 2.4 3.32 ± 0.13 
B2-3 30.1 ± 1.5 2.26 ± 0.05 
B2-4 56.9 ± 9.1 3.47 ± 0.45 
B2-5 25.2 ± 1.6 3.92 ± 0.10 
B2-6 27.9 ± 3.8 2.31 ± 0.37 
B2-7 43.3 ± 2.3 5.82 ± 0.05 
B2-8 78.8 ± 13.2 7.35 ± 0.06 
B3-1 13.9 ± 0.7 1.85 ± 0.10 
B3-2 12.0 ± 1.0 1.34 ± 0.06 
B4-1 19.9 ± 4.0 1.43 ± 0.06 
B4-2 15.5 ± 0.3 1.01 ± 0.04 
C1-1 29.5 ± 2.6 2.00 ± 0.04 
C1-2 >100 1.42 ± 0.01 
C2-1 >100 >400 
C2-2 >100 >400 
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Compound DC50 (µM)a  for DNA intercalation EC50 (µM)b for redox cycling 
C2-3 >100 >400 
C3-1 >100 >400 
C3-2 >100 >400 
C4-1 >100 >400 
C4-2 >100 >400 
AB1 20.8 ± 1.3 6.10 ± 0.38 
AB2 21.3 ± 3.2 3.47 ± 0.08 
AB3 22.7 ± 1.6 7.61 ± 0.07 
AB4 17.6 ± 1.2 3.86 ± 0.11 
AB5 14.7 ± 1.5 3.48 ± 0.01 
AB6 12.0 ± 0.3 2.75 ± 0.18 
AB7 12.7 ± 0.5 7.55 ± 0.71 
Doxorubicin 2.64 ± 0.16 195 ± 7 
Naphthoquinone >100 0.333 ± 0.008 
a DC50: Concentration required to reduce basal fluorescence of thiazole orange (10 µM) by 50%. 
A higher value indicates a lesser tendency to displace ThO (i.e. weaker binding affinity for 
DNA). Mean and SD of n=3 separate determinations. b EC50: Concentration required to reduce 
oxidized phenol red absorbance to 50% of control values. Mean and SD of n=3 separate 
determinations.   
 
The DC50 of YM155 was 20.3 µM as compared to 2.6 µM for doxorubicin. Since ThO was 
evaluated at a fixed concentration of 10 µM, this would imply that YM155 had half the binding 
affinity of ThO for DNA as compared to doxorubicin which had 4 times the DNA binding affinity 
of ThO. Clearly, YM155 is a significantly weaker DNA intercalator than doxorubicin.  
        
Some interesting trends in DNA binding affinities were deduced from the DC50 values in Table 
4.1. With regard to series C, it is striking that attempts to reduce the size of the tricyclic scaffold 
abolished binding affinity. Thus, the monocyclic (C2-2) and bicyclic (C1-2, C2-1, C3-X,) analogs 
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had DC50 exceeding 100 µM. This was also true of naphthoquinone and analogs that retain 
modified tricyclic scaffolds (C2-3, C4-X). The only permissible modification was the extension of 
the C2 methyl to ethyl (C1-1) but even this minor alteration increased DC50 to 30 µM. These 
results underscore the importance of the intact dioxonaphthoimidazolium scaffold for DNA 
intercalation.  
 
To explore functionalization at N3, the DC50 values of series A compounds were analyzed. A key 
observation was that modifications to the N3 pyrazin-2’-ylmethyl side chain were poorly 
tolerated. In particular, alkyl substitution at N3 (A6-X) and altering the length of the methylene 
spacer (A4-1, A5-1) adversely affected intercalation. Isosteric changes to the pyrazine ring gave 
better, albeit modest, outcomes as seen from A3-2 (pyridine-3’-ylmethyl, DC50 16.4 μM) and A3-
3 (pyridine-4’-ylmethyl, DC50 20.0 μM). The regioisomeric bias against azines with ortho-




On the other hand, replacement of pyrazine with non-azines (A1-1, benzyl; A1-2, 
cyclohexylmethyl; A1-3, thien-2’-ylmethyl; A2-1, imidazole-5’-yl) was not favored. Methyl 
substitution of the pyrazine ring as in A3-8 (5’-methylpyrazin-2-ylmethyl, DC50 18.4 μM) did not 
adversely affect intercalation. 
 
The role of functionalization at N1 was deduced from series B. It is noted that 5 of the 15 series 
B analogs (33%) had DC50 values > 30 µM (arbitrarily taken to reflect poor binding), as 
compared to 13 of the 22 series A analogs (59%). In series B, DC50 values ranged from 13 µM 
to 79 µM (6-fold variation) whereas in series A, the variation was wider (16 – 99 µM, ca. 15-
fold). Thus, there were fewer “poor” binders in series B which together with the narrower 
variation in DC50 values suggests that modifications at the N1 position affected intercalation to a 
lesser extent as compared to the N3 position. Interestingly, poor binders were highly 
represented among the N1-alkyl substituted analogs (B2-X), as in the case of series A. 
Acceptable groups at N1 included diverse cyclized entities (B3-1, benzyl; B3-2, pyrazin-2’-
ylmethyl; B1-2, tetrahydrofurfuryl), N’, N’-disubstituted aminoalkyl side chains (B4-1, B4-2), and 
minor modifications to the N1 2’-methoxyethyl moiety (B1-3, 2’-ethoxyethyl; B1-1, 2’-
hydroxyethyl). The binding affinities of these analogs were nearly equivalent to that of YM155. 
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Unlike the others, series AB yielded consistently good DNA intercalators (DC50 12 – 23 μM). It is 
noted that the intercalation ability of AB1 – AB6 were closely aligned to that of the 
corresponding series A analogs. Thus, AB1 and AB2 which have in common a pyridin-4’-
ylmethyl side chain had DC50 values that were within the range of A3-3 which has a similar side 
chain at N3. This was again observed for AB5, AB6 (compared to A3-2) and AB3 (compared to 
A3-6). AB4 was an outlier, being more potent than A3-6. The strong binding affinity of the N1, 
N3-dimethyl substituted AB7 (DC50 13 µM) was unusual because the mono-methyl analogs, 






4.3.2 Redox cycling  
Redox cycling by YM155 and the synthesized compounds was first investigated by an in vitro 
assay centered on the oxidation of phenol red by hydrogen peroxide (HRP).187, 188 In this assay, 
the thiol groups of dithiothreitol are oxidized to the disulfide. The electrons released in the 
process reduce the quinone to semiquinone or hydroquinone. When this reaction is reversed in 
the presence of oxygen, superoxide anions are formed and these rapidly dismutate to hydrogen 
peroxide which then oxidizes phenol red in the presence of horseradish peroxidase. In the 
presence of a redox cycler, phenol red is continually oxidized and its absorbance at 610 nm 
increases. The redox cycling propensity of the test compound is given by EC50 which is the 
concentration required to increase the absorbance of oxidized phenol red at 610 nm to half the 
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maximum value (Table 4.1). A strong redox cycler will have a lower EC50 and vice versa. Dose 
response plots of YM155 and naphthoquinone (positive control) are shown in Figure 4.2. 
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Figure 4.2. Representative redox cycling dose response plot of YM155 and naphthoquinone 
(NQ) on the phenol red-HRP assay. 
 
Besides naphthoquinone, the assay was also carried out on doxorubicin. Naphthoquinone (EC50 
0.33 μM) was found to be a more effective redox cycler than doxorubicin (EC50 195 μM). Thus a 
quinone presence does not always ensure redox cycling activity on this assay. Tentatively, 
minimal substitution around the quinone (naphthoquinone) may be preferred to embedding the 
quinone within a scaffold (doxorubicin). However, in spite of it having an embedded quinone, 
YM155 was a surprisingly good redox cycler (EC50 1.4 μM), which would suggest that the 
substitution on the scaffold played a decisive role in influencing activity. 
 
SAR for redox cycling was deduced for the various series. Only two of the 9 analogs in Series C 
were redox cyclers. They were C1-1 (EC50 2.0 μM) which is the C2-ethyl homolog of YM155, 
and the positively charged bicyclic quinone C1-2. None of the non-quinone analogs (C2-X, C3-
X) were redox cyclers but some quinone containing analogs (C4-1, C4-2) also failed to redox 
cycle. C4-1 and C4-2 are not substituted at N3 and consequently are not positively charged. 
This may imply that the charged imidazolium and quinone must both be present for redox 
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cycling. The outstanding activity of naphthoquinone (YM155 without imidazolium) would then be 
anomalous. Thus, pending additional data, a reasonable conclusion would be that (i) the 
quinone moiety per se is not sufficient to ensure redox cycling and (ii) the intact 
dioxonaphthoimidazolium scaffold is not required for redox cycling.  
 
 A 10-fold variation in EC50 values (1.4 – 13 μM) was observed in series A. Nearly 77% of the 
analogs had ½ the redox cycling ability of YM155 (EC50 > 2.8 μM, taken arbitrarily as a 
threshold for “weak” activity). Interestingly, these same compounds, namely N1-alkyl analogs 
(A6-X), methylene homologs (A4-1, A5-1), and non-azinylmethyl bearing analogs (A1-X, A2-1), 
were also weak DNA intercalators. The azinylmethyl bearing analogs (A3-X) were generally 
better redox cyclers. The regioisomeric bias against azines with ortho-nitrogens was not 
consistently observed here, as seen from A3-1 and A3-4.  
 
Analysis of series B analogs showed a similar fold variation in EC50 values (11-fold, 0.7 – 7.4 
μM) as series A, but with fewer members (47%) having half the redox cycling ability of YM155. 
The similarity in fold variation suggest that redox cycling is equally affected by changes at N1 
and N3, but alterations at N1 (i.e. series B) were better placed to yield potent compounds. 
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Trends in redox cycling were generally less consistent when compared to DNA intercalation 
where there was a clearer SAR trend. For example, variable effects were noted for analogs with     
N1-alkyl groups (B2-X), cyclized entities (B1-2, B3-X) and bearing isosteric changes at the 2’-
methoxyethyl side chain (B1-X). However, B4-X analogs were good redox cyclers.  
 
Series AB compounds were found to be poor redox cyclers (EC50 2.8 – 7.6 μM). No discernible 
correlation in activity could be drawn between AB1 – AB6 and their corresponding series A 
analogs. AB7 was in fact a weak redox cycler.  
 
Having shown that YM155 and several analogs were redox cyclers in the in vitro assay, the next 
step was to confirm these findings in a cell based assay using 2’,7’-dichlorodihydrofluorescein 
(H2DCF) diacetate.189, 190 The diacetate is readily taken up into cells and hydrolyzed 
intracellularly by esterases to give H2DCF. The latter is trapped within cells due to its negatively 
charged state. In the presence of reactive oxygen species, H2DCF is oxidized to 
dichlorofluorescein which is fluorescent. When H2DCF loaded cells are treated with a redox 




The following compounds were tested: YM155, A3-3, B1-3, C1-2, AB1 and AB7. In terms of the 
in vitro redox cycling activities, B1-3 was the most potent (EC50 0.68 µM).  C1-2 (EC50 1.42 µM) 
was comparable to YM155 (EC50 1.38 µM) and the remaining compounds were less effective 
(EC50 2.0 - 7.6 µM). Naphthoquinone was included as a positive control (EC50 0.33 μM). The 
compounds were tested over a range of concentrations equivalent to 1x, 2x, 5x and 10x growth 
inhibitory IC50 on RCC786-0 and H1299 cells (Table 3.1). As seen from Figure 4.3, the 
compounds had similar effects on both cell lines. In each case, YM155, A3-3, B1-3, AB1 and 
AB7 did not alter the basal level of fluorescence over the entire concentration range, indicating 
that at concentrations relevant to their respective IC50 values, these compounds did not 
generate significant amounts of ROS. In contrast C1-2 demonstrated a dose dependent 
increase in fluorescence matching that of naphthoquinone at 5x IC50 (RCC786-0) and exceeding 
it at 2x IC50 (H1299). Thus, among the test compounds, only C1-2 generated significant levels of 







Figure 4.3. Generation of free radicals in RCC786-0 and H1299 cells at different concentrations 
of test compounds as determined by the fold change in H2DCF fluorescence. 
 
4.3.3 Correlation between growth inhibition, DNA intercalation and redox cycling 
Thus far, growth inhibitory IC50 (4 cell lines), DNA intercalation DC50 and redox cycling EC50 
values have been obtained for YM155 and its analogs. SAR has been established for these 
activities and some recurring trends were observed which may suggest that these activities are 







































































conducted. As seen in Table 4.2, DC50 and EC50 values were not significantly correlated to IC50 
values on all cell lines.  
 
Table 4.2. Spearman correlation of growth inhibitory IC50 on malignant cell lines, redox cycling 
EC50 values and DNA intercalation DC50 values.a 
 IC50 RCC786-0 IC50 RCC4/VA IC50 H1299 IC50 H1666 
EC50  -0.015 -0.02 -0.129 -0.002 
DC50 0.311 0.341 0.254 0.304 
a Only compounds with measurable values were included in the analyses (47 compounds for 
redox cycling; 46 compounds for DNA intercalation). 
 
4.3.4 Phosphorylation of γH2AX and evidence of apoptosis 
Glaros et al have proposed that YM155 intercalates with DNA and induces DNA damage by 
generating ROS.55 Evidence of DNA damage was deduced from dose dependent increases in 
phosphorylated histone H2AX (γH2AX) and phosphorylated KAP1 (pKAP1) which are 
biomarkers for double strand breaks in DNA.191, 192 γH2AX levels also increase in response to 
DNA fragmentation which is a sequel of apoptosis. As such it is necessary to establish if the 
elevated γH2AX levels in YM155 treated cells is a consequence of DNA damage or DNA 
fragmentation due to apoptosis. In general, DNA damage is initiated more rapidly than apoptotic 
cell death. Thus, a time-based experiment in which levels of an apoptotic marker cleaved 
caspase 3 and γH2AX from treated cells are concurrently monitored, would be informative. If 
γH2AX is observed earlier than cleaved caspase 3, this would implicate DNA damage as the 
initiating event, but if cleaved caspase 3 precedes or appears at the same time as γH2AX, then 




RCC786-0 and H1299 cells were treated with YM155, AB1 and AB7 at concentrations 
approximating to their IC50 values for 6, 24, 48 and 72 h. Cell lysates were prepared and probed 
for cleaved caspase 3 and γH2AX by Western blotting. AB1 (IC50 34 nM) is more potent than 
YM155 (IC50 54 nM) on RCC786-0 but comparable to it on H1299 (IC50 36 nM for both). AB7 is 
more potent than YM155 on both cell lines.  
 
As seen from Figure 4.4, γH2AX and cleaved caspase 3 increased with time on both cell lines. In 
RCC786-0, γH2AX was detected at 24h in YM155 treated cells and 48 h in AB1 and AB7-treated 
cells. Cleaved caspase 3 was observed to increase in tandem with γH2AX. In H1299 cells, both 
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Figure 4.4. Levels of cleaved caspase 3 and γH2AX after 6, 12, 24 72 h treatment of RCC786-0 
or H1299 with YM155, AB1 or AB7. Concentrations used were 50 nM (YM155), 37.5 nM (AB1) 
and 30 nM (AB7) on 786-0 cells, and 37.5 nM (YM155, AB1), and 30 nM (AB7) on H1299 cells.  
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Figure 4.5. YM155 and AB1 induced concentration dependent increases in γH2AX in RCC786-
0 and H1299 cells. Cells were incubated with test compounds at 0.5x, 1x and 2x IC50 for 48 h, 
following which γH2AX and cleaved caspase 3 (p17, p19) levels were probed by 
immunoblotting. The p19 fragment of cleaved caspase 3 is the precursor of p17. GADPH was 
used as loading control.  
 
Next, RCC786-0 and H1299 cells were treated with different concentrations (0.5x, 1x, 2x IC50) of 
YM155 and AB1 at a fixed time point (48 h). Levels of γH2AX and cleaved caspase 3 were then 
determined. As seen from Figure 4.5, both compounds induced concentration-dependent 
increases in γH2AX and cleaved caspase 3.   
 
Taken together, YM155, AB1 and AB7 induced time-dependent increases in γH2AX levels in 
both RCC786-0 and H1299 cells. These increases were aligned to increases in cleaved 
caspase 3 levels. Concentration dependent increases in these markers were also observed in 
YM155 and AB1-treated cells. 
 
4.4 Discussion  
Based on the in vitro ThO displacement assay, YM155 is a DNA intercalator. Its binding affinity 
to DNA is modest compared to doxorubicin. The modifications undertaken in the present series 
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of compounds failed to significantly improve intercalation although several analogs were found 
to be comparable or marginally more potent than YM155. The SAR identified the intact 
dioxonaphthoimidazolium scaffold as an essential feature for DNA intercalation but the relative 
importance of the different motifs in the scaffold could not be distinguished, as was possible for 
growth inhibition. Features that promoted intercalation were ring bearing side chains at N1 and 
N3. At N3, azinylmethyl side chains were permissible. The regioisomeric bias against ortho-
substituted azines that was prominently observed for growth inhibition was again apparent for 
DNA intercalation. At N1, diverse cyclized moieties (benzyl, pyrazinylmethyl, tetrahydrofurfuryl) 
and N’, N’-disubstituted aminoalkyl side chains which had adversely affected growth inhibition, 
were acceptable features for DNA intercalation. In fact, aside from the common requirement of 
an intact scaffold, there were few overlapping structural features for DNA intercalation and 
growth inhibition. Notably, there was a marked preference for cyclized or bulky substituents at 
N1, C2 and N3 which was not permitted for growth inhibition. It is noted however that N1, N3-
dimethyl substituted AB7 was good for both activities. 
 
In spite of the quinone presence in YM155, the present evidence does not support a strong 
redox cycling role for YM155. On the in vitro assay, YM155 was weaker than naphthoquinone 
and on the cell-based H2DCF assay, it failed to generate free radicals under conditions that saw 
strong responses from naphthoquinone. Limited overlaps were observed in the SAR trends for 
redox cycling and growth inhibition. First, there is less certainty as to whether the intact scaffold 
is required for redox cycling or even if the presence of quinone will ensure redox cycling. Cases 
in point are C1-2 (no benzene ring) and naphthoquinone (no imidazolium) which are good redox 
cyclers, and C4-1 and C4-2 which are not redox cyclers in spite of a quinone presence.  
Second, contrary to growth inhibitory requirements, ring bearing groups on N1 or N3 (but not 
small alkyl groups at the same positions) were generally well tolerated for redox cycling. Third, 
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N3-azinylmethyl analogs with ortho-nitrogens were surprisingly good redox cyclers, in contrast to 
their poor growth inhibitory properties.   
 
The question that needs to be addressed in this chapter is whether growth inhibition by 
functionalized dioxonaphthoimidazoliums and YM155 in particular, is due to DNA damage 
brought about by intercalation and redox cycling. The present evidence does not unequivocally 
support this hypothesis.  
 
Firstly, there is limited overlap in the structural requirements for growth inhibition and DNA 
intercalation/redox cycling. The intact dioxonaphthoimidazolium scaffold is required for growth 
inhibition and DNA intercalation but is optional for redox cycling. Side chain requirements are 
also different as highlighted in the preceding paragraphs.  
 
Secondly, YM155, AB1, AB7 and A3-3 did not generate free radicals on the cell based H2DCF 
assay, at least not at the concentrations investigated with the sole exception of C1-2. YM155, 
B1-3 and C1-2 had comparable redox cycling EC50 values (0.7 – 1.4 μM) but only C1-2 was 
active on the cell based assay. This discrepancy between the in vitro and in vivo results is 
puzzling. A possible reason may be that YM155 and B1-3 have lower IC50 values where at 
those concentrations, the generation of ROS in vivo was insignificant, compared to the 
significantly higher IC50 value (0.58 μM) of C1-2.  
 
Third, although YM155 and some of its potent analogs (AB1, AB7) induced the formation of 
DNA damage biomarker γH2AX in treated cells, it was detected only after 24 h or longer which 
is inconsistent with the rapidity of the DNA damage response. There was also a close alignment 
in the appearance γH2AX and the apoptotic marker cleaved caspase 3. As γH2AX is also 
formed as a consequence of DNA fragmentation which occurs during apoptosis, one may 
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question if the detection of γH2AX observed here solely reflected direct DNA damage by the 
test compounds.   
 
Lastly, a compound that induces DNA damage response or triggers redox cycling would 
discriminate poorly between malignant and non-malignant cells. Doxorubicin and 
naphthoquinone are cases in point. Doxorubicin acts primarily by DNA intercalation followed by 
inhibition of topoisomerase II, and to lesser extent, by generating ROS.194 As DNA transcription 
and replication are essential processes in both malignant and non-malignant cells, doxorubicin 
has a narrow therapeutic window. Naphthoquinone is a redox cycler and the generation of ROS 
would affect both malignant and non-malignant cells.195 In the present investigation, the average 
growth inhibitory IC50 values of doxorubicin and naphthoquinone were 103 nM and 6.3 μM 
(Table 4.3) respectively. Compared to their IC50 values on non-malignant IMR-90, they were 
only 2.4 – 2.6 times more potent on malignant cells. On the other hand, YM155 is more potent 
(average IC50 34 nM) and more selective (selectivity ratio 9-fold) than doxorubicin and 
naphthoquinone. Furthermore, the preclinical and clinical experiences with YM155 have been 
positive. Taken together, this is not a profile one would expect from a compound that induces 
DNA damage.  
 
Table 4.3. Growth inhibitory IC50 values of doxorubicin and naphthoquinone.a 
 Growth inhibitory IC50, μM 












Naphthoquinone 6.38 ± 0.13 5.51 ± 0.96 3.42 ± 0.56 9.78 ± 0.56 13.3 ± 2.0 




It was noted that there are several YM155 analogs (A5-1, B3-X, B4-X, C1-2) which are weaker 
growth inhibitors (0.58 – 8.8 μM), but are comparable or exceed YM155 in terms of DNA 
intercalation and redox cycling and have poor selectivity ratios (2 to 4-fold). C1-2 was also 
active on the cell based H2DCF assay. Taking this together with the above points, it is 
conceivable that DNA damage arising from intercalation and redox cycling contribute 
significantly to the mode of action of these significantly weaker compounds. On the other hand, 
YM155 and analogs that are more potent and exhibit greater selectivity may act by a 
mechanism/target that does not involve DNA damage. 
 
4.5 Conclusion 
YM155 and its dioxonaphthoimidazolium analogs were modest DNA intercalators, with limited 
potential as redox cyclers. Thus, their capacity to inflict direct DNA damage by these 
mechanisms should be reconsidered. While it would be remiss to disregard DNA as a target of 
YM155 and its potent analogs altogether, its involvement in growth inhibition may not be as 
significant as originally proposed.  
 
4.6 Experimental  
4.6.1 Materials 
Media for RCC786-0 and H1299 cells and subculturing conditions were as described in Chapter 
3. Herring sperm DNA was obtained from Promega Ptd. Ltd. (Madison, WI, USA). Doxorubicin, 
naphthoquinone, thiazole orange, phenol red sodium, dithiothreitol, horseradish peroxidase and 
Cellytic M® buffer were purchased from Sigma-Aldrich (St. Louis, MO, USA). 2’, 7’-
Dichlorodihydrofluorescein (H2DCF) diacetate was purchased from Life Technologies 
Corporation (Carlsbad, CA, USA). Anti-cleaved caspase-3 and anti-γH2AX antibodies were 
obtained from Cell Signalling Technology Inc. (Danvers, MA, USA) and anti-GADPH antibody 
was from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). The microplate reader (Tecan 
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InfiniteTM M200 Pro) was used to obtain readings. Dose response curves were plotted using 
GraphPad Prism 5 (San Diego, CA). 
 
4.6.2 Fluorescent intercalator displacement assay 
Previously reported methods were followed with modifications.185, 186 To each well in a black 96-
well plate was added 98.5 μL of BPE (biphosphate-phosphate-EDTA) buffer (comprising 6.0 
mM Na2HPO4, 2.0 mM NaH2PO4, 1.0 mM Na2EDTA; total Na+ concentration 16.0 mM; pH 7.0) 
containing 2 mg/mL herring sperm DNA and 1 μL of 10 μM thiazole orange (ThO) in deionised 
water. The resulting mixture was incubated at room temperature (25°) for 5 min. 0.5 μL of 
compound (200-fold concentration in DMSO) was added, kept at room temperature for 8 
minutes, with agitation (500 rpm on a plate shaker) and fluorescence read at excitation = 503 nm, 
emission = 536 nm on a microplate reader. DMSO per well was kept at 0.5% v/v. Test compound 
and doxorubicin (positive control) were tested over a range of concentrations in at least 3 
separate experiments. The percentage of undisplaced thiazole orange at a specific 
concentration of test compound was determined from the expression:  
 
 % Undisplaced thiazole orange = RFUcompound/RFUcontrol x 100%, where RFUcompound = 
fluorescence of test compound and thiazole orange, and RFUcontrol = fluorescence of thiazole 
orange without test compound. The DC50 of test compound (concentration to reduce basal 
fluorescence of thiazole orange (10 µM) by 50%) was determined by plotting % undisplaced 
thiazole orange against logarithmic concentration of test compound.  
 
4.6.3 Phenol red-horseradish peroxidase redox cycling assay 
Previously reported methods were followed with modifications.187, 188 2 μL test compound (200-
fold concentration in DMSO), 18 μL Hank’s Balanced Salt Solution (HBSS) and 40 μL 
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dithiothreitol (DTT) solution (2.5 mM in HBSS)  were sequentially added to each well in a 96-
well clear plate. The contents were shaken for 45 min at 600 rpm on a plate shaker, after which 
was immediately added 40 μL of horseradish peroxidase-phenol red solution (150 μg/mL 
horseradish peroxidase, 1 mM phenol red sodium in HBSS) and the plate shaken again for 
another 10 min at 600 rpm. 15 μL 1M NaOH was added to each well, agitated (1 min) and 
absorbance readings were read at 610nm on a microplate reader. DMSO content per well was 
kept at 1% v/v. Test compound and positive control naphthoquinone were tested over a range of 
concentrations. The absorbance at 610 nm was plotted against logarithmic concentration of test 
compound from which EC50 (concentration required to increase oxidized phenol red absorbance 
to 50% of maximum value) was determined.  
 
4.6.4 Dichlorodihydrofluorescein (H2DCF) diacetate assay 
RCC786-0 and H1299 cells were seeded at 1.0 x 104 cells/well and 1.5 x 104 cells/well 
respectively in black-walled, clear-bottom 96-well cell culture plates and incubated for 24 h at 
37°C, 5% CO2 in 100 μL of media. 2 μL H2DCF-diacetate in DMSO was then added to each well 
to give a final concentration of 20 μM and cells were incubated for another hour. The media was 
removed by aspiration and replaced by 100 μL of pre-warmed PBS containing test compound 
and 0.5% v/v of DMSO. After incubation for 2 h, plates were read on a microplate reader at 
excitation = 495 nm, emission = 526 nm. Test compounds were tested at concentrations 
corresponding to 1x, 2x, 5x and 10x cell-based IC50 and fluorescence at each concentration was 
expressed as fold-change of control fluorescence recorded in untreated cells. 
 
4.6.5 Western blotting 
RCC786-0 and H1299 cells were seeded at a cell density of 5.0 x 105 cells/plate in 100mm petri 
dishes (24 h, 37°C, 5% CO2) containing 5 mL of media. The media was removed by aspiration 
and replaced by 10 mL of fresh media containing test compound and 0.5% v/v of DMSO. After 
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incubation for the indicated times (6, 24, 48 or 72 h), cells were harvested and lysed in Cellytic 
M® buffer (Sigma-Aldrich, St. Louis, MO, USA). Protein content was assessed by Bradford 
assay and subjected to SDS-PAGE. Cells were blocked in 5% non-fat milk and probed with anti-
cleaved caspase 3 or anti-γH2AX antibodies to determine protein levels. Anti-GADPH antibody 





Chapter 5: Effects of YM155 and selected analogs on the NF-κB pathway 
5.1. Overview of the NF-κB pathway 
The nuclear factor-kappaB (NF-κB) pathway is widely associated with immune response115, 
inflammation196 and the pathogenesis of inflammatory diseases such as asthma, rheumatoid 
arthritis and inflammatory bowel disease197. More recently, it has been implicated in 
tumorigenesis and cancer.116, 117 The nuclear factor-kappaB family of transcription factors 
comprises 5 members or subunits (p65/RelA, p105/50, p100/52, RelB, c-Rel) characterized by a 
Rel Homology Domain (RHD) which recognizes and binds to the NF-κB response elements 
(Figure 5.1).198 RHD is also required for dimerization between NF-κB members and binding to 
the inhibitor of kappaB (IκB), a specific inhibitory factor that retains the NF-κB dimers in the 
cytoplasm.199 p65, Rel-B and c-Rel possess a transactivation domain (TAD) which is absent in 
p100/52 and p105/50. TAD is required to activate transcription and hence, the upregulation of 
target genes. NF-κB heterodimers that have TAD in at least one monomeric unit would be able 
to activate transcription whereas homodimers made up of  p50 or p52 which do not have TAD, 
are thought to suppress transcription.200 p105 and p100 are precursors of p50 and p52 
respectively. They contain ankyrin domains which mask the nuclear localization signals on the 
subunits and block the ability of dimers to bind to DNA.201 Cleavage of the ankyrin repeats 





Figure 5.1. Members of the NF-κB family of transcription factors. Members contain a Rel 
homology domain (RHD) that is required for binding to the consensus sequence 
GGGPNNPyPyCC (where P is A/G, Py is C/T, and N is any base) on DNA. Only p65, RelB and 
c-Rel contain transactivation domains (TAD) which are necessary for upregulating NF-κB 
controlled genes. p52 and p50 are synthesized as the larger p100 and p105 precursor proteins. 
The ankyrin repeats are cleaved from the C-terminal to give p52 and p50. 
 
There are three pathways which are well characterized in NF-κB signaling. The canonical 
pathway which was the first to be elucidated, is activated by a variety of cytokines, notably 
tumor necrosis factor-α (TNF-α). When TNF-α binds to its cognate receptor, various cytosolic 
proteins such as TRAF2 are recruited and activated.200 Downstream transduction leads to the 
phosphorylation and activation of the inhibitor of IκB kinase (IKK) complex which consists of 
IKKα, IKKβ and IKKγ (NEMO). IκB, which binds to and prevents nuclear translocation of p65 by 
masking its nuclear localization signal, is then phosphorylated by the active IKK complex and 
subsequently marked for ubiquitination and proteasomal degradation. p65 is thus liberated and 
forms a dimer with p50 which translocates to the nucleus where it upregulates various target 
genes after further phosphorylation events and recruitment of other transcription factors. In 






















when the ankyrin domains are removed from its precursor p105. It is noteworthy that IκB is also 
phosphorylated by casein kinase 2 (CK2) besides the IKK complex, typically as a result of DNA 
damage induced by UV radiation or xenobiotics. This constitutes the atypical pathway.202 
 
Figure 5.2. Activation of the NF-κB pathway. (A) In the canonical pathway, activation of the IKK 
complex leads to phosphorylation of IκB and its eventual proteosomal degradation. p65 is 
released, dimerizes with p50 and translocates to the nucleus, where it upregulates the 










































canonical pathway, NIK activation is followed by activation of an IKKα homodimer which then 
phosphorylates p100 and release of p52 upon p100 cleavage. p52 heterodimerizes with RelB, 
translocates to the nucleus and upregulates genes responsible for lymphoid organogenesis and 
B-cell development. (C) The atypical pathway is triggered by DNA damage which activates p38 
and CK2 sequentially, leading to phosphorylation of IκB in an IKK independent manner. The 
subsequent steps converge with the canonical pathway. 
 
The non-canonical pathway involves RelB and p52, with lymphotoxin B receptor (LTBR), CD40 
and receptor activator of nuclear factor kappa-B (RANK) as typical upstream receptors. Upon 
activation by cytokines such as lymphotoxin B and RANK ligand (RANKL), a phosphorylation 
cascade is triggered starting from NF-κB inducing kinase (NIK), then IKKα homodimer and 
finally p100 which is then cleaved to produce the active p52 subunit. p52 dimerizes with RelB to 
form a heterodimer which translocates to the nucleus and upregulates relevant genes. 203 
 
The non-canonical pathway has been implicated in lymphoid organogenesis and B-cell 
development and survival. It is also implicated in the carcinogenesis of certain lymphoid 
malignancies such as multiple myeloma.203, 204 The canonical pathway has been extensively 
investigated over the past two decades for its role in inflammation and inflammatory 
diseases.205-207 There is increasing evidence that the canonical pathway is constitutively 
activated in several cancers, 208, 209 although the mechanisms are not well elucidated. Many of 
the gene products regulated by the canonical pathway are involved in angiogenesis (VEGF)210, 
211, anti-apoptosis (survivin, XIAP, Bcl-2, Bcl-xl, Mcl1)20, 212-215, metastasis (ICAM-1, VCAM-1)208 





The involvement of the NF-κB pathway in the tumorigenesis of RCC has been mentioned in 
Chapter 3. The p65 and p50 subunits have been shown to be overexpressed in several RCC 
cell lines.202 In the clinical setting, NF-κB activity was first shown in 2003 to be upregulated in a 
small cohort of patients where it was noted that 69% of patients with metastatic disease 
presented with upregulated expression of p50 and p65, along with downregulated IκB.217 
Subsequent studies reported p65 overexpression in at least 70% of patient samples218 while a 
meta-analysis revealed that the NF-κB pathway is upregulated in around 40% of RCC cases.219 
Upregulation of NF-κB is also associated with poor prognostic outcomes. The majority of 
ccRCCs are associated with mutations in the von Hippel Lindau (VHL) tumor suppressor gene. 
In the absence of a functional VHL, the NF-κB pathway is upregulated through the accumulation 
of HIF-1220 and activation of the NF-κB agonist Card9 which is normally suppressed by VHL.202 
Studies have shown that the promoter region of the HIF-α gene contains an NF-κB binding 
sequence, and HIF-α levels increase when the canonical pathway is stimulated by TNF-α.220, 221 
Even in tumors with functional VHL, NF-κB signalling is constitutively activated.202, 222 Thus, 
inhibiting the NF-κB pathway might be viewed as delivering a “one-two punch” on RCC: First by 
curtailing the production of pro-survival proteins controlled by p65, and secondly by disrupting 
HIF-induced angiogenesis.  
 
Constitutive activation of the NF-κB pathway in NSCLC was reported earlier than RCC.223 These 
and later studies found p50 overexpression in at least 80% of clinical samples.224, 225 Activation 
of the NF-κB pathway was associated with poor prognosis and higher mortality, indicating its 
importance to the tumorigenic process.226 Evidence from studies performed on NSCLC cell lines 
confirmed the overexpression of p65 and p50, and current evidence supports the view that the 
p50 plays a larger role in NSCLC.227 Although commonly regarded as a repressor, the p50/p50 
homodimer may activate transcription upon association with Bcl-3, a member of the IκB 
family.228 This association was found to be potentially oncogenic in nasopharyngeal cancer. The 
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NF-κB pathway also crosstalks with the EGFR pathway and mTOR which is downstream of 
EGFR is able to phosphorylate IKK complexes, thereby activating the NF-κB pathway.229 
Therefore there is a sound rationale for targeting the NF-κB pathway in NSCLC. 
 
Survivin overexpression has been shown to be a biological sequela of NF-κB activation in 
several malignancies. NF-κB inhibition in multiple myeloma cells downregulate survivin 
expression.230 In adult T cell lymphoma, the viral protein Tax produced by its etiological agent 
human T lymphotropic virus 1 (HTLV-1) directly activates the survivin gene. An NF-κB binding 
site on the survivin promoter was required for Tax-induced survivin expression and deletion of 
this site resulted in a loss of Tax responsiveness.212 Cross-talk between p53 and NF-κB was 
reported to modulate survivin expression.231 In quiescent cells, p53 binds to the survivin 
promoter to inhibit transcription of the gene but under conditions of replication stress, p53 
induces survivin transcription 45, 232, 233 by a mechanism that involves NF-κB. 44 In yet another 
study on animal xenografts bearing head and neck squamous cell carcinoma cells, the 




The preceding discussion has highlighted the tumorigenic role of the NF-κB pathway and the 
causality between NF-κB signaling and survivin expression. Hence, it is of interest to determine 
if disruption of NF-κB signaling has a part to play in the suppression of survivin by YM155. As 
survivin is downstream of many signaling pathways that are constitutively activated in cancer 
cells, interception of an upstream target by YM155 would result in altered levels of survivin, and 
possibly other apoptotic proteins as well. Thus it is hypothesized that YM155 disrupts the NF-κB 
pathway and that this effect contributes to the suppression of survivin and by extension, the cell 
killing effects of YM155. To this end, the effects of YM155 and a selected analog AB1 were 
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investigated on selected proteins and processes in the NF-κB pathway, namely the 
phosphorylation of p50 and p65, binding of NF-κB dimers to their consensus elements and 
expression of NF-κB controlled genes.  
 
5.3. Results 
5.3.1. YM155 and analogs induced apoptotic cell death in RCC786-0 and H1299 cells.  
The apoptogenic effects of YM155 have been widely reported and in Chapter 4, it was shown 
that its potent analogs (AB1, AB7) increased levels of the apoptotic protein marker, cleaved 
caspase 3. To confirm that apoptosis is the primary mechanism of cell death induced by YM155 
analogs, other approaches were employed to investigate this phenomenon.  
 
First, a commercial multiplex assay (ApoTox-GloTM) was used to simultaneously monitor cell 
viability, cytotoxicity and apoptotic events in RCC786-0 and H1299 cells treated with YM155, 
AB1, A4-1 and B2-4. The growth inhibitory activity of AB1 was comparable to YM155 but B2-4 
and A4-1 were less potent. If these compounds also induced apoptosis, it would support the 
notion that this mode of cell death is characteristic of the dioxonaphthoimidazolium scaffold and 
applies to analogs with a broad range of potencies. The assay would also report on the 
prevalence of necrotic vis-à-vis apoptotic cell death in treated cells.  
 
Second, fluorescence-activated cell sorting (FACS) analysis of treated cells double stained with 
Annexin V-FITC (fluorescein isothiocyanate) conjugate and propidium iodide (PI) was 
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undertaken to determine the extent to which apoptosis and necrosis contribute to cell death. 
Only YM155 and AB1 were investigated. Third, levels of anti- and pro-apoptotic proteins in 
treated cells were probed to confirm the occurrence of apoptosis. 
 
5.3.1.1. Multiplex assay for apoptosis 
Briefly, viability and cytotoxicity are monitored in the multiplex assay by the activities of two 
proteases (“live-cell” protease and “dead-cell” protease) on their respective peptide substrates. 
The substrate for the “live-cell” protease enters intact cells where it is cleaved by the live-cell 
protease to release a fluorophore which generates a fluorescence signal that is proportional to 
the number of live cells. When a cell undergoes necrosis, it loses its membrane integrity. Live-
cell protease activity will cease and “dead-cell” proteases are released into the surrounding 
medium and act on a cell-impermeable substrate to generate a different fluorescent signal. If 
cell viability is found to decrease without a concurrent increase in necrosis (cytotoxicity), then 
apoptosis, not necrosis, is the major mechanism of cell death. Confirmation of apoptosis is 
provided by the 3rd component of the multiplex assay which detects the release of caspases 3 
and 7. The caspases remove luciferin from a peptide substrate which then reacts with luciferase 
to generate a luminescence signal proportional to the amount of active caspases.  
 
RCC786-0 and H1299 cells were incubated with YM155, AB1, B2-4 and AB1 at concentrations 
of 0.2x to 5x IC50 for 48 h before being analyzed on the multiplex assay. The results on 
RCC786-0 and H1299 cells are given in Figures 5.3 and 5.4 respectively. The test compounds 
decreased viabilities on both cell lines in a dose dependent manner and 50% viability was 
observed at concentrations that approximated to IC50 values determined on the MTT assay. On 
the other hand, dose-dependent increases in “dead-cell protease” activity which is a measure of 
necrosis/cytotoxicity were not consistently observed. Thus, decreases in cell viability were not 
accompanied by increases in necrotic cell death. On the other hand, dose dependent increases 
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in caspase activities (except at the highest concentration, possibly due to declining number of 
viable cells) were observed. These results support the notion that the loss in cell viability was 
largely due to caspase-mediated apoptosis with negligible contribution from necrotic cell death. 
 
It should be mentioned that to quantify caspase activation, the presence of viable cells at each 
test concentration was taken into account. This was achieved by dividing the change in caspase 
induced increase in luminescence (relative to control) by the fluorescence reading attributed to 
the “live cell” protease (relative to control) to give the “normalized” caspase activation (caspase 


















































































































































































Figure 5.3. Evaluation of YM155, AB1, A4-1 and B2-4 on cell viability, cytotoxicity and 
caspases 3 and 7 activation using the multiplex Apotox-GloTM assay. Compounds were 
incubated with RCC786-0 cells for 48 h at concentrations ranging from 0.2x to 5x IC50 on 
RCC786-0. Y axis on left hand side monitors % viability while the right hand side axis monitors 
fold change in cytotoxicity or normalized caspase activation compared to untreated control cells. 




Figure 5.4. Evaluation of YM155, AB1, A4-1 and B2-4 on cell viability, cytotoxicity and 
caspases 3 and 7 activation using the multiplex Apotox-GloTM assay. Compounds were 








































































































































































5.3.1.2. Annexin V-FITC/Propidium iodide (PI) assay 
In the 2nd approach, cells were treated with varying concentrations of YM155 and AB1 (0.5x, 1x, 
2x or 5x IC50) for 24 h or 48 h, double stained with Annexin V-FITC and PI, and subsequently 
analyzed by FACS. Briefly, the onset of apoptosis is characterized by translocation of 
phosphatidylserine from the inner to outer surfaces of cell membranes. Once positioned in the 
outer membrane, the phosphatidylserine residues bind to Annexin V and are detected by the 
fluorescence of FITC. On the other hand, PI which is a fluorescent DNA intercalator, is excluded 
from viable cells and only permeates membranes of cells in late apoptosis or necrosis.235 Thus, 
apoptotic cells are positively stained by Annexin V but not PI (early apoptosis) or positively 
stained by both Annexin V and PI (late apoptosis). Necrotic cells are only stained by PI. The 
distribution of cells in the various phases under the different treatment conditions are shown in 
Figures 5.5 (RCC786-0) and 5.6 (H1299).  
 
It can be seen that the apoptogenic effects of YM155 and AB1 were both time and 
concentration dependent. Stronger and faster responses were elicited on RCC786-0 than 
H1299 cells suggesting differences in their susceptibilities to the test compounds. For instance, 
nearly 40% of RCC786-0 cells were found in the early and late apoptotic state after 48 h of 
exposure to the highest concentration (4x IC50, 250 nM) of YM155 and AB1. In comparison, no 
more than 15% of H1299 cells were found to be apoptotic under similar conditions. Lastly, the 
compounds did not substantially increase the proportion of necrotic cells, except for YM155 and 
AB1 on RCC786-0 cells at 48 h. Even then, the proportion of apoptotic cells exceeded that of 
necrotic cells for each treatment condition, indicating that apoptosis is the main driver of cell 






 necrosis;  early apoptosis;  late apoptosis;   total apoptosis 
Figure 5.5. YM155 and AB1 induce apoptosis in RCC786-0 cells. Percentage of cells 
undergoing necrosis and apoptosis when treated with different concentrations of YM155 or AB1 
at 24 and 48 h time points. Error bars represent the standard deviations of three separate 
experiments. * p < 0.05; ** p < 0.01; *** p < 0.001 (Tukey post-hoc test of respective populations 













































































 necrosis;  early apoptosis;  late apoptosis;   total apoptosis 
Figure 5.6. YM155 and AB1 induce apoptosis in H1299 cells. Percentage of cells undergoing 
necrosis and apoptosis when treated with different concentrations of YM155 or AB1 at 24 and 
48 h time points. Error bars represent the standard deviations of three separate experiments. * p 
< 0.05; ** p < 0.01; *** p < 0.001 (Tukey post-hoc test of respective populations of treated 







































































Figure 5.7. Dot plots of Annexin V-FITC fluorescence vs. PI fluorescence for vehicle control, 
YM155 or AB1 treated RCC786-0 cells after 48 h incubation. Clockwise from the upper left 
quadrant of each plot: Q1 (necrotic cells), Q2 (late apoptotic cells), Q4 (early apoptotic cells) 


























Figure 5.8. Dot plots of Annexin V-FITC fluorescence vs. PI fluorescence for vehicle control, 
YM155 or AB1 treated H1299 cells after 48 h incubation. Clockwise from the upper left quadrant 
of each plot: Q1 (necrotic cells), Q2 (late apoptotic cells), Q4 (early apoptotic cells) and Q3 
(healthy cells). 
 
Figures 5.7 and Figure 5.8 depict the dot plots of Annexin V-FITC against PI fluorescence of 
treated RCC786-0 and H1299 respectively at the 48 h time point (dot plots at 24 h time point are 
provided in Appendix 2). These plots provide a “kinetic” aspect to the changing proportion of 
cells in various phases at different concentrations of YM155 and AB1. Low concentrations of 























saw a progression towards the late stages of apoptosis (Q2). Noticeably, the proportion of 
necrotic cells (Q1) remained small. 
 
5.3.1.3. Western Blotting 
Lastly, levels of cleaved caspase 3, Bcl-2, Mcl1, BAX and survivin were monitored in H1299 and 
RCC786-0 cells treated at various time points and varying concentrations of YM155 and AB1. 
AB7 was also investigated in some of these assays. It should be mentioned that γH2AX was 
monitored concurrently in these blots but are not shown here. As γH2AX levels were probed to 
assess strand breaks in DNA, they were discussed in Chapter 4 together with cleaved caspase 
3. The latter is shown again in Figures 5.9, 5.10 and discussed in the following paragraph as it 
is an important marker of apoptosis. 
 
Figure 5.9 shows time dependent changes (6, 24, 48, 72 h) in cleaved caspase 3 levels in cells 
treated with YM155, AB1 and AB7 at their respective IC50 concentrations. On RCC786-0 cells, 
cleaved caspase 3 levels were observed early (24 h) in YM155 treated cells but later (48 h) in 
AB1 and AB7 treated cells. However on treated H1299 cells, cleaved caspase 3 was 
consistently detected at the 48 h time point for all three compounds.  
 
Figure 5.10 shows dose dependent increases in cleaved caspase 3 in cells treated with 
increasing amounts of YM155 or AB1 at a fixed time point of 48 h. AB7 was not investigated. 
Cleaved caspase 3 levels in both cell lines were detected at a lower concentration (0.5x IC50) of 
YM155 as compared to AB1 (IC50). YM155 is likely more apoptogenic than AB1.   
 
YM155 and AB1 were also investigated for their effects on selected anti-apoptotic (survivin, Bcl-
2, Mcl1) and pro-apoptotic (BAX) proteins. AB7 was investigated on survivin only. As in the 
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case of cleaved caspase 3, the effects of varying incubation times and concentrations were 
explored.  
 6 h 24 h 48 h 72 h  
 C YM AB1 C YM AB1 C YM AB1 C YM AB1  
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Figure 5.9. Levels of cleaved caspase 3 and other apoptosis-related proteins after 6, 24, 48, 72 
h treatment of RCC786-0 or H1299 with YM155, AB1 or AB7. Concentrations used were 50 nM 
(YM155), 37.5 nM (AB1) and 30 nM (AB7) on RCC786-0 cells, and 37.5 nM (YM155, AB1), 
and 30 nM (AB7) on H1299 cells. GAPDH was used as a loading control. 
 
YM155, AB1 and AB7 reduced survivin levels in treated H1299 and RCC786-0 cells. The 
reductions increased with time and were observed earlier in H1299 cells (24 h) as compared to 
RCC786-0 cells (48 h). That AB1 and AB7 were comparable to YM155 in this regard suggest 
that side chain modifications at N1 and N3 do not affect survivin suppressant activity. YM155 and 
AB1 also reduced levels of Mcl1 on both cell lines. The decreases were observed by 6 h in 
RCC786-0 cells but later (48 h) in H1299 cells. On the other hand, levels of Bcl-2 and BAX 
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Figure 5.10. Levels of cleaved caspase 3 and other apoptosis-related proteins after 48 h 
treatment of RCC786-0 or H1299 with YM155 or AB1 at 0.5x, 1x and 2x IC50 (as in Fig 5.9). 
GAPDH was used as a loading control. 
 
As for YM155 and AB1-induced dose dependent changes in the levels of the afore-mentioned 
proteins, this was only observed for survivin and Mcl1, but not Bcl-2 and BAX (Figure 5.10). 
Another anti-apoptotic protein Bcl-xl was also probed and YM155 and AB1 were found to 
induce dose dependent reductions as well. Based on the concentrations required to initiate 
reductions in survivin, Mcl1 and Bcl-xl, there are indications that H1299 cells were more 
susceptible to the test compounds and in particular AB1. For instance, AB1 at 0.5x IC50 
significantly reduced Mcl1 and Bcl-xl levels in H1299 but not RCC786-0 cells. 
   
In summary, YM155 and AB1 suppressed survivin, Mcl1 and Bcl-xl on both cell lines. BAX and 
Bcl-2 levels were not affected by these compounds. The suppression of Mcl1 and Bcl-xl by 
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YM155 and AB1 is noteworthy because these proteins regulate apoptosis at the mitochondrial 
level which is an early event preceding caspase activation. The downregulation of Mcl1 by 
YM155 has been investigated in some detail and found to occur at the transcriptional level, 
independent of survivin expression and caspase activity.49    
 
5.3.2. Silencing of p65 and p50 affected the viability of RCC786-0 and H1299 cells 
Before investigating for effects of YM155 and AB1 on the NF-κB pathway, it was necessary to 
assess the importance of this pathway for cell viability and survival. To this end, RCC786-0 and 
H1299 cells were transfected with p50 and p65 silencing RNAs (siRNA) at 10 nM and 50 nM. 
Viabilities were assessed after 48 h and 72 h by the MTT assay.  
 
As seen from Figure 5.11, viability was significantly affected by the silencing of the p50 and p65 
genes in RCC786-0 cells. The losses increased with time and concentration of the siRNA. On 
H1299 cells, silencing of the p65 gene caused smaller losses in viability. Even after 72 h, 
viability was reduced by only 20%, with limited evidence of dose or time dependency. In 
contrast, greater losses were observed when p50 was silenced. Thus, there is a strong cell line-
specific effect with regard to the silencing of these NF-κB subunits and cell viabilities appear to 
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Figure 5.11. (A) Silencing of p50 and p65 leads to loss of cell viability in both RCC786-0 and 
H1299 cells. Error bars represent the standard deviations of three separate experiments. * p < 
0.05; ** p < 0.01; *** p < 0.001 (Tukey post-hoc test of respective populations of siRNA-treated 
groups vs control). (B) Western blotting showing successful silencing of p50 and p65 in H1299 
and RCC786-0 cells 72 h post-transfection. p105 is the precursor form of p50 and is cleaved to 
give the latter. All siRNA were used at 50 nM for Western blotting. Negative control cells were 
treated with empty Lipofectamine 3000. Non-targeting siRNA treated cells were treated with 

















































































5.3.3. YM155 and AB1 reduced the binding of p50 and p65 to their consensus elements in an 
in vitro assay. 
NF-κB dimers (p50/p65, p50/p50) translocate from cytosol to nucleus where they bind to 
specific DNA sequences (consensus elements) on the κB sites to initiate gene transcription. To 
determine if YM155 and AB1 interfere with the binding of NF-κB dimers to their consensus 
sequences, an enzyme-linked immunosorbent assay (ELISA) was carried out on a commercially 
purchased kit. Briefly, the kit comprises biotin-conjugated short oligonucleotide sequences (5’-
GGGACTTTCC-3’) corresponding to the NF-κB response elements which are immobilized onto 
96-well plates coated with streptavidin. Wells are treated with nuclear lysates containing NF-κB 
units (p50/p65, p50/p50). These bind to the response elements and are detected by anti-p65 or 
anti-p50 primary antibodies and HRP-linked secondary antibodies. A substrate of HRP is then 
added which on cleavage, generates a chemiluminescent signal which is proportional to the 
extent to which the NF-κB dimers are bound to the consensus elements. 
 
Figure 5.12. YM155 and AB1 caused losses in the binding of p65 and p50 to the consensus 
NF-κB response elements. Cells were treated with 0.5x, 1x or 2x growth inhibitory IC50 of 
YM155 or AB1 for 48 h, nuclear lysates were prepared and tested as described in text. Error 
bars represent the standard deviations of three separate experiments. Significant statistical 
difference from vehicle control is indicated as follows: * p < 0.05; ** p < 0.01; *** p < 0.001 





























































As seen from Figure 5.12, YM155 and AB1 reduced the binding of p50 and p65 to their 
consensus elements in RCC786-0 and H1299 cells. Both compounds caused comparable dose-
dependent losses in p65 binding on both cell lines. YM155 also reduced p50 binding in a dose-
dependent manner on both cell lines. The losses were broadly aligned to that observed for p65. 
Interestingly, AB1 caused steeper losses in p50 binding in H1299 cells as compared to 
RCC786-0 cells. Notably, significant reductions (~40%) were observed at 0.5x IC50 (17.5 nM) of 
AB1 in H1299 cells. This level of loss was elicited by 2x IC50 of AB1 (70 nM) in RCC786-0 cells 
and 2x IC50 of YM155 (100 nM) in H1299 cells. 
 
The experiments were repeated in the presence of TNF-α which serves to stimulate the NF-κB 
pathway.236 Losses in p50 and p65 binding in YM155- and AB1-treated cells were again 
observed and were particularly pronounced in RCC786-0 cells where p50 and p65 binding were 
reduced to only 10% at 2x IC50 of YM155 and AB1 (Figure 5.13). Interestingly, the dramatic 
reduction in p50 binding that was observed earlier in H1299 cells treated with 0.5x IC50 AB1 
was not evident in TNF-α stimulated cells.  
 
These results come with the caveat that the diminished binding of p50 and p65 to their 
consensus sequences may be due to the downregulation of p65 and p50 protein expression by 
the test compounds. To explore this possibility, p65 and p50 levels in total cell lysates were 





Figure 5.13. YM155 and AB1 induced losses in binding of p65 and p50 to the consensus NF-
κB response element DNA sequence. Cells were treated with 0.5x, 1x or 2x growth inhibitory 
IC50 of YM155 or AB1 for 48 h in the presence of 25 ng/mL TNF-α. Error bars represent the 
standard deviations of three separate experiments. Significant statistical difference from vehicle 
control is indicated as follows: * p < 0.05; ** p < 0.01; *** p < 0.001 (Tukey post-hoc test of 
respective populations of treated groups vs control). 
 
5.3.4. YM155 and AB1 inhibit phosphorylation of p50 in H1299 and RCC786-0 cells 
RCC786-0 and H1299 cells were treated with a fixed concentration (IC50) of YM155 and AB1 at 
various time points (6, 24, 48, 72 h) after which lysates were prepared and probed for IκBα, p50, 
p65 and p105 by western blotting. As mentioned earlier, IκBα is a specific inhibitory factor that 
retains the NF-κB dimers in the cytoplasm and p105 is the precursor of p50. As seen from 
Figure 5.14, there was no change in the levels of IκBα, p50, p65 and p105 over time. Neither 
were there changes when cells were treated with increasing amounts (0.5x IC50 to 2x IC50) of 
YM155 and AB1 for 48h (Figure 5.15).   
  
p50 and p65 are converted to their functionally active states by phosphorylation. 
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p50 at Ser337 regulates DNA binding.237-239 Hence, levels of phospho-p65 and phospho-p50 
were also monitored in treated cells over time (Figure 5.14) and at varying concentrations of 
YM155 and AB1 (Figure 5.15). 
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Figure 5.14. Levels of IκBα, NF-κB subunits p50 (p105), p65 and their respective 
phosphorylated forms (p.p50, p.p65) after 6, 24, 48, 72 h treatment of RCC786-0 or H1299 with 
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YM155 or AB1. Concentrations used were 50 nM (YM155) or 37.5 nM (AB1) on 786-0 cells, 
and 37.5 nM (YM155, AB1) on H1299 cells. GAPDH was used as a loading control. 
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Figure 5.15. Levels of IκBα, NF-κB subunits p50 (p105), p65 and their respective 
phosphorylated forms (p.p50, p.p65) after 48 h treatment of RCC786-0 or H1299 with YM155 or 
AB1 at 0.5x, 1x and 2x IC50 (as in Fig 5.14). GAPDH was used as a loading control. 
 
Neither YM155 nor AB1 reduced phospho-p65 levels in a time-dependent manner. Dose-wise, 
reductions in phospho-p65 levels were only noted in H1299 cells treated with higher 
concentrations (2x IC50) of both compounds. This was not observed in RCC786-0 cells where 
phospho-p65 levels were unchanged.  
 
In contrast, phospho-p50 levels were markedly reduced in YM155/AB1-treated cells. Decreases 
were more pronounced in RCC786-0 cells where hardly any phospho-p50 was detected after 24 
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h in the treated cells. It was again reinforced in the dose-dependent experiments where stronger 
responses were elicited from RCC786-0 cells as seen from the lower concentrations (1/2 x IC50) 
of YM155 and AB1 required to completely suppress phospho-p50 levels as compared to H1299 
cells.  
 
From these results, it is deduced that YM155 and AB1 do not disrupt the expression of IκBα, 
p65, p50 and its precursor p105 in the NF-κB signalling pathway. That IκBα levels remained 
unchanged suggests that the NF-κB/IκB complex is not targeted. Rather the compounds 
intercepted the phosphorylation of p50 which is required for the binding of p50- containing 
dimers (p50/p65, p50/p50) to their consensus sequences in DNA. On the other hand, 
phosphorylation of p65 was not impeded by YM155 and AB1, pointing to selective targeting of 
the p50 subunit.   
 
A caveat to these findings is that YM155 and AB1 could have blocked the translocation of NF-
κB dimers from the cytoplasm to the nucleus as this would also result in diminished levels of 
phospho-p50. To investigate this possibility, lysates from treated cells were separated into 
nuclear and cytoplasmic fractions and probed for phospho-p50 and phospho-p65 by western 
blotting. 
 
5.3.5. YM155 and AB1 selectively suppressed the phosphorylation of p50 in the nuclear 
compartment  
Cytoplasmic and nuclear fractions prepared from H1299 and RCC786-0 cells treated with 
YM155 and AB1 (IC50, 48 h) were separately probed by western blotting for total and 
phosphorylated p65 and p50. As seen in Figure 5.16, p65 and p50 were found in the 
cytoplasmic and nuclear compartments of the treated cells and their levels were comparable to 
that of the untreated controls. Thus, YM155 and AB1 did not perturb p50 or p65 levels in either 
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compartment and it is unlikely that they interfere with the translocation of NF-κB dimers 
(p50/p65, p50/p50) from cytoplasm to nucleus.  
 
 RCC786-0 – 48 h  H1299 – 48 h 
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Figure 5.16. Cytoplasmic and nuclear levels of p105, p50, p65 and their phosphorylated forms 
(p.p50 and p.p65) after 48 h treatment of RCC786-0 or H1299 with YM155 or AB1 at ½ x, 1x 
and 2x IC50 (as in Fig 5.14). Lamin B and α-tubulin were used as loading controls for the nuclear 
and cytoplasmic fractions respectively. 
 
Levels of p105, the precursor protein of p50, in the cytoplasm and nuclei of treated cells were 
also examined. No change in p105 was observed in the cytoplasm of treated cells which was in 
keeping with the unaltered cytoplasmic levels of p50. Although p105 is generally regarded to be 
confined to the cytoplasm, traces of it were detected in the nuclei of control H1299 and 
RCC786-0 cells, with slightly higher levels in RCC786-0 cells. In any case, p105 levels in the 





Next, the distribution of phospho-p50 and phospho-p65 in the cytosol and nuclei of treated cells 
were examined (Figure 5.16). Phospho-p65 was almost entirely localized in the cytoplasm of 
untreated cells and the cytoplasmic levels were not reduced in the presence of YM155 or AB1. 
Curiously, both compounds induced a slight elevation in nuclear levels of phospho-p65 in 
RCC786-0 cells.  
 
In contrast, phospho-p50 was detected in nuclear extracts of untreated RCC786-0 and H1299 
cells. In RCC786-0 cells, phospho-p50 was exclusively localized in the nuclei whereas in H1299 
cells it was found in both compartments, with higher levels in the cytoplasm. Exposure to 
YM155 or AB1 resulted in significant reductions in nuclear phospho-p50 but minimal changes to 
cytoplasmic phospho-p50 levels. The reductions in nuclear phospho-p50 were particularly 
pronounced in RCC786-0 cells as compared to H1299 cells, which were aligned to the 
observations on the time- and concentration-dependent changes in total phospho-p50 levels.   
 
In summary, the analyses of the cytoplasmic and nuclear contents of phosphorylated p65 and 
p50 support the notion that YM155 and AB1 did not block the cytosol to nuclear translocation of 
NF-κB dimers. The present evidence points to suppressed phosphorylation of nuclear (but not 
cytoplasmic) p50 at serine 337.  
 
5.3.6. YM155 and AB1 reduce expression of NF-κB controlled genes 
Since the NF-κB subunits act as transcription factors, it was of interest to determine if YM155 
and AB1 inhibited the transcription of NF-κB controlled gene. A luciferase reporter assay was 
employed in which GloResponse™ NF-κB-RE-luc2P HEK293 cells containing a stably 
transfected luciferase gene controlled by a minimal TATA box promoter with several NF-κB 
response elements were incubated with increasing amounts (1 – 10 nM) of YM155 and AB1 for 
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48h. TNF-α was then added to stimulate the pathway. If transcription was interrupted, a 
diminished luminescent signal would be detected. Figure 5.17 shows that both compounds 
reduced NF-κB reporter activity in a dose dependent manner. At low concentrations (2.5 – 5 
nM), AB1 elicited greater reductions than YM155 but at the highest concentration (10 nM), both 
compounds reduced reporter activity to the same extent. Thus, YM155 and AB1 attenuated NF-
κB transcriptional activity and reduced the expression of NF-κB controlled genes.  
 
Figure 5.17. NF-κB reporter activity as assessed by HEK293 NF-κB-RE-luc2P cells. Cells were 
treated with 4 different concentrations of YM155 or AB1 in addition to vehicle control and 
incubated for 48 h before assay. Error bars represent the standard deviations of three separate 
experiments. Significant statistical difference from vehicle control is represented by an asterisk 
(*) when p<0.05, two asterisks (**) when p<0.01 and three asterisks (***) when p<0.001 (Tukey 
post-hoc test of respective populations of treated groups vs control). 
 
5.4. Discussion 
The objective of this chapter is to investigate if YM155 and a representative potent analog 
(AB1) disrupted the NF-κB pathway in a way that would contribute to the suppression of 





































on the phosphorylation of the p50 subunit of NF-κB. This property was also observed in AB1, 
suggesting that it is common to the functionalized dioxonaphthoimidazolium scaffold.  
 
Both YM155 and AB1 induced time- and dose-dependent reductions in total phospho-p50 
extracted from treated H1299 and RCC786-0 cells. A closer analysis revealed that only the pool 
of phospho-p50 in the nuclear compartments of treated cells were diminished. Notably, 
cytoplasmic levels of phospho-p50 (when present) were minimally affected. Intriguingly, p50 
levels in the cytosol and nuclei of treated cells were unchanged, implicating a specific effect on 
the phosphorylation of nuclear p50.  
 
The effects of YM155 and AB1 were conspicuously limited to the p50 subunit. Neither 
compound affected p65 or phospho-p65 levels in whole cell lysates nor the cytoplasmic/ nuclear 
compartments. The unaltered levels of p50 and p65 in the cytosolic and nuclear compartments 
of treated cells lend support to the notion that the nuclear translocation of the NF-κB dimers was 
not intercepted by YM155 or AB1.   
 
Levels of the inhibitory protein IκBα were also unchanged in treated cells, indicating that the NF-
κB/IκB complex and by extension, proteins that lie upstream of IκBα in the NF-κB signaling 
pathway, were not targeted by YM155 and AB1.  
 
Phosphorylation on p50 on serine 337 has been found to be critical for DNA binding237, 238, 240, 
and it is conceivable that the inhibition of p50 phosphorylation would compromise the 
functionality of the p50/p65 and p50/p50 dimers. Indeed, YM155 and AB1 inhibited the binding 
of p50 and p65 to the κB consensus sequences and attenuated transcription in the luciferase 
reporter assay. This would imply a disruption in the transcriptional activities of the NF-κB 
subunits. Thus, genes activated by p50/p65 would be repressed while those repressed by 
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p50/p50 would be activated. YM155 and AB1 were in effect “silencing” the NF-κB pathway and 
the consequences, as seen from the silencing experiments of p50 and p65 genes, was a 
significant loss in cell viability.  
 
Notwithstanding, the question remains as to how YM155 and AB1 suppressed the 
phosphorylation of p50. Various kinases have been proposed to effect phosphorylation of p50. 
Guan et al  posited that a protein kinase A subunit was responsible for phosphorylating Ser 337 
of p5054  while others have proposed phosphorylation at alternative serine residues in p50 by a 
DNA-dependent protein kinase, which was necessary not only for DNA binding but 
transcriptional activity as well.241 It is conceivable that YM155 and AB1 inhibited the activities of 
these or other putative enzymes involved in p50 phosphorylation.   
 
Another question that needs to be addressed relates to how disruption of p50 phosphorylation 
would affect survivin levels. The survivin gene is activated by many transcription factors, 
including NF-κB.44, 45 Previous reports have highlighted that YM155 suppresses survivin by 
inhibiting the binding of transcription factors ILF3 and Sp1 to the survivin promoter. The present 
results would implicate NF-κB as another transcription factor that is intercepted by YM155 by 
inhibiting the phosphorylation of p50. Furthermore, it is tempting to speculate that survivin is not 
the only protein whose transcription is intercepted by YM155 and AB1. Levels of the anti-
apoptotic proteins Mcl1 and Bcl-xl were also diminished by both compounds and their 
reductions could also be due to diminished transcription arising from disrupted p50 
phosphorylation. There is literature support to show that Mcl1 and Bcl-xl are controlled in part by 






The findings in this chapter have shown that YM155 and AB1 disrupted the phosphorylation of 
the p50 subunit which regulates the binding of NF-κB dimers to DNA and transcription of NF-κB 
controlled genes. These effects were observed in RCC786-0 and H1299 cells at concentrations 
that were relevant to growth inhibition. Both compounds suppressed phosphorylation of nuclear 
(not cytoplasmic) p50, obstructed the binding of p50 to its consensus sequence and reduced 
NF-κB reporter activity in luciferase transfected HEK293 cells. The interception of p50 
phosphorylation could have disrupted the transcription of survivin, Mcl1 and Bcl-xl and led to 
apoptotic cell death. Together these results elucidate a novel mechanism that could account for 
the potent effects of these dioxonaphthoimidazolium analogs on cell viability.  
 
Figure 5.18. Summary of assays, results and conclusions for Chapter 5. 
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5.6. Experimental  
5.6.1. General biology 
Cell culture reagents were obtained from sources described in Chapter 3. GloResponse™ NF-
κB–RE-luc2P HEK293 cells were obtained from Promega (Madison, WI, USA). They were 
grown in complete DMEM supplemented with 50 μg/mL hygromycin B (Sigma-Aldrich Co., St. 
Louis, MO, USA). Cells were sub-cultured at a ratio of 1:6 on reaching 90% confluence. 
Lipofectamine 3000®, TNF-α and ON-TARGETplus® non-targeting siRNAs were obtained from 
Life Technologies Inc (Carlsbad, CA, USA), Peprotech, (Rocky Hill, NJ, USA) and GE 
Dharmacon® (Little Chalfont, Buckinghamshire, UK) respectively. The Annexin V-FITC 
apoptosis detection kit and Cellytic M® buffer were from Sigma-Aldrich (St. Louis, MO, USA). 
The Pierce transcription factor assay kits for NF-κB p65/p50 and NE-PER® nuclear and 
cytoplasmic extraction reagents were from Thermo Scientific (Rockford, IL, USA). All antibodies 
were obtained from Cell Signalling Technology Inc. (Danvers, MA, USA) except for the anti-
GADPH antibody which was purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, 
USA). p50 or p65 siRNA were also obtained from Santa Cruz. ONE-Glo™ Luciferase assay 
reagent was from Promega (Madison, WI, USA). A Tecan Infinite™ M200 Pro microplate reader 
was used to obtain fluorescence/luminescence readouts. 
 
5.6.2. ApoTox-GloTM assay 
The commercially available Apotox-GloTM assay kit was used for the simultaneous 
determination of compound-induced viability, necrosis and caspase activation in cells. The kit 
utilized two fluorescent substrates to simultaneously detect viable cells and dead cells and a 
luminogenic peptide substrate which when cleaved by caspases-3/7 produced a light signal that 
was indicative of apoptosis. RCC786-0 cells were seeded in black-walled clear-bottom 96-well 
plates at a density of 3.5 x 103 cells/well and incubated for 24 h at 37°C, 5% CO2 in 100 μL of 
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media. The media was removed by aspiration and replaced with 100 μL of fresh media 
containing test compound and 0.5% v/v DMSO. Control wells comprised the same media 
without test compound. After incubation for 48 h, the assay was performed according to the 
manufacturer’s instructions. Fluorescence and luminescence were read on a microplate reader 
and plots of viability, cytotoxicity and caspase activation versus concentration of test compound 
were generated. Caspase activation readings were normalized against fluorescence readings 
for viability at the same concentration of test compound in order to take into account cell 
viability. 
 
5.6.3. Detection of apoptosis  
RCC786-0 and H1299 cells were seeded in 6-well plates at a density of 2 x 105 cells/well in 1 
mL of media. After 24 h at 37°C, 5% CO2, the media was removed by aspiration and replaced 
with 2 mL media containing test compound and 0.5% v/v DMSO. Control wells contained 
untreated cells. Cells were incubated for another 24 or 48 h after which they were harvested, 
washed, and resuspended in an Eppendorf tube containing the supplied binding buffer (800 μL). 
The Annexin V-FITC conjugate and propidium iodide (PI) were added to the cell suspension 
following manufacturer’s instructions, incubated for 10 min, filtered (61 μm filter) and assessed 
by flow cytometry on the BD LSRFortessa® Cell Analyzer (BD Biosciences, Franklin Lakes, NJ, 
USA). Results were analyzed on the FACSDiva Version 6.2 (BD Biosciences, Franklin Lakes, 
NJ, USA) software. Each test compound was evaluated at 5 concentrations with no less than 
three separate experiments. 
 
5.6.4. p65 and p50 small-interfering RNA (siRNA) transfection 
RCC786-0 and H1299 cells were seeded in 96-well plates at 3 x 103 cells/well (100 μL media) 
or 10mm plates (5 x 105 cells/plate, 5 mL media). After incubation for 24 h (37°C, 5% CO2), the 
media was removed by aspiration and cells transfected with p50 or p65 siRNA using 
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Lipofectamine 3000® following manufacturer’s instructions. ON-TARGETplus® non-targeting 
siRNAs were used as a negative control. Transfected cells were subjected to either the MTT 
assay or Western blotting after 48 or 72 h of incubation. 
 
5.6.5. Transcription factor assay for p65 and p50 
RCC786-0 and H1299 cells were seeded in 6-well plates at 2 x 104 cells/well in 1 mL of media. 
After 24 h at 37°C, 5% CO2, the media was removed by aspiration and replaced with 2mL 
media containing test compound and 0.5% v/v DMSO with or without 25 ng/mL TNF-α. Control 
wells contained untreated cells with or without 25 ng/mL TNF-α. Cells were incubated for 
another 24 or 48 h, harvested and lysed with NE-PER® nuclear and cytoplasmic extraction 
reagents to give nuclear and cytoplasmic fractions. Protein content of the nuclear fractions were 
quantified by Bradford assay. The presence of active p65 or p50 in each fraction was 
determined with the Pierce NF-κB p65 or p50 transcription factor assay kits.  
 
5.6.6. Western blotting 
RCC786-0 and H1299 cells were seeded at a cell density of 5 x 105 cells/plate in 100mm Petri 
dishes (5 mL media per dish) for 24 h at 37°C, 5% CO2. The media was then removed by 
aspiration and replaced with 10 mL of fresh media containing test compound and 0.5% v/v of 
DMSO. After incubation for a specified period (6, 24, 48, 72 h), cells were harvested and lysed 
in Cellytic M® buffer or NE-PER® nuclear and cytoplasmic extraction reagents. Protein content 
of lysates/extracts were assessed by Bradford assay and subjected to SDS-PAGE. After 
transferring proteins to PVDF membranes, blocking was performed in 5% non-fat milk and 
probed with various primary antibodies to determine protein levels. Anti-GAPDH antibody was 
used as a loading control. Bands were visualized with Western Bright ECL substrate from 




5.6.7. NF-κB-RE luc2p reporter assay 
GloResponse™ NF-κB-RE luc2P HEK293 cells were used to assess the effect of test 
compounds on NF-κB promoter activity. GloResponse™ HEK293 cells were seeded in white-
walled 96-well plates at 3 x 104cells/well in 100 μL of complete DMEM for 24 hours (37°C, 5% 
CO2). The media in each well was removed and test compound (100 μL DMEM, 0.5% v/v 
DMSO) was added. After incubation for 48 h, TNF-α was added to give a final concentration of 
20 ng/mL, and incubated for another 5 h. Subsequently, 100 μL of ONE-Glo™ Luciferase assay 
reagent was added, plates were agitated (350 rpm, 3 min), luminescence was read on a plate 
reader and normalized against viability at the same concentration of test compound to give % 
promoter activity of cells. 
 
5.6.8. Statistical analysis 
Data were expressed as mean ± standard deviation. One-way analysis of variance (ANOVA) 
with Tukey post-hoc tests were performed (IBM SPSS Statistics v19.0) for comparison of means 




Chapter 6: SAR and mechanistic studies on YM155 as a stem cell clearing agent 
6.1. Introduction 
Organ and tissue transplantations have saved millions of lives since their inception, and 
continue to do so each year especially for end-stage organ failure where they are the only 
treatment option.243 Significant advances in surgical techniques and supportive care have 
propelled the field forward, but shortages in donated organs, a problem exacerbated by the 
aging population, is a pressing bottleneck. Patients who have received organs face the prospect 
of life-long immunosuppressant therapy to stave off organ rejection. Immunosuppressants like 
cyclosporine are associated with several toxicities and may increase the risk of cancers and 
infections.244-246  
 
Regenerative medicine is a viable means of addressing the many limitations of organ 
transplantation. By growing fresh organs and tissues, the problem of organ shortage is 
alleviated. Immunocompatibility is further assured if the cells used in generating the desired 
organs and tissues are from the patient.247 In this regard, the use of stem cells for regenerative 
medicine can be said to have revolutionized the field.  
 
Stem cells exhibit the capacity for plasticity which under the correct stimuli, are able to 
differentiate into a variety of cell types. They also exhibit the ability for self-renewal, that is, 
replicating without loss of pluripotency.247 Stem cells may be classified into three main types – 
embryonic stem (ES) cells, adult/somatic stem cells and induced pluripotent stem (iPS) cells. ES 
cells possess the greatest plasticity. They are arguably the best known and also the most 
controversial as they originate from the inner cell mass of the blastocyst.248 Harvesting these 
cells invariably destroys the blastocyst, raising ethical objections as it is widely viewed as the 
start of “life”.249 Indeed, ethical issues concerning ES cells are the main impediment to their 
deployment in regenerative medicine. Adult stem cells are found in differentiated tissues and 
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can be used to regenerate these tissues. They are multipotent rather than pluripotent, which 
means that they can develop into some but not all cell types. This limits their utility in 
regenerative medicine since organs contains a wide range of cell types. Examples of adult stem 
cells are those found in the bone marrow which generate blood cells of various lineages,250 and 
the stroma which are the source of cells (osteoblasts, chondrocytes, myocytes, adipocytes) in 
connective tissues.251, 252   iPS cells were discovered in 2006-2007 when Takahashi and 
Yamanaka demonstrated that mice and human fibroblasts could be converted to a stem cell-like 
state by transfection of four transcription factors - Oct4, Sox2, Klf4 and c-Myc.253, 254 Of these 
“Yamanaka factors”, Klf4 and c-Myc are associated with cancer and indeed, a large proportion 
of the transformed cells eventually became malignant. Varying the “recipe”, in particular 
replacing one or more of the four factors, particularly Klf4 and c-Myc, with other genes like 
Nanog, LIN28 provided a partial solution.255 iPS cells differentiate into cells derived from all 3 
germ layers in the embryo and are thus as pluripotent as ES cells. If the original pool of 
differentiated /somatic cells are derived from the patient, their conversion to iPS cells would 
overcome the ethical objections and problems with immune incompatibility which plague ES 
cells. Hence iPS cells are a promising alternative to ES cells for regenerative medicine.  
 
However, one critical hurdle that limits the widespread adoption of stem cells in regenerative 
medicine is the need to completely eliminate remnant undifferentiated stem cells with teratoma 
(tumour)-forming potential within the regenerated tissues and organs. A study has shown that 
as few as ten thousand residual undifferentiated cells were sufficient to trigger tumour formation 
in immunodeficient mice.70 Furthermore, many of the pluripotent transcription factors and iPSC 
reprogramming factors are oncogenes or closely associated with tumour formation.69  
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Consequently, to fully unleash the therapeutic potential of stem cells in the field of regenerative 
medicine, undifferentiated stem cells must be fully and specifically eradicated from their 
differentiated counterparts. 
 
Various strategies have been proposed to achieve this end. The simplest would be to extend 
the time required for differentiation as this would reduce the number of undifferentiated cells. 
However this approach may be unsuitable for certain applications where the regenerated tissue 
needs to be transplanted within a certain time frame before over-maturation sets in.256 
Alternatively, monoclonal antibodies may be employed to target a specific antigen (such as 
podocalyxin-like protein 1, SSEA-4 or TRA-1-60) on the stem cell.257, 258 When coupled with 
magnetic or fluorescence activated cell sorting, clearing efficiencies as high as 80% or more 
have been reported. However, this technique is not readily translated to the clinical setting since 
properly formed tissues and organs cannot be subjected to cell sorting without incurring 
considerable losses in viability.  
 
Another approach involves the site specific insertion of a herpes simplex virus 1 thymidine 
kinase (HSV1-TK) suicide gene at the Oct4 locus of iPSC.259 As the endogenous Oct4 promoter 
is only active in undifferentiated cells, the suicide gene will be exclusively propagated in these 
cells. They can then be selectively removed by an antiviral drug like ganciclovir. However, this 
approach would further complicate the genetic makeup of the ES cells and may indirectly 





Figure 6.1. Small molecules with ability to clear remnant stem cells. 
 
A relatively simple and cost effective method of eradicating remnant stem cells is the use of 
small molecules to specifically target rogue undifferentiated stem cells while sparing normal 
differentiated populations. Several have been reported in the literature (Figure 6.1). The oleate 
synthesis inhibitor PluriSIn #1 induced ER stress, attenuated protein synthesis and triggered 
apoptosis in iPSC.260 Another compound JC011, a structural analog of capsaicin, selectively 
eliminated iPSC by up-regulating the ER stress response.261 Lee et al identified quercetin and 
YM155 as inhibitors of iPSC-derived teratoma formation.68 Both compounds targeted survivin, 
and their efficacies reflected the potential of exploiting the unique signature of pro- and anti-
apoptotic gene expression in hESC as a means of eradicating teratomas. As mentioned earlier, 
stem cells express more pro-apoptotic genes than anti-apoptotic genes compared to their 
differentiated counterparts. Hence, the survival of stem cells is critically dependent on the few 
resident anti-apoptotic genes, which if inhibited would induce apoptosis of residual 
undifferentiated stem cells and hence reduce the likelihood of teratoma formation.  
 
YM155 induced apoptosis in ES and iPS cells with an IC50 of around 5 nM and eliminated 
teratomas in animal models.68 It is not known if YM155 inhibits the stem cell transcription factors 
responsible for triggering the differentiation process. If it does, it would abolish both the self-
renewal and pluripotent characteristics of stem cells. In view of the findings in Chapter 5 where 
YM155 and AB1 were found to disrupt the transcription of NF-κB controlled genes and possibly 
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that of anti-apoptotic proteins survivin, Mcl1 and Bcl-xl by blocking phosphorylation of p50, it is 
tempting to propose a similar action on the stem cell factors by these compounds.   
 
6.2. Objectives 
In this chapter, YM155 and its analogs are investigated for their effects on the viability of 
embryonal carcinoma (EC) cell lines NCCIT and NTERA-2 with the aim of establishing the SAR 
for growth inhibition on EC cells and drawing comparisons to the SAR deduced from RCC and 
NSCLC cells (Chapter 3). Overlapping structural requirements would hint at a similar mode of 
action by these compounds on these two cell types (stem cells and malignant cells). The 2nd 
objective is to investigate the effects of YM155 and selected analogs on various stem cell 
factors (Sox 2, Nanog, Oct4) that are important for maintaining stem cells (ES, EC and an iPS 
cell line) in their undifferentiated state. A reduction in the transcription or protein expression of 
Sox2, Nanog or Oct4 would indicate that YM155 and its analogs potentially promote the 
differentiation of stem cells which would in turn reduce the likelihood of the cells transforming to 
the malignant phenotype. 
 
6.3. Results 
6.3.1. Growth inhibitory activity of YM155 and analogs on EC cell lines 
The growth inhibitory activities of YM155 and its analogs (Series A, B, C and AB) were 
evaluated on two embryonal carcinoma (EC) cell lines NCCIT and NTERA-2. ECs are a rare 
form of germ cell tumors. They are pluripotent and have similar genetic profiles as ES cells. EC 
cells are the malignant counterparts of ES cells and widely used as their substitutes.262-264 They 
are particularly useful for screening purposes as their growth requirements are comparatively 
less demanding than those of ES and iPS cells. Table 6.1 lists the growth inhibitory IC50 values 




YM155 is more potent on the EC cells (IC50 1.5 – 2.1 nM) than on RCC and NSCLC cells (14 – 
54 nM). As for the YM155 analogs, the range of determinable IC50 values was 1.99 nM (A3-3) to 
34.3 µM (C4-2) on NCCIT (median IC50 24.2 nM) and 1.49 nM (YM155) to 28.9 µM (C4-1) on 
NTERA-2 (median IC50 13.8 nM). This translates to approximately 104 fold difference in potency, 
exceeding that observed on RCC and NSCLC cells where there was only 103 fold difference (9 
nM to 9 μM) but with higher median values (113 – 633 nM). IC50 values from NCCIT and 
NTERA-2 were strongly correlated (Spearman correlation coefficient ρ = 0.973) (Table 6.2), 
suggesting that the SAR deduced from NCCIT should apply to NTERA-2 and vice versa. 
Significant correlations (ρ = 0.83 – 0.87) were also observed between IC50 values from EC and 
malignant RCC and NSCLC cell lines. Thus, one would expect overlapping structural 
requirements EC and malignant cells.  
 
Table 6.1. Growth inhibitory IC50 values of YM155 and synthesized analogs on EC cell lines and 
IMR-90. 
Compound 
Growth Inhibitory IC50, nMa Average 
selectivity 
ratio b NCCIT NTERA-2 IMR-90 
YM155 2.09 ± 0.07 1.49 ± 0.08 247 ± 37 142 
A1-1 43.7 ± 3.2 31.9 ± 3.9 1160 ± 70 31.4 
A1-2 75.6 ± 11.8 30.8 ± 3.4 5270 ± 960 120 
A1-3 53.6 ± 1.5 44.2 ± 7.3 1450 ± 50 29.9 
A2-1 76.6 ± 8.6 71.6 ± 1.5 2010 ± 110 27.2 
A3-1 19.7 ± 3.3 13.8 ± 1.0 2520 ± 110 155 
A3-2 5.46 ± 0.32 3.79 ± 0.55 611 ± 44 137 
A3-3 1.99 ± 0.26 1.55 ± 0.15 176 ± 9 101 
A3-4 25.7 ± 4.7 9.36 ± 1.83 3180 ± 40 232 
A3-5 2.23 ± 0.11 1.98 ± 0.40 205 ± 14 97.7 
A3-6 6.22 ± 0.58 4.62 ± 0.22 276 ± 27 52.1 




Growth Inhibitory IC50, nMa Average 
selectivity 
ratio b NCCIT NTERA-2 IMR-90 
A3-8 20.6 ± 1.98 10.6 ± 0.8 2000 ± 130 143 
A4-1 104 ± 8 52.0 ± 2.4 2810 ± 520 40.5 
A5-1 2411 ± 175 2803 ± 506 8820 ± 1210 3.40 
A6-1 17.8 ± 1.94 13.2 ± 0.9 743 ± 89 49.0 
A6-2 26.2 ± 0.9 12.3 ± 1.6 345 ± 38 20.6 
A6-3 22.2 ± 2.2 12.9 ± 1.5 1230 ± 130 75.4 
A6-4 24.2 ± 3.5 16.4 ± 3 1720 ± 83 88.0 
A6-5 60.3 ± 2.8 35.3 ± 5.9 3890 ± 290 87.3 
A6-6 24.0 ± 0.6 12.0 ± 2.3 1160 ± 140 72.5 
A6-7 45.1 ± 4.0 17.3 ± 1.0 2640 ± 540 106 
A6-8 57.1 ± 7.0 23.2 ± 3.7 6790 ± 290 206 
B1-1 25.6 ± 2.8 21.1 ± 3.3 2480 ± 320 107 
B1-2 188 ± 9 56.4 ± 9.6 9890 ± 170 114 
B1-3 21.9 ± 1.04 13.8 ± 0.7 1430 ± 260 84.5 
B2-1 13.8 ± 1.8 7.62 ± 1.37 582 ± 89 59 
B2-2 8.86 ± 0.85 3.63 ± 0.56 480 ± 22 93.2 
B2-3 5.71 ± 0.82 3.45 ± 0.67 565 ± 27 131 
B2-4 20.9 ± 2.1 13.5 ± 2.8 1420 ± 150 86.7 
B2-5 4.88 ± 0.57 1.99 ± 0.30 213 ± 20 75.3 
B2-6 10.2 ± 1.1 4.69 ± 0.26 1620 ± 140 252 
B2-7 48.4 ± 1.4 31.4 ± 2.9 7970 ± 180 209 
B2-8 158 ± 3 109 ± 23 6580 ± 180 50.6 
B3-1 149 ± 5 105 ± 14 5610 ± 380 45.5 
B3-2 59.1 ± 5.7 19.0 ± 1.8 3570 ± 710 124 
B4-1 501 ± 90 512 ± 30 7420 ± 760 14.6 
B4-2 1364 ± 71 919 ± 74 3730 ± 110 3.40 
C1-1 34.8 ± 1.9 19.6 ± 2.0 1900 ± 110 75.8 
C1-2 441 ± 32 318 ± 20 1360 ± 150 3.68 




Growth Inhibitory IC50, nMa Average 
selectivity 
ratio b NCCIT NTERA-2 IMR-90 
C2-2 >100 µM >100 µM >100 µM - 
C2-3 >100 µM >100 µM >100 µM - 
C3-1 >100 µM >100 µM >100 µM - 
C3-2 >100 µM >100 µM >100 µM - 
C4-1 24000 ± 1000 28900 ± 3400 55400 ± 4600 2.11 
C4-2 34300 ± 5700 8290 ± 1190 73000 ± 4500 5.47 
AB1 2.46 ± 0.20 2.56 ± 0.25 287 ± 59 115 
AB2 7.61 ± 1.03 4.44 ± 0.35 310 ± 51 55.3 
AB3 40.5 ± 2.4 34.6 ± 0.8 649 ± 79 17.4 
AB4 20.1 ± 2.1 15.2 ± 0.9 440 ± 7 25.4 
AB5 10.4 ± 1.4 9.15 ± 0.92 484 ± 64 49.7 
AB6 8.38 ± 0.54 5.72 ± 0.48 475 ± 91 69.9 
AB7 24.2 ± 2.0 6.08 ± 0.60 159 ± 16 16.4 
a Evaluated by MTT assay, 72 h incubation, 37oC, 5% CO2. Mean ± SD for n = 3 determinations; 
b Mean of IC50 IMR-90 / IC50 EC cell line. 
 
Table 6.2. Spearman correlation matrix of  values derived from IC50 values of test compounds 
on EC (NCCIT, NTERA-2), ccRCC (RCC786-0, RCC4/VA) and NSCLC (H1299, H1666) cell 
lines.a 
 NCCIT NTERA-2 RCC786-0 RCC4/VA H1299 H1666 
NCCIT 1.000 0.973 0.854 0.827 0.855 0.903 
NTERA-2 0.973 1.000 0.867 0.852 0.870 0.920 
RCC786-0 0.854 0.867 1.000 0.950 0.942 0.965 
RCC4/VA 0.827 0.852 0.950 1.000 0.924 0.919 
H1299 0.855 0.870 0.942 0.924 1.000 0.950 
H1666 0.903 0.920 0.965 0.919 0.950 1.000 




In the following paragraphs, the SAR of YM155 was analyzed on NCCIT with a view of drawing 
comparisons with SAR deduced on H1666 cells.  
 
Analysis of the series C compounds once again highlighted the importance of the quinone 
moiety. Analogs that retain the quinone moiety (C2-1, C4-1, C4-2) showed smaller losses in 
activity as compared to those without the quinone (C2-X, C3-X). The relative importance of the 
various features in the tricyclic scaffold were discernible. After the quinone, the next most 
important feature was the positive charge on the imidazolium N, followed by the distal benzene 
ring. This sequence was also observed for growth inhibitory activities. The C2 ethyl homolog of 
YM155 (C1-2) showed diminished activity, similarly indicating limited tolerance for even a minor 




Analysis of the series A compounds revealed many overlapping structural requirements that 
were also critical for growth inhibition of H1666. These were: 
(i) Maintaining a methylene linker between N3 and the pyrazine ring as seen from the reduced 
activities of A4-1 and A5-1. A5-1 was in fact the least potent compound in Series A.  
 
(ii) Preference for azinylmethyl moieties at N3: Analogs with non-azinylmethyl residues (A1-X, 
A2-1) had poor activity.  
 
(iii) Regioisomeric bias against azines with ortho azomethine N atoms. The adverse effect of an 




There were however noticeable differences in structural requirements. First, although alkyl 
substituents were permissible at N3, structural preferences were less well defined. Thus IC50 
values varied within a narrower range (26 – 60 nM) on NCCIT as compared to H1666 (29 – 280 
nM) for the same set of A6-X analogs. Differences in growth inhibitory activities of analogs with 
methyl, ethyl, propyl and cyclopropyl at N3 were not readily distinguished. 
 
Second, the symmetrically substituted analog A6-1 had surprisingly good activity. It was more 
potent than all the N3-alkyl analogs on NCCIT and comparable to the most potent analog (A6-6) 
on NTERA-2. In contrast, it was significantly less potent than the N3-alkyl analogs in H1666 and 
other malignant cells.  
 
Several SAR similarities were also detected in series B. These were: 
(i) Losses in activity when the 2’-methoxyethyl side chain at N1 was modified by demethylation 





(ii) Poor tolerance for ring containing side chains at N1 as seen from the diminished activities of 
B1-2, B2-8, B3-1 and B3-2. Mention should be made of the anomalous activity of B3-2 in that it 
was surprisingly potent on NTERA-2 (IC50 19 nM) and in fact, equipotent to the other 
symmetrically substituted analog A6-1 (IC50 13 nM). This is contrary to the prevailing notion that 
ring bearing substituents were poorly tolerated on the scaffold and not observed on the 
RCC/NSCLC cells. 
 
(iii)  Analogs with N1-alkyl groups were permissible. Potencies of N1-alkyl analogs decreased in 
the order of cyclopropyl > propyl > ethyl > butyl > methyl > isopropyl > isobutyl, which broadly 
concurred with the sequence observed in H1666. The N1-cyclopropyl analog (B2-5) was also 




As for the series AB compounds, they were not as potent as anticipated in spite of bearing 
“optimal” substituents identified from series A (N3) and series B (N1). AB1 was the most 
promising but no better than YM155 on the EC cells. In this series, analogs with pyridin-4’-
ylmethyl at N3 (AB1, AB2) were the most potent, followed by those with pyridin-3’-ylmethyl 
(AB5, AB6) and finally, pyrimidin-5’-ylmethyl (AB3, AB4). In contrast, the N1 substituent (ethyl 
or cyclopropyl) had limited influence on activity. These findings were also observed on RCC and 
NSCLC cells. A notable difference was AB7 which was only modestly potent on EC cells in 




Moving on to the selectivity of compounds, it is immediately apparent that YM155 and its 
analogs had excellent selective activities on the EC cells. Compared to non-malignant IMR-90 
cells, YM155 was 142 times more potent on the EC cells. Selectivity ratios for its analogs were 
in the range of 2 (C4-1) to 250 (B2-6), a significant improvement over RCC/NSCLC cells where 
ratios were 1.5 to 19. Tellingly, potent analogs like A3-3, A3-5, B2-5 and AB1 had selectivity 
ratios exceeding 70 (in favor of EC cells) as compared to ratios of only 10 on RCC/NSCLC cells. 
Furthermore, some analogs (A3-4, A6-8, B2-6, B2-7) that had outstanding selectivities ( 200) 
on EC cells, had nanomolar potencies (IC50 5 – 50 nM). While growth inhibitory activities were 
admittedly weaker than YM155 and its potent analogs, these compounds still merit attention in 
view of their strong selective activities. 
 
Taken together, the SAR profiles of YM155 and its analogs on EC cells closely mirrored that 
observed on RCC/NSCLC cells. In both instances, the intact dioxonaphthoimidazolium scaffold 
was identified as a critical feature for activity whereas functionalization at N1 and N3 served 
mainly to fine-tune activity. However, even the most promising modifications resulted only in 
minor improvements in activity. Thus while several compounds could match YM155 in terms of 
potency, none could exceed it by 2-fold or more.  
 
6.3.2. Growth inhibitory activity of YM155 and selected analogs on other stem cell lines 
Having shown that YM155 and its analogs inhibited the viability of EC cells, a follow-up 
investigation was carried out on a human embryonic stem cell (hESC) H9 and an induced 
pluripotent stem cell line HCT-8 3.11. HCT-8 3.11 was derived from its non-stem cell malignant 
counterpart HCT-8, a colorectal carcinoma, through transfection of the Yamanaka factors (Sox2, 
Oct4, Klf4, c-Myc).253, 254 The analogs selected for evaluation covered a range of potencies – 
A3-3, AB1 (potent, IC50 2 – 3 nM); AB2, AB7 (moderately potent, IC50 5 – 25 nM); A2-1, B2-8, 
B3-1 (weakly potent, IC50 > 100 nM). The results are given in Table 6.3. 
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Table 6.3. Growth inhibitory IC50 values of YM155 and 7 synthesized analogs on ES cell line 
H9, colorectal carcinoma cell line HCT-8, and iPS cell counterpart HCT-8 3.11. 
Compounds 
IC50 (nM) a 
H9 b HCT-8 c HCT-8 3.11 c EC (NTERA-2/NCCIT) d 
YM155 10.0 ± 1.6 21.8 ± 2.6 6.43 ± 0.97 1.5 / 2.1 
A3-3 11.6 ± 1.6 11.8 ± 0.5 7.26 ± 1.32 1.6 / 2.0 
A4-1 174 ± 7 1210 ± 152 215 ± 41 52 / 104 
B2-8 156 ± 31 1250 ± 269 367 ± 71 110 / 160 
B3-1 739 ± 148 2130 ± 367 604 ± 80 110 / 150 
AB1 4.21 ± 0.49 15.4 ± 2.3 5.47 ± 0.80 2.5 / 2.6 
AB2 4.31 ± 0.54 28.9 ± 1.7 7.66 ± 1.00 4.4 / 7.6 
AB7 24.9 ± 0.2 32.9 ± 1.5 13.9 ± 1.5 6.1 / 24 
a Determined by MTT assay after 24 h (b) or 72 h (c) incubation and presented as mean ±SD of 
n = 3 separate determinations. d IC50 of EC cells were included for comparison. 
 
Growth inhibitory potencies on H9 were determined after 24 h incubation. In spite of the shorter 
incubation time, IC50 values remained in the nanomolar range, although they were generally 
higher than those obtained on the EC cells. An exception was AB2 which retained the same 
level of potency on both H9 and the EC cells. The rank order of potencies were broadly similar 
to that observed on the EC cells, but AB1 and AB2 were now the most potent analogs 
exceeding that of YM155 and A3-3.   
136 
 
The growth conditions of H9 were unlike those of HCT-8 3.11 and the EC cells in that mouse 
embryonic fibroblasts (MEF) were required as feeder cells. When a co-culture of untreated H9 
and MEF cells was examined microscopically, the spindle-shaped MEF feeders and the colony 
forming H9 cells were readily distinguished (Figure 6.2, 1st column). When the H9 cells lost their 
viabilities, a “hollowing out” was observed as the colonies collapsed and the sharp boundaries 
of the colonies were lost. This was observed when H9 cells were treated with YM155 and AB1 
at 50 nM (Figure 6.2, 3rd column). Importantly, the MEF cells remained viable with no 
observable morphological changes. They retained their viabilities even at 10x IC50 of YM155 
and AB1, thus confirming the selective activities of these compounds on the stem cells.  
 
(A) YM155 
     
0.5% v/v DMSO 5 nM 50 nM 
(B) AB1 
     
0.5% v/v DMSO 5 nM 50 nM 
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Figure 6.2. Morphology of H9-MEF cultures following 24 h treatment with 5 nM and 50 nM of 
(A) YM155 and (B) AB1 in comparison with DMSO vehicle control. The characteristic clear 
demarcation of colonies’ boundaries were lost as the concentration of YM155 and AB1 
increased. Eventually, the colonies collapsed, indicating loss of viability. A set of background 
control with only MEF showed negligible loss of viability for MEF (< 5%) under similar conditions 
(data not shown). Images presented are representative of the triplicates performed in the 
experiment. 
 
The test compounds were also found to affect the viability of the iPSC HCT-8 3.11. YM155, A3-
3, AB1 and AB2 were the most active (IC50 5 – 8 nM) whereas A4-1, B2-8, B3-1 were less 
active (IC50 200 – 600 nM). Interestingly, growth potencies on HCT-8 3.11 exceeded that of 
HCT-8 by 1.5 – 5 fold, suggesting an increase in sensitivity of the transformed cells to growth 
inhibition. 
 
6.3.3. Effects of YM155, AB1 and AB7 on the transcriptional activities of Sox2, Oct4, Nanog 
and p50 in NCCIT, H9, HCT-8 and HCT-8 3.11 cells. 
Having shown that YM155 and AB1 adversely affected viability of various stem cell types (EC, 
hESC, iPSC), experiments were planned to investigate their effects on the pluripotent markers 
that maintain stem cells in the undifferentiated state. The effects of YM155, AB1 and AB7 on 
the expression of mRNAs by Sox2, Oct4 and Nanog were monitored in treated NCCIT, H9, 
HCT-8 and HCT-8 3.11 cells. Of these markers, Sox2 and Oct4 are the most critical and 
essential.265 Nanog, which is downstream of Sox2 and Oct4 is another important factor.266 
 
The role of NF-κB signalling in maintaining pluripotency of iPSC was highlighted by Takase et al 
who showed that the pathway was upregulated in undifferentiated iPSC.267 When suppressed 
with p65 siRNA, the expression of Oct4 and Nanog were found to be reduced. Furthermore, 
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Armstrong et al also showed that disrupting the NF-κB pathway in hESC led to downregulation 
of Sox2, Oct4 and Nanog.268 In view of the effects of YM155 and AB1 on the phosphorylation of 
p50 (Chapter 5), the expression of p50 mRNA was also monitored in treated cells. 
 
Table 6.4. IC50 values of YM155, AB1 and AB7 after 24 h treatment on NCCIT, H9, HCT-8 and 
HCT-8 3.11. 
Compounds 
IC50 (nM) at 24 h 
NCCIT H9 HCT-8 HCT-8 3.11 
YM155 10 10 55 15 
AB1 30 4 45 20 
AB7 150 25 145 40 
 
The expression of mRNAs by Sox2, Oct4, Nanog and p50 were probed by qRT-PCR. Briefly, 
cells were incubated with a fixed concentration (IC50 determined after 24 h incubation, Table 6.4) 
of the test compound for 12 h (NCCIT, H9, HCT-8, HCT-8 3.11) and 24 h (NCCIT, H9) after 
which, mRNAs were harvested and converted to cDNA for analysis by qRT-PCR. mRNA levels 
of the housekeeping gene GAPDH were used for normalization. The 24 h analysis was carried 
out on YM155 and AB1 treated cells only. 
 
Figure 6.3 shows the fold change in mRNA expression of Sox2 in treated cells after an 
incubation period of 12 h and 24 h. At the 12 h time point, mRNA levels of Sox2 were 
significantly reduced in NCCIT cells treated with YM155, AB1 and AB7. These reduction, 
particularly those induced by AB1 and AB7, were more pronounced after 24 h. Time dependent 
reductions were also observed in H9 cells. At the 12 h time point, only YM155 reduced Sox2 
mRNA levels but after 24 h, reductions were also observed in AB7 treated cells but not in AB1 
treated cells. The delayed response elicited by AB7 suggests that it is slower acting compared 
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to YM155. Likewise, AB1 may be slow acting as well and requires a longer time period to 
produce significant Sox2 reductions in H9 cells. 
 
Figure 6.3. Expression levels of Sox2 mRNA following 12 or 24 h of treatment with YM155, 
AB1 or AB7 quantified by qRT-PCR. Bars represent the fold-change of cDNA normalized 
against GAPDH in the same sample. Error bars represent the standard deviations of three 
separate experiments. Significant statistical difference from vehicle control is represented by an 
asterisk (*) when p<0.05, two asterisks (**) when p<0.01 and three asterisks (***) when p<0.001 
(Tukey post-hoc test of respective populations of treated groups vs control). 
 
The transcriptional activity of the Sox2 gene was also reduced in treated HCT-8 at the 12 h time 
point. These reductions were almost comparable to those observed in treated NCCIT (12 h) but 
were less pronounced in HCT-8 3.11. Since a significant proportion of Sox2 expression in HCT-
8 3.11 is due to a transfected gene, it is possible that the latter is not regulated in the same way 
as the native gene. The smaller reductions in HCT8 3.11 may well reflect the effects of the 
compounds on the non-transfected gene. Time dependency was not investigated in HCT-8 and 
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Figure 6.4. Expression levels of Oct4 mRNA following 12 or 24 h of treatment with YM155, AB1 
or AB7 quantified by qRT-PCR. Bars represent the fold-change of cDNA normalized against 
GAPDH in the same sample. Error bars represent the standard deviations of three separate 
experiments. Significant statistical difference from vehicle control is represented by an asterisk 
(*) when p<0.05, two asterisks (**) when p<0.01 and three asterisks (***) when p<0.001 (Tukey 
post-hoc test of respective populations of treated groups vs control). 
 
In the case of Oct4 (Figure 6.4), there was no discernible reduction in the mRNA levels across 
all the stem cell lines treated with the test compounds. Small increases were observed in 
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Figure 6.5. Expression levels of Nanog mRNA following 12 or 24 h of treatment with YM155, 
AB1 or AB7 quantified by qRT-PCR. Bars represent the fold-change of cDNA normalized 
against GAPDH in the same sample. Error bars represent the standard deviations of three 
separate experiments. Significant statistical difference from vehicle control is represented by an 
asterisk (*) when p<0.05, two asterisks (**) when p<0.01 and three asterisks (***) when p<0.001 
(Tukey post-hoc test of respective populations of treated groups vs control). 
 
The transcriptional activity of Nanog is reportedly moderated by Sox2 and Oct4 which lie 
upstream to it.266 As Sox2 and Oct4 activities were affected differently by the test compounds on 
NCCIT, the effects on Nanog are not readily explained with the present data. It is however 
noteworthy that YM155 reduced Nanog mRNA levels in H9 cells at 12 h and this reduction was 
more pronounced at 24 h. The concurrent strong decreases in Sox2 mRNA may have a role in 
the decreases of Nanog. AB1 and AB7 did not affect Nanog mRNA levels even after 24 h, 
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Figure 6.6. Expression levels of p50 mRNA following 12 or 24 h of treatment with YM155, AB1 
or AB7 quantified by qRT-PCR. Bars represent the fold-change of cDNA normalized against 
GAPDH in the same sample. Error bars represent the standard deviations of three separate 
experiments. Significant statistical difference from vehicle control is represented by an asterisk 
(*) when p<0.05, two asterisks (**) when p<0.01 and three asterisks (***) when p<0.001 (Tukey 
post-hoc test of respective populations of treated groups vs control). 
 
Figure 6.6 shows the fold change in mRNA expression of p50 in treated cells after an incubation 
period of 12 h and 24 h. Levels were elevated in treated NCCIT cells at the 12 h time point but 
decreased after 24 h. In H9, only YM155 and AB1 slightly reduced p50 mRNA levels and 
likewise the effect was no longer apparent at 24 h. On HCT-8 cells, p50 mRNA levels were 
increased by all three compounds to varying extents, but they were reduced by YM155 and 
increased by AB1 in HCT-8 3.11.   
 
Taken together, this section has shown YM155, AB1 and AB7 have limited effects on the 
transcriptional activities of the genes that maintain stem cells in their undifferentiated state. Only 
Sox2 transcriptional activity was consistently reduced by YM155, AB1 and AB7 in NCCIT (12 
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levels were significantly reduced by all three compounds in HCT-8 and to a lesser degree in its 
iPS counterpart HCT-8 3.11, possibly due to the additional control of Sox2 expression by the 
transfected promoter. Oct4 activity was conspicuously unaffected by the test compounds on all 
cell lines, barring a slight increase at 12 h in HCT-8 3.11. Nanog, which is under the control of 
Sox2 and Oct4 appeared to be modestly affected by changes in levels of the former two genes, 
except in H9 cells treated with YM155. 
 
As for p50 transcriptional activity, no definitive changes were observed across all the treated 
stem cell lines. This was largely anticipated since the findings in Chapter 5 showed that the 
main effect of YM155 and AB1 was on the phosphorylation of p50 and not on its levels per se.  
 
6.3.4. Effects of YM155 and AB1 on levels of Sox2, survivin, cleaved caspase 3, p100, p65, 
phospho-p65, p50 and phospho-p50 in NCCIT, HCT-8 and HCT-8 3.11 cells. 
Having noted that YM155 and AB1 reduced Sox2 mRNA levels, Western blotting was carried 
out to determine if it would lead to a downregulation of Sox2 protein levels. Survivin, cleaved 
caspase 3, NF-κB subunits p65 and p50 were also probed under similar conditions. Briefly, 
NCCIT, HCT-8 and HCT-8 3.11 were incubated with YM155 and AB1 at their IC50 and 2x IC50 
concentrations for 48 h. Lysates were then prepared and probed with the relevant antibodies. 
 
As seen in Figure 6.7, YM155 diminished Sox2 levels in treated cells at both concentrations 
(IC50, 2x IC50). Sox2 levels were also decreased in AB1 treated cells, with greater losses at 2 × 
IC50. These changes were in keeping with the down-regulation of Sox2 transcription observed 
earlier. 
 
Cleaved caspase 3 and survivin were probed for evidence of the apoptogenic effects of YM155 
and AB1 on the stated cells. This was duly observed as seen from the appearance of cleaved 
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caspase 3 and reduction in survivin levels in the treated cells. The changes were more 
pronounced at 2x IC50 of YM155 and AB1.  
 
Figure 6.7 shows that p50 and p65 levels were unchanged in the treated cells. p105, a 
precursor of p50, was similarly unaltered. On the other hand, phospho-p50 was significantly 
reduced by both compounds whereas phospho-p65 was unchanged. These findings were 
similar to those observed in RCC and NSCLC cells.  
 NCCIT  HCT-8  HCT-8 3.11  
  YM155 AB1   YM155 AB1   YM155 AB1 
 
 Ctrl 2 4 2.5 5  Ctrl 22 44 15.5 31  Ctrl 6.5 13 5.5 11  
clvd- 































































Figure 6.7. Cleaved caspase 3, survivin, Sox2 and NF-κB subunits p50, p65, p105 and their 
phosphorylated forms (p.p50, p.p65) levels in NCCIT, HCT-8 and HCT-8 3.11 after treatment 
with YM155 and AB1 for 48 h. GAPDH was used as loading control. 
 
6.4. Discussion 
The main objectives of this chapter were to provide a better understanding of the effects on 
YM155 and its analogs on the viability and pluripotency of stem cells, namely to (i) establish the 
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SAR for growth inhibition of EC cells and to determine if these requirements coincided with 
those highlighted for malignant cells (Chapter 3) and (ii) determine if differentiation of stem cells 
would be intercepted by these compounds. 
 
With regard to the 1st objective, it is abundantly clear that there were overlapping structural 
requirements for growth inhibition on the EC and malignant cells. Foremost was the importance 
of retaining an intact dioxonaphthoimidazolium scaffold. The contributions of the various 
components in the scaffold to activity were aligned to those observed earlier. At N3, the 
pyrazinylmethyl side chain was preferentially replaced by isosteric azinylmethyl moieties and the 
regioisomeric bias against ortho substituted azines was again observed. At N1, the most suitable 
replacement for the 2’-methoxyethyl side chain were short chain alkyl groups, with N1- 
cyclopropyl the most favored. Lack of tolerance for bulky groups at N1 and C2 were again 
observed.   
 
The most noticeable difference in structural requirements was the modest activity of AB7 on EC 
cells, which stood in marked contrast to its highly ranked activity (twice more potent than 
YM155) on RCC/NSCLC cells. This may hint at a unique mode of action by AB7 which is a 
minimally substituted dioxonaphthoimidazolium that is structurally different from YM155. 
Mention should also be made of the lesser contributions to activity when alkyl groups were 
introduced at N1 or N3, especially at N3. These same modifications had a greater impact on 
RCC/NSCLC cells.   
 
Aside from SAR considerations, the median IC50 values of YM155 and its analogs point to 
overall greater potency on EC cells as compared to RCC/NSCLC cells. This could have 
contributed to the greatly improved selective activities of these compounds on the EC cells. The 
spread of growth inhibitory IC50 values was also wider which may suggest that side chain 
146 
 
modifications were less well tolerated on EC cells and thus caused greater variations in activity. 
Tellingly, no analog that was more potent than YM155 on EC cells was identified from this 
exercise.    
 
The growth inhibitory activities of YM155 and its potent analogs (A3-3, AB1, AB2, AB7) were 
not limited to EC cells but extended to H9 and HCT-8 3.11 cells. Nanomolar IC50 values were 
again observed. Selective activity was evident from the retention of viability in MEF cells in the 
co-culture with H9, as well as the higher IC50 values recorded for HCT-8 as compared to its 
induced pluripotent stem cell counterpart. 
 
With regard to the 2nd objective, the results showed that YM155 and AB1 blocked Sox2 
expression in NCCIT and HCT-8 3.11 cells at both the gene and protein levels. The 
transcriptional activity of Sox2 was also reduced in H9 cells treated with YM155 and AB1. In 
contrast, the activities of Oct4 and Nanog were not consistently affected across the different 
stem cell types by YM155 and its analogs. As Sox2 is an important driver of the pluripotent 
state, the reduction in its activity would suggest that YM155 and AB1 could potentially promote 
differentiation of stem cells.  
 
Sox2 also protects cells from apoptosis and several studies have shown that in malignant cells, 
the anti-apoptotic properties of Sox2 was mediated (in part) by survivin.269-271 Furthermore, 
survivin has been implicated in the maintenance of pluripotency.65 The inter-related effects of  
Sox2 and survivin and concurrent declines in treated stem cells raises the possibility of another 
upstream event regulating the levels of Sox2 and hence, survivin. 
 
NF-κB signalling is augmented in stem cells and is important for maintaining the self-renewing 
and pluripotent properties of these cells. Disrupting this pathway was reported to significantly 
147 
 
reduce Sox2, Nanog and Oct4 in ES and iPS cells as well as inducing differentiation.267, 268 
Survivin overexpression is also the result of NF-κB activation in several malignancies.213 In the 
light of the present results which showed down-regulation of survivin, phospho-p50 and Sox2 in 
YM155 and AB1-treated stem cells (NCCIT, HCT-8 3.11), it is tempting to implicate a role for 
the NF-κB pathway in intercepting Sox2 expression and the suppression of survivin activity. The 
loss in p50 phosphorylation would disrupt gene transcription and if the affected gene products 
are involved in cell survival (like Sox2 and survivin), this would translate to an increased 
susceptibility to apoptotic cell death. 
 
6.5. Conclusion 
This chapter has provided insights into the potential of YM155 and its analogs as potent agents 
for the eradication of remnant stem cells from differentiated cell populations. They are well-
positioned for this role because of their potent cell killing effects and their ability to promote cell 
differentiation. The first would markedly reduce residual stem cells while the second would 
further ensure their removal by promoting conversion to the differentiated state which would in 
turn lower the risk of reversion to the malignant phenotype.  
 
6.6. Experimental  
6.6.1. Cell lines and growth conditions 
Human EC cells (NCCIT, NTERA-2) and human colorectal carcinoma HCT-8 cells were 
obtained from American Type Culture Collection (ATCC, USA). HCT-8 3.11, a pluripotent stem 
cell line induced from HCT-8, was a gift from Professor Wang Shu (Department of Biological 
Sciences, National University of Singapore). It was generated using a baculovirus vector to 




RPMI-1640 and DMEM were supplemented with 10% heat-inactivated FBS and 0.01% w/v 
penicillin G-streptomycin before culturing. NCCIT was maintained in RPMI-1640, while NTERA-
2 and HCT-8 in DMEM. The media DMEM/F-12 (1:1) (Hyclone®, GE Healthcare, 
Buckinghamshire, UK) was supplemented with 1% FBS, 0.005% penicillin G-streptomycin, 5 mL 
of GlutaMax (Gibco®, Life Technologies Corporation, Carlsbad, CA, USA) and epidermal 
growth factor (Peprotech, Rocky Hill, NJ, USA) for the propagation of HCT-8 3.11.  
 
Human embryonic stem (ES) cell H9 and mouse epithelial fibroblast (MEF) cells were gifts from 
Dr Chan Woon Khiong (Department of Biological Sciences, National University of Singapore) 
and originated from WiCell Research Institute Inc.(Madison, WI, USA). Passaging and 
maintenance of H9 cells was done by Ms Lam Kuen Kuen, Millie (Department of Biological 
Sciences, National University of Singapore). H9 cells were maintained in DMEM/F-12 (1:1) 
(Gibco®, Life Technologies Corporation, Carlsbad, CA, USA) prepared according to the 
following formulation: 
Component Volume Final Concentration 
DMEM/F12 (1:1) 40 mL - 
Knockout™ Serum Replacer 10 mL 20% 
L-Glutamine (200 mM) 250 μL 1 mM 
β-Mercaptoethanol (55 mM in PBS) 91 µL 0.1 mM 
Non-essential Amino Acids 10 mM 500 μL 1x (0.1 mM) 
Basic Fibroblast Growth Factor (FGF) Solution 
(25 µg/mL) 
8 μL 4 ng/µl 
Total volume 50 mL - 
 
Knockout™ Serum Replacer, L-glutamine, β-mercaptoethanol and non-essential amino acids 





MEF cells were maintained in high glucose DMEM (Gibco®, Life Technologies Corporation, 
Carlsbad, CA, USA), supplemented with 10% FBS, 2 mM L-glutamine and 0.1 mM non-
essential amino acids solution. 
 
35mm culture dishes were coated with 1mL of 0.1% gelatin and incubated at 37°C for 1 h. 3.6 x 
105 gamma-irradiated MEF cells were seeded onto each gelatin coated 35mm culture dish and 
incubated for 24 h for adherence. Thereafter, the MEF layer was washed once with PBS and 
~100-120 H9 colonies suspended in H9 media were seeded. H9 media was changed daily and 
passaging was performed every 7 – 10 days depending on the size of colonies. During 
passaging, each large colony was carefully separated into 200 – 300 μm large pieces using a 
small scalpel. Roughly 100 – 120 pieces were then collected and seeded onto another 35mm 
culture dish previously seeded with MEF cells. 
 
6.6.2. MTT assay 
The MTT assay for NCCIT, NTERA-2, HCT-8 and HCT-8 3.11 was carried out as described in 
Chapter 3. The following cell densities were used: 3.0 × 103 cells/well (HCT-8, HCT-8 3.11), 4.0 
× 103 cells/well (NTERA-2), 6.0 × 103 cells/well (NCCIT). Incubation with MTT was 2 h for the 
above cell lines.  
 
For H9 cells, the above method was modified. MEF cells were seeded at a density of 5 x 104 
cells/well on 24-well plates in MEF media and allowed to attach overnight at 37°C, 5% CO2. 
Post attachment, MEF media was removed and H9 cells were seeded at 8 x 105 cells/well in 
500 μL H9 media and incubated for 48 h. After the stated times, media was removed from each 
well by aspiration and replaced with 497.5 µL of media and 2.5 µL of test compound (prepared 
in DMSO stock solution at 200-fold higher concentration) and incubated for another 24 h. 
Compound-containing media was then removed and a 500 μL aliquot of 0.5 mg/mL MTT in 
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media was added per well and incubated for 2 h. The resulting formazan was dissolved in 250 
μL DMSO and quantified at 570 nm on a microplate reader. It was necessary to correct for 
changes in absorbance due to the presence of MEF cells, so wells with only MEF were set up 
and treated with test compound as well. Absorbance from these wells were subtracted from 
those containing H9 before calculating percentage viability. Percentage viability was determined 
from the following expression 




Where At = Average of absorbance of compound-treated H9 + MEF cells 
Ablank,t = Average of absorbance of compound-treated MEF cells 
Acontrol = Average of absorbance of untreated/control H9 + MEF cells 
Ablank,control = Average of absorbance of untreated/control MEF cells 
 
6.6.3. qRT-PCR 
NCCIT, H9, HCT-8 and HCT-8 3.11 were seeded at 8.0 × 105 cells/well into 6-well plates for 24 
h followed by exposure to test compound for 12 or 24 h. RNA extraction was performed 
following manufacturer’s protocol (Qiagen RNeasy Mini Kit, Qiagen, Netherlands). RNA content 
was quantified using a ND-1000 spectrophotometer (NanoDrop Technologies, USA). All 
samples showed OD260/OD280 ratios between 1.73 and 2.11 with concentrations ranging from 
~400 to ~1200 ng/µL. Results from an Agilent Bioanalyzer 2000 analysis showed that all 
samples had RIN (RNA Integrity Number) of 9.4 – 10. 
 
RNA (1.7 µg) was withdrawn from each sample for cDNA synthesis using Promega M-MLV 
reverse transcriptase according to the recommended protocol (Promega, USA). Five primers, 
namely Sox2, Nanog, Oct4, p50 and GAPDH, were ordered from AIT Biotech (Singapore) 
based on sequences sourced from PrimerBank (Harvard Medical School, USA). PCR was 
carried out in a volume of 20 µL using SYBR Green Dye on Applied Biosystem 7500 Fast Real 
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Time PCR system (Life Technologies, USA). Data analysis was performed using a comparative 
CT (Threshold cycle) method and normalized to GAPDH expression levels. 
 
6.6.4. Western blotting 
Western blotting was performed in a similar manner as detailed in Chapter 4. Here, cell 
densities of 6.0 × 105 cells/100mm plate, 8.0 × 105 cells/100mm plate and 1.2 × 106 
cells/100mm plate were used for NCCIT, HCT-8 and HCT-8 3.11 respectively. Anti-Sox2 
antibodies were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). 
 
6.6.5. Statistical analysis 
Data were expressed as mean ± standard deviation. One-way analysis of variance (ANOVA) 
with Tukey post-hoc tests were performed (IBM SPSS Statistics v19.0) for comparison of means 




Chapter 7: Conclusions and Future Work 
The aim of this thesis is to test the hypothesis that a detailed understanding of the mode of 
action of YM155 would promote the development of dioxonaphthoimidazolium analogs as a 
promising class of potent anti-cancer therapeutics. To investigate this hypothesis, two broad 
approaches were followed. The first approach focused on preparing a library of YM155 analogs 
to query the structural requirements for growth inhibition. In spite of the advanced status of 
YM155 as a clinical candidate for cancer, surprisingly little is known of its structure-activity 
relationship (SAR). Without this information, developing more potent analogs would pose a 
formidable challenge. The second approach focused on investigating the mode of action of 
YM155. Various reports have questioned if the suppression of survivin is the sole and main 
effect of YM155-induced cytotoxicity. The consensus is that YM155 is a DNA intercalating agent 
and induces a DNA damage response that leads to apoptotic cell death. There is a sound 
structural basis to support this claim. The positively charged planar scaffold of YM155 would 
promote DNA intercalation while the embedded quinone in the scaffold would generate free 
radicals via redox cycling and initiate DNA strand breaks. The library of YM155 analogs would 
permit a detailed assessment of the SAR for DNA intercalation and redox cycling, with the 
premise that overlapping structural requirements with growth inhibition would support a 
prominent role for DNA damage in the antiproliferative activity of YM155. 
 
In the first approach, a library of 53 compounds were synthesized to interrogate the structural 
requirements for growth inhibition on two different malignant cell types (RCC and NSCLC). The 
library was designed to probe the importance of the side chains at N1 and N3 (series A, B and 





Figure 7.1. Summary of growth inhibitory structure-activity relationships of YM155 
 
The intact scaffold was mandatory for potent activity (nanomolar to low micromolar IC50) and 
dramatic losses were incurred when one or more rings were omitted from the tricyclic scaffold. 
In terms of relative contribution to activity, the quinone (ring B) was of foremost importance, 
followed by the imidazolium (ring C) and lastly the distal phenyl ring A. The side chains served 
to essentially fine-tune activity. Notwithstanding, specific structural requirements were evident, 
such as the regioisomeric preference of the N3-azinylmethyl side chain, limited tolerance for  
bulky / ring bearing substituents at N1, C2 and N3 and the favored presence of short, unbranched 
alkyl groups at N1 or N3. The inclusion of methyl at N1 and N3 yielded the only analog (AB7) that 
was consistently more potent than YM155. Although the fold difference was slight (2-fold), AB7 
was unusually potent (IC50 8.6 – 29 nM) with a selectivity against malignant cells (9.5-fold) that 
was comparable to YM155. More intriguing was its minimally substituted state which was in 
- Distal phenyl not 
critical for activity 
- Positive charge is 
important for 
activity 
- C2 does not 
tolerate bulk 
- Quinone moiety 
absolutely essential 
for activity 
- Homologation of 
methylene linker is 
poorly tolerated 
- Preference for azines 
with N at meta/para 
positions, with a 
preference for para 
- Small alkyl groups are 
well tolerated 
- Bulky groups and 
presence of hydrogen 
bond donors/ + 
charged side chains 
are poorly tolerated 
- Small alkyl groups or 




sharp contrast to the polar, H- bonding side chains found in YM155 and the other members of 
the library. 
 
Following reports that YM155 inhibited the viability of stem cells68, the synthesized compounds 
were evaluated on embryonic carcinoma (EC) cell lines, which are the malignant counterparts of 
embryonic stem (ES) cells. Nanomolar growth inhibitory potencies were found for YM155 and 
several analogs. SAR revealed the importance of the intact scaffold as before but there was 
less overlap in the structural requirements for the side chains. A notable difference was that 
analogs with short alkyl side chains at N1 or N3 were less effective on stem cells. Thus AB7 had 
only modest growth inhibition. More striking was the significantly improved selectivity ratios 
associated with the EC cells. Potent analogs like YM155, A3-3, A3-5 and AB1 had ratios as 
high as 100 or more, as compared to narrower 10-fold selectivities observed for the same 
compounds on malignant cells. Growth inhibition was not limited to EC cells but extended to a 
human embryonic stem cell line (H9) and an induced pluripotent stem cell line (HCT-8 3.11). As 
only a few analogs were evaluated on these cell lines, no SAR could be deduced but observed 
trends point to similar requirements for the different stem cell types.  
 
Taken together, functionalized dioxonaphthoimidazolium analogs displayed potent growth 
inhibitory activities against malignant and stem cells. Notwithstanding some differences in SAR, 
core features for activity remained the same, hinting at a possible shared mode of action. The 
potent and selective targeting of stem cells underscored the potential of this scaffold as stem 
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cell clearing agents. Several potent analogs (A3-3, A3-5, AB1, AB2, AB7) were identified, 
which depending on the cell line, were either equipotent or modestly more potent than YM155. 
 
The thrust of the 2nd approach was to determine the role of the DNA damage in the mode of 
action of YM155. To this end, DNA intercalation and redox cycling properties of YM155 and its 
analogs were investigated by in vitro assays. The results showed that YM155 and its analogs 
were weak DNA intercalators, with limited potential as redox cyclers. Analysis of the structural 
requirements revealed a closer alignment between the SAR for DNA intercalation and growth 
inhibition. Notably the intact scaffold was mandatory for both activities although the relative 
importance of the individual rings could not be established for DNA intercalation. In the case of 
redox cycling, the scaffold was optional and intriguingly, even the presence of the quinone 
moiety did not always ensure measurable redox activity. Side chain requirements for 
intercalation and redox cycling also differed from that required for growth inhibition. Notably, ring 
bearing side chains at both N1 and N3 were preferred as opposed to smaller, non-ring groups at 
the same positions for growth inhibition. The regioisomeric preference associated with N3-
azinylmethyl side chains for growth inhibition was noticeably absent for redox cycling but still 
retained for intercalation. Alkyl groups at N1 or N3 which were acceptable modifications for 
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growth inhibition were not favored for either activity. AB7 was a poor redox cycler but a more 
potent intercalator than YM155. Evidence from cell based assays showed that YM155 and 
several potent antiproliferative analogs (AB1, AB7) failed to generate significant amounts free 
radicals, indicating that redox cycling had a limited role in the mode of action of these 
compounds.  
 
Notwithstanding these SAR deductions, YM155, AB1 and AB7 elevated levels of the DNA 
damage marker γH2AX in treated cells. However, these increases were not entirely compatible 
with the DNA damage response for several reasons. First, they were unusually delayed in terms 
of detection in treated cells and second, they were closely aligned to the appearance of the 
apoptotic marker protein cleaved caspase 3. This raises the possibility that the elevation of 
γH2AX is due to DNA fragmentation which accompanies apoptotic cell death. Future work 
should be directed towards determining the transcriptional profiles of RCC/NSCLC cells to 
determine if DNA repair genes are activated in the presence of YM155 or its analogs, as would 
be expected if the DNA damage response is a major contributor to cell death. 
 
Taken together, the present findings have shown that the dioxonaphthoimidazolium analogs of 
YM155 were modest DNA intercalators with limited capacity to generate free radicals. 
Intercalation per se will not directly cause DNA damage but it will cause unwinding of the DNA 
helix which could render it susceptible to misreading, mutations and interference with 
transcription and replication. These events would in turn perturb gene products in several 
canonical pathways that are required for cell survival. Notwithstanding, the present results do 





The NF-κB pathway was investigated as a possible target of YM155 in view of literature reports 
linking NF-κB activation to the overexpression of survivin in several malignancies. The corollary 
that suppression of survivin is due to inhibition of NF-κB signaling may thus hold true. 
Furthermore, anti-apoptotic proteins Mcl1 and Bcl-xl were downregulated in YM155 or AB1-
treated RCC/NSCLC cells. The expression of these proteins are controlled in part by the NF-κB 
pathway.   
  
A significant finding to emerge from these investigations was that YM155 and AB1 induced time 
and dose dependent losses in phospho-p50 in RCC and NSCLC cell lines. These losses were 
confined to phospho-p50 in the nuclear compartment of treated cells. p50 levels and p65 in the 
cytosol and nuclei of treated cells were not affected. Neither were there any changes in the 
levels of phospho-p65 or IκBα in treated cells. Thus, YM155 and AB1 did not inhibit the release 
of NF-κB dimers from the NF-κB/IκB complex and by extension, proteins that were upstream of 
IκBα in the signaling pathway. Neither did it inhibit the translocation of the NF-κB dimers from 
cytosol to nucleus.    
 
Phosphorylation of p50 regulates the binding of NF-κB dimers to consensus DNA sequences on 
NF-κB response elements (κB sites). When impeded, this would attenuate the transcriptional 
activity of the NF-κB dimers and reduce the expression of NF-κB controlled genes. Indeed, both 
compounds suppressed NF-κB reporter activity in luciferase transfected HEK293 cells. In effect, 
the NF-κB pathway was inhibited by YM155 and AB1, and the consequence, as seen from the 
silencing experiments of the p50 gene, was a significant loss in cell viability. Interestingly, a 
specific loss in phospho-p50 with no change in p50, p65 or phospho-p65, was also observed in 




YM155 was reported to inhibit the self-renewal capacity of stem cells through its cell-killing 
effects. The present investigations have shown that YM155 also promoted the differentiation of 
stem cells through its inhibition of Sox2 (a Yamanaka transcription factor required for “stem 
cellness”) at the mRNA and protein levels. By promoting their differentiation, YM155 will prevent 
transformation of the stem cells to the malignant phenotype. As these properties were also 
found for several of its analogs (AB1, AB7) at nanomolar concentrations, the 
dioxonaphthoimidazolium scaffold should be explored further as potential inhibitors of stem cell-
derived teratomas in regenerative medicine.  
 
There are still many unanswered questions in this thesis. One question pertains to AB7 which is 
structurally the least similar to YM155 among the dioxonaphthoimidazolium analogs. In spite of 
its minimally substituted structure, AB7 shared many of the properties of YM155 (DNA 
intercalation, suppression of survivin and p50 phosphorylation) and was modestly more potent 
than YM155 on malignant cells but not stem cells. A larger library of N1, N3-dialkyl substituted 
analogs may yet uncover more potent analogs, besides providing insight into the importance of 
the substitution motif.  
 
A recent report proposed that the cytotoxic effects of YM155 was contingent on the expression 
and activity of a solute carrier SLC35F2 which is highly expressed in human cancers. Intriguingly, 
this may imply that the SAR deduced from the malignant cells is in fact the SAR for affinity to the 
solute carrier. If so, the anomalous activity of AB7 on stem cells may reflect a weaker affinity to 
the resident solute carrier, which presumably is not identical to the one found in malignant cells. 
Screening the present library of compounds for binding affinity to the solute carrier would serve 
to address these issues. Specifically, it would be of interest to determine if the SAR derived for 




Another question that requires clarification relates to the mechanism by which YM155 and AB1 
suppressed p50 phosphorylation. It would be of interest to determine if these compounds inhibit 
the kinase-mediated phosphorylation, and if so, the identity of the affected kinase. Screening 
YM155 and selected analogs on a kinome screen would provide some answers. Alternatively, 
transcriptome analyses of YM155/AB-1 treated cells will disclose the global profile of targets 
affected by these compounds. Careful validation of the results would yield useful mechanistic 
clues.   
 
The present data on stem cells has also opened up a new frontier for 
dioxonaphthoimidazoliums. Discovery that YM155 and AB1 specifically downregulate Sox2 
hints at another pathway that these compounds may target. Interestingly, Sox2 levels in HCT-8 
were also downregulated, highlighting a possible role of Sox2 in malignant cells. That p50 
phosphorylation is also inhibited in stem cells may therefore imply a common mechanism of 
action of YM155 in both malignant and stem cells. What is required thus are knockdown studies 
of NF-κB subunits to examine if these affect Sox2 levels significantly, which will provide further 
evidence for a link between the NF-κB pathway and Sox2 as well as bringing forth the above 
pathway as a critical one in maintenance of stem cell pluripotency and viability. 
 
This thesis has shown that YM155 and its analogs are suppressors of survivin and other anti-
apoptotic proteins (Bcl-xl and Mcl1) and in stem cells, inhibitors of Sox2 transcription. Most 
significantly, they are also inhibitors of p50 phosphorylation. YM155 and its analogs are also 
able to intercalate DNA and redox cycle to a measurable degree, but these properties are 
unlikely to account for the major part of their mechanism of action. Instead, the present thesis 
suggests that YM155 and its analogs induce apoptosis in both malignant and stem cells through 
disruption of the NF-κB pathway. This disruption downregulates anti-apoptotic proteins, thereby 
tilting the balance of the cell towards apoptosis. In stem cells, an additional effect on 
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downregulation of Sox2 (which has also been found to be under NF-κB control) may also 
promote differentiation of pluripotent stem cells. As a final note, Sox2 downregulation was also 
observed in the colorectal carcinoma cell line HCT-8, highlighting a possible role of Sox2 in 
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